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(ii) Abstract 
Poorly controlled diabetes mellitus is associated with the development of 
chronic vascular complications which cause morbidity and premature mortality. 
Many studies have highlighted maintenance of normal blood glucose levels in all 
people with diabetes as the most effective way in which chronic complications can 
be reduced and prevented . 
Presently, the underlying mechanisms associated with the manifestation 
and progression of vascular complications are poorly defined. Therefore, this study 
considered how the increased oxidative demand placed upon cells by high glucose 
concentration would result in a state of pseudo hypoxia, and potentially the 
expression of hypoxia inducible factor-a. (HIF-1a.). 
In an animal model of diabetes, HIF -1 a protein expression was seen to 
increase in the vasculature surrounding the sciatic nerve at 1 0 and 24 weeks 
diabetes duration, which was seen to be reversed at 24 weeks in response to 
treatment with the antioxidant a.-lipoic acid. 
In vitro, exposure of HUVEC to 20mM glucose for 24h induced perinuclear 
expression of HIF -1 a protein, as opposed to nuclear expression evident under 
hypoxic conditions. Furthermore, at 24h in 20mM glucose, HIF-1a. mRNA level 
detected was significantly higher than that seen in all other conditions (p<O.OOI). 
The increase in HIF-la. mRNA detected was seen to be dependent upon 
mRNA stability, and potentially its association with RN A-binding proteins and/or 
the natural antisense, aHIF. Pi3K and to a lesser extent p42/44 MAPK signalling 
pathways were also implicated, and a.-lipoic acid treatment reversed the stability of 
HIF-la. mRNA. The effect of high glucose on HIF-la. mRNA level was not seen in 
response to partially/non-metabolisable glucose analogues, indicating glucose 
metabolism to be central to the stabilisation ofHIF-la. mRNA. 
In conclusion, regulation ofHIF-la. at the level ofmRNA and protein by the 
metabolism of high concentrations of glucose, may contribute to the generation of 
chronic vascular disease associated with diabetes, and should be further explored as 
a potential mechanism by which such complications may be prevented. 
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1.1 Overview 
Poorly controlled diabetes mellitus is associated with the development of 
chronic vascular complications which cause morbidity and premature mortality. 
The need for maintaining normal blood glucose levels in all diabetic patients has 
been highlighted, as blood glucose which is elevated for several years is a major 
factor in the development and progression of vascular complications (The Diabetes 
Control and Complications Trial (DCCT), 1993; The UK Prospective Diabetes 
Survey (UKPDS), 1998). 
The underlying mechanisms associated with the manifestation and 
progression of vascular complications, however, are still poorly defined. This 
thesis considers how a state of functional hypoxia arising from the need to 
metabolise elevated levels of glucose, resembling that experienced in poorly 
controlled diabetes, may contribute to the development of vascular disease 
associated with diabetes. This state of pseudo hypoxia arises even though oxygen 
supply to the cells may be physiologically normal. However, the increased demand 
for oxidative phosphorylation of high concentrations of glucose will inevitably 
create a state of functional hypoxia, and potentially the expression of hypoxia-
inducible genes associated with angiogenesis, glucose transport and metabolism. 
A critical regulator of gene expression in response to hypoxia is a 
heterodimeric transcription factor termed hypoxia-inducible factor-1 (HIF-1), the 
inducible subunit of which is HIF-1a. By investigating the expression ofHIF-1a in 
a rat model of diabetes, and in response to high glucose concentration under normal 
and decreased oxygen levels in cell culture, it may then be possible to determine the 
level at which any regulation is occurring, and also the mechanism( s) and signalling 
pathway(s) involved. 
The outcome of this work is potentially very important, as it may help to 
elucidate whether glucose itself, glucose metabolite(s) or particular steps within the 
metabolic pathway could be targeted by therapies to prevent and treat the chronic 
vascular complications associated with diabetes. 
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1.2 Diabetes mellitus 
Diabetes mellitus is a long term progressively debilitating disease, the only 
known insulin-independent therapy for which remains to be successful pancreatic 
transplantation, first performed in 1966 (Kelly et al., 1967). Advancements made 
in pancreatic transplant technology in the past 10 years have resulted in a steady 
rise in graft function and patient survival rates (Gruessner et al., 2005). However, 
post-operative vascular complications resulting in graft dysfunction do present a 
significant problem (Freund et al., 2004). 
According to a recent report from Diabetes UK (Diabetes: State of the 
nations 2005), the number of people in the UK diagnosed with the condition has 
risen from 1.4 million in 1996 to over 2 million in 2005. Of this figure, close to 
250,000 have type 1 diabetes, also known as early onset, juvenile or insulin-
dependent diabetes, and is the most severe, requiring insulin therapy to sustain life. 
Non insulin-dependent diabetes mellitus (NIDDM) or type 2, also known as adult 
or late-onset diabetes, affects approximately 1.8 million of those suffering from the 
disease. The incidence rate of diabetes is not significantly different between men 
and women until age 75, at which point diabetes affects more men than women 
(Watkins, 2003). 
Diabetes is characterised by the inability of the body to maintain levels of 
glucose in the blood, which would normally be regulated by insulin secretions from 
the pancreas. The person with diabetes either produces no insulin, or produces it in 
levels that are inadequate. In the case of type 1 diabetes, the body's autoimmune 
system destroys insulin-producing cells. Type 2, whereby the body becomes 
resistant to insulin although it still may be producing insulin normally, is highly 
correlated with age, and may be controlled effectively with diet and lifestyle 
changes. 
The person with diabetes is susceptible to a series of late stage 
complications that cause morbidity and premature mortality. Onset of symptoms 
develop on average 15 - 20 years after the appearance of overt hyperglycaemia. 
However, this time period may be decreased if diagnosis is delayed, which can 
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occur in the case of type 2 diabetes. Therefore, the identification of risk markers 
for vascular disease in diabetes is significant in preventing long term disabilities. 
Several studies have highlighted the importance of good blood glucose control in 
the prevention of diabetic complications (DCCT, 1993; UK.PDS, 1998), and it 
would appear that maintenance of tight blood glucose control is critical for the 
prevention of early cellular damage which can lead to blindness, end-stage renal 
disease, amputation and fatality from myocardial infarction. As a result, much 
work has gone into furthering the understanding of the mechanisms by which either 
high or low glucose levels impair normal cell growth, and how this impacts upon 
the development of complications of diabetes (Ng et al., 2005; Yamagishi et al., 
2004; Caldwell et al., 2003). 
1.3 Vascular complications of diabetes 
1.3.1 Microvascular complications 
1.3.1.1 Neuropathy 
Neuropathy is a common complication associated with diabetes mellitus 
(Akbari et al., 1997). Signs and symptoms of the disease include reduced 
nociception and burning sensation in the peripheral extremities. The DCCT of 
1993 demonstrated that intensive blood sugar control resulted in a 60% decrease in 
clinically detected neuropathy, however, at the moment, little is known about the 
mechanisms underlying such abnormalities in nerve function. 
Metabolic abnormalities in diabetes appear to affect nerve function through 
vascular effects, and improving neural blood flow corrects nerve function in 
experimental diabetes (Cameron et al., 2003a). Potential factors involved include 
increased protein glycation, accumulation of polyols, altered lipid metabolism, 
decreased myoinositol content, abnormal Schwann cell function, microangiopathy 
resulting in ischaemia and/or lack of neurotrophic factors (Thomas et al., 1993; 
Dyck et al., 1996). 
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Assessment of the microvasculature accompanying the diabetic nerve has 
uncovered pathological changes including basement membrane thickening, pericyte 
degeneration and increased endothelial cell proliferation, which correlate strongly 
with the degree of nerve fibre defect (Gianinni & Dyck 1995; Malik, 1997). 
1.3.1.2 Retinopathy 
Diabetic retinopathy (DR) is the commonest cause of blindness in the 
working population of the Western world. The incidence and severity ofDR has 
also been shown to correlate closely with poor glucose control (DCCT, 1993). The 
pathophysiology ofDR involves basement membrane thickening and retinal 
oedema as a result of poor glucose control, causing loc'al ischaemia within the 
retina associated with microaneurysms and excessive vascular permeability. At the 
advanced stage, the disease is known as proliferative diabetic retinopathy (PDR) 
characterised by the development of new blood vessels which grow in an attempt to 
perfuse ischaemic areas. Other factors that contribute to the retinopathic condition 
include increased platelet adhesiveness, erythrocyte aggregation, and increased 
blood viscosity. As the disease progresses, the proliferation of new blood vessels 
and fibrous tissue on the surface of the retina may increase the risk of vitreous 
haemorrhage and retinal detachment (Winters & Jernigan 2000). The retinal 
microvasculature appears to be the main target of glucose mediated damage in PDR 
(Forrester et al., 1993), and angiogenesis initiated by vascular endothelial growth 
factor (VEGF) occurs in response to ischaemia in the retina of patients with 
diabetes (Shima et al., 1995). 
1.3.1.3 Nephropathy 
Diabetic nephropathy is a major cause of end-stage renal disease and even 
in the early stages is associated with increased death rates. The early stages of 
nephropathy are asymptomatic. Microalbuminuria related to endothelial 
dysfunction (Verrotti et al., 2003), is the first clinical sign of nephropathy, and only 
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detectable after the onset of severe renal damage. However, some 50% of patients 
with microalbuminuria die from cardiovascular disease before progressing to end-
stage renal disease (Deckert et al., 1992). 
1.3.2 Macrovascular complications 
Though the incidence of microvascular disease is higher in people with 
diabetes compared to the general population, it is macrovascular disease which 
accounts for most fatalities. Macrovascular diseases are characterised by 
atherosclerosis and involve vessels of the heart, cerebrum and peripheral arteries. 
People with diabetes have a three-fold higher risk of developing atherosclerosis and 
its associated clinical complications compared to those without diabetes, which in 
the case of type 2 coexists with other contributing factors such as hypertension and 
obesity (Fumeron et al., 2006). 
1.3.3 Pathogenic mechanisms of vascular complications of diabetes 
Diabetes through hyperglycemia is widely known to be a major factor 
leading to microvascular and neural complications (Brownlee, 200 1). 
Hyperglycemia-induced end-organ damage in diabetes is thought to be associated 
with increased flux of glucose by means of the polyol metabolic pathway 
(Yagihashi et al., 2001; Obrosova et al., 2002), accumulation of advanced glycation 
end products (Soulis et al., 1999), increased oxidative stress (Cameron & Cotter, 
1999; Coppey et al., 2001), and activation of the protein kinase C pathway 
(Cameron et al., 1999; Booth et al., 2002). However, the pathogenesis of the 
vascular complications of diabetes remains controversial (Stehouwer et al., 1997). 
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1.3 .3 .1 Glycolysis and the Warburg effect 
Under hypoxic conditions, energy release by means of oxidative 
phosphorylation becomes impaired. Metabolic requirements are therefore met by a 
shift to anaerobic glycolysis, as shown in figure 1.1. As anaerobic glycolysis 
generates less adenosine triphosphate (ATP) than oxidative phosphorylation, the 
enzymatic activity and gene expression of glycolytic enzymes is increased during 
hypoxia (Webster et al., 1987). Hypoxia-induced upregulation of anaerobic 
glycolysis is demonstrated in the expression of the monocarboxylate transporter 
type-1 (MCT -1) in an ischemic human retinal model, in response to the high 
concentrations of lactate generated via enhanced anaerobic glycolysis (Knott et al., 
1999). This adaptive response to hypoxia also involves the activation of genes that 
facilitate glucose transport and utilisation (Gleadle & Ratcliffe, 1998). 
However, hypoxia is not the only trigger for anaerobic glycolysis. In 
cancer, the preferred pathway of energy production is anaerobic glycolysis, even 
under normoxic conditions, a phenomenon known as the Warburg effect (reviewed 
by Semenza, 2000b ). Elevated hexokinase (HK) and phosphofructokinase (PFK) 
activity are hallmarks of many cancer cells. PFK is also stimulated by insulin and 
other growth factors under normoxic conditions (Feldser et al., 1999). 
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Figure 1.1 The anaerobic glycolytic pathway. Anaerobic glycolysis is the 
transformation of glucose to lactate when limited amounts of oxygen ({h) are 
available. It is less efficient than aerobic glycolsis, producing only 2 A TP 
molecules per glucose molecule, or about 5% of glucose's energy potential (38 ATP 
molecules). The pH in the cytoplasm quickly drops when lactic acid accumulates, 
eventually inhibiting enzymes involved in glycolysis. The liver later gets rid of this 
excess lactate by transforming it back into an important glycolysis intermediate 
called pyruvate. 
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1.3.3.2 The sorbitol pathway 
Elevated glucose levels produce increased flux through the sorbitol (or 
polyo1) pathway, with resultant de novo synthesis of diacylglycero1 (DAG), which 
activates protein kinase C (PKC) isoforms (Williamson et al., 1993). The rate-
limiting enzyme of the sorbitol pathway, aldose reductase (AR), is widely 
distributed in the mammalian tissues susceptible to diabetic complications (Collier 
et al., 1991 ), linking vascular and neural damage associated with diabetes with 
hyperglycaemia via sorbitol pathway-linked enzyme modulator dysfunction 
(Williamson et al., 1992). 
To combat increases in oxidative stress, it is necessary for the cell to 
increase its production of reduced nicotinamide adenine dinucleoide phosphate 
(NADPH) and nicotinamide adenine dinucleotide (NADH). These molecules serve 
as cofactors for antioxidant enzymes and for maintaining high levels of reduced 
glutathione (GSH), which is the major antioxidant of the cell. 
The sorbitol pathway involves an increase in the NADHINAD ratio as a 
consequence of increased oxidation of sorbitol to fructose and stimulation of the 
pentose phosphate shunt (PPP) as shown in figure 1.2. Altering the redox state of 
the cell decreases its ability to deal with oxidative stress and leads to accumulation 
of triose phosphate intermediates and de novo synthesis of the second messenger 
DAG, which activates some of the PKC isoforms (ldris et al., 2001). 
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Figure 1.2: The sorbitol pathway. Alteration in redox state as a result of 
oxidation ofNADH to NAD+ during conversion of glucose to fructose. Increased 
fructose levels result in osmotic changes and formation of advanced glycation end 
products and non-enzymatic fructosylation. AR- aldose reductase, SDH- sorbitol 
dehydrogenase, PPP-pentose phosphate pathway. 
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1.3.3.3 Kinase/phosphatase pathways 
Mitogen activated protein kinase (MAPK) pathways, phosphoinositol-3 
protein kinase (Pi3K) pathways and protein kinase C (PKC) are sensitive to 
elevated glucose levels (Campbell et al., 2003; Nakamura et al., 2001). 
The p42/44 MAPKs are believed to play a major role in the manner by 
which many mitogens transduce their extracellular signals into intracellular 
responses. These kinases are ubiquitously expressed and activated in response to 
many different growth factors by a cascade of sequential protein phosphorylation. 
Other MAPK homologs such as c-jun, NH-2 terminal kinase (JNK) and p38 MAPK 
are activated by distinct but parallel phosphorylation cascades. The transcriptional 
and post-transcriptional response of c-jun to hypoxia has been reported in various 
normal and transformed cells (Ausserer et al., 1994; Alfranca et al., 2002). The 
relationship between c-jun, glucose and oxygen is seen in the superinduction of c-
jun mRNA and protein expression during simultaneous oxygen and glucose 
deprivation by an apparent oxidative stress related pathway (Ausserer et al., 1994). 
Oncogenic transformation is characterised by the gain of function in growth 
promoting oncoproteins and loss of function in growth attenuating tumour 
suppressor proteins, both of which are seen in the signalling pathway mediated by 
Pi3K (Jiang et a/,. 2000). Pi3K acts through phosphorylating inositollipids, 
producing phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-
trisphosphate. Pi3K is linked via its regulatory subunit p85 to upstream receptors 
that are activated by growth factors or insulin. A downstream target ofPi3K is the 
serine threonine-kinase, Akt, that is activated by phosphatidylinositol-dependent 
kinase 1 (Chan et al., 1999; Vanhaesebroeck & Alessi, 2000). The mammalian 
target of rapamycin, m TOR, situated downstream of Akt is also subject to enhanced 
kinase activity in response to elevated glucose, resulting in upregulation of protein 
translation and cell cycle progression (Xu et al., 2003). 
Studies performed in vivo and in vitro have established a link between the 
cell-damaging effects of high glucose concentration and/or elevation in intracellular 
PKC (Shiba et al., 1993). The activation of PKC in the presence of high glucose 
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concentrations has already been shown to be an important pathway by which 
glucose toxicity may be mediated in retinal cells. This is also suggested by the 
finding that increased glucose metabolism increases intracellular calcium and 
cAMP linked to p42/44 MAPK and p70 activation in pancreatic beta cells (Briaud 
et al., 2003). Glucose-potentiated vascular smooth muscle cell (VSMC) 
chemotaxis and associated morphological changes are dependent on the Pi3K and 
p42/44 MAPK pathways, and also on cross-talk between these pathways (Campbell 
et al., 2004). VSMC speed and direction of migration, and adhesion via focal 
adhesion kinase (F AK) in response to elevated glucose is modified by PKC, and 
therefore has implications for the formation of atherosclerotic plaques in the 
diabetic patient (Campbell et al., 2005). 
Several mechanisms are known to be responsible for upregulation of the 
Pi3K pathway in human cancer, for example the gene coding for the catalytic 
subunit of Pi3K is amplified in cervical carcinoma (Ma et al., 2000) while the 
tumour suppressor phosphatase and tensin homologue (PTEN) is frequently lost in 
glioblastoma and endometrial cancer (Cantley et al., 1999; Besson et al., 1999). 
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Figure 1.3: Interaction between protein kinase signalling pathways in 
response to elevated glucose. Synthesis of DAG via the sorbitol pathway 
stimulates PKC dependent induction of MAPK and Pi3K cascades, which, through 
the activation of downstream targets, may contribute to the pathogenesis of 
atherosclerosis, a significant complication associated with diabetes (as adapted 
from Campbell et al., 2005). 
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1.3.3.4 Advanced glycation end products (AGE) 
Advanced glycation end products (AGE) result from the non-enzymatic 
glycation of amines in response to glucose binding to protein which accumulates in 
vascular tissue during diabetes and aging. At the tissue and cellular level, AGE 
affects many biochemical processes, including increased cell membrane 
permeability and matrix changes. Diabetic nephropathy is seen to be synergistic 
with atherosclerosis, whereby accumulation of AGE in blood vessel walls and on 
lipoproteins may result in increased vascular permeability, increased uptake of 
cholesterol and acceleration of atherogenesis (Manske, 1993 ). In experimental 
diabetes, the interaction of circulating AGE and endothelial AGE receptors (RAGE) 
appear to mediate microvascular leakage, possibly via AGE-RAGE-dependent 
enhanced oxidant stress (Bonnardel-Phu et al., 1999). 
1.4 Role of the vascular endothelium in diabetic complications 
1.4.1 Physiology of the vascular endothelium 
The vascular endothelium primarily has a barrier function, whereby 
endothelial cells (EC) make up the continuous layers of cells linked by tight 
junctions which line the blood vessels. It has enormous power of regeneration, as 
seen through the reassembly of its cytoskeletal F-actin filaments within a 3 hour 
recovery period following almost complete destruction by energy depletion (Kuhne 
eta/., 1993). 
Numerous endothelial cell derived products, such as vasoactive mediators, 
affect the functioning of other cells, including muscle, leukocyte and platelet cells 
(reviewed by Michiels et al., 2000). Due to its location as the first line of contact 
with the blood, ECs are susceptible to changes in the substances contained in blood. 
As such, poorly controlled blood glucose promotes endothelial cell dysfunction and 
is a major factor in the development of micro and macrovascular disease associated 
with diabetes mellitus. 
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1.4.2 Mediators of dysfunction of the vascular endothelium 
Glucose concentration and oxygen availability are able to influence a 
number of parameters within the endothelium, including regulation of the 
expression and responsiveness of cells to reactive oxygen species (ROS), adhesion 
molecules, vasoactive enzymes and growth factors, all of which in turn mediate 
changes in cell growth. 
1.4.2.1 Reactive oxygen species (ROS) 
ROS are elevated by metabolic changes in diabetes, including auto-
oxidation and increased advanced glycation. Local formation ofROS by ECs 
initiates a host of unwanted effects, and free radical generation has been implicated 
in various pathological changes associated with hyperglycaemia. Dietary 
antioxidants may be effective in combating diabetic pathologies. This is further 
elucidated through the findings that antioxidant treatment with lipophilic 
scavengers such as butylated hydroxyl-toluene, probucol and vitamin E, or more 
hydrophilic agents such as a-lipoic acid and acetyl cysteine, can prevent or reverse 
nerve conduction velocity deficits in diabetic rats (Cameron & Cotter, 1999) and 
lessen the oxidative damage caused by dysregulation of glucose metabolism in 
NIDDM (Ruhe & McDonald, 2001). 
1.4.2.2 Neutrophil attraction and adherence 
Perhaps the most marked effect of hypoxia on ECs is the increased ability to 
attract neutrophils. The binding of leukocytes to the ECs is mediated by several 
adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1 ), along 
with chemoattractant/activator molecule interleukin-8 (IL-8) or platelet-activating 
factor (P AF). P AF is a neutrophil activating agent, promoting neutrophil 
adherence to the endothelium following hypoxia or ischaemia. During conditions 
of inflammation, endothelial E-selectin also mediates transient adhesion between 
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ECs and leukocytes (Bevilacqua et al., 1989), an action which may be attributable 
to hypoxia-induced upregulation ofE-selectin during states of inflammation (Zund 
et al., 1996). The contact of neutrophils with the activated endothelium not only 
results in adherence and activation, but also delays apoptosis, thereby prolonging 
the life of the endothelial cell in a hypoxic environment (Ginis & Faller, 1997). 
1.4.2.3 Vasoactive substances 
Hypoxia differentially affects vascular tone by regulating the release of 
vasorelaxing molecules e.g. nitric oxide (NO) and prostacyclin, and 
vasoconstricting molecules, such as endothelin-1 (ET -1 ). The result of this 
regulation is to create conditions favourable to vasoconstriction (Kourembanas & 
Bernfield, 1994), inhibiting the release ofvasorelaxing molecules, possibly through 
a decrease in endothelial nitric oxide synthase (eNOS) expression. In hypoxic 
ECs, an initial decrease in the second messenger cyclic adenosine monophosphate 
(cAMP) levels may be linked to increased vascular leakage, resulting in an increase 
in cytosolic calcium, which in turn may activate vasoactive enzymes such as 
bradykinin, histamine or phospholipase A2. It has also been suggested that cyclo-
oxygenase-2 (COX-2) expression is induced via nuclear factor KB (NF-KB) in 
hypoxic ECs (Schmedtje et al., 1997). 
1.4.2.4 Growth factors 
Glucose-mediated increased levels of transforming growth factor-P (TGF-P) 
protein and mRNA levels have been demonstrated in human retinal endothelial 
cells (HREC) (Pascal et al., 1999). TGF-P inhibits endothelial cell proliferation by 
blocking progression through the cell cycle to the S-phase. Therefore, decreased 
TGF-P bioavailability and the resultant reduction in endothelial growth inhibition 
may also allow uncontrolled cell growth in response to other growth factors, as 
observed in the proliferative phase of DR. TGF-P is also a potent chemotactic 
agent for peripheral blood monocytes (W ahl et al., 1987) thus representing an 
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indirect role for TGF-~ in the disease process within retinal endothelial cells, due to 
the association between monocytes and microaneurysms in the retina. 
Hypoxic regulation of vascular endothelial growth factor (VEGF) occurs in 
most cell lines and tissues, and is widely recognised as the primary angiogenic 
factor responsible for EC mitogenesis and capillary proliferation (Shweiki et a/, 
1992). The ability ofVEGF to induce ICAM-1 and eNOS, clearly demonstrates the 
involvement of VEGF in the initiation of early diabetic retinalleukocyte adhesion 
and consequent vascular damage in vivo (Joussen et al., 2002). 
Expression of the components of the insulin growth factor (IGF) system, 
including IGF-1, IGF binding proteins (IGFBP) and IGF-1 receptor (IGF-1R) in 
ECs is regulated by various conditions, including vascular origin, hypoxia (Tucci et 
al., 1998), TGF-~1 and VEGF (Dahlfors et al., 2000). 
Hyperglycaemia and IGF-1 stimulate EC migration and tubular formation 
(Shigematsu et al., 1999). The relationship between hyperglycaemia and IGF-1 
may therefore account for the observation of a strong migratory response of bovine 
corneal endothelial cells (BCEC) toward D-glucose at concentrations exceeding 
10mM (Vogel et al., 1993). IGF-1 has also been reported to inhibit 
phosphorylation pathways in bovine retinal endothelial cells (BREC) exposed to 
high glucose, thereby exerting a protective effect on the cell (McBain et al., 2003) 
through coupling cell proliferation with glucose delivery (DeBosch et al., 2001). 
The role of the IGF-1 system in diabetic retinopathy is unclear (Wang et al., 
1995). Although IGFs are important modulators of cellular proliferation and 
differentiation, it has been suggested that the insulin-like growth factor binding 
protein (IGFBP), as opposed to IGF, may be the dominant paracrine regulator of 
proliferation of EC, as well as maintenance of endothelium integrity during hypoxia 
(Tucci et al., 1998) as bovine macro and microvessel ECs widely display IGFBP-2 
through to BP-6 (Moser et al., 1992). Furthermore, in human retinal ECs, long 
term exposure to high concentrations of glucose was able to reduce IGF-1-induced 
mitogenesis by decreasing the expression of stimulatory IGFBPs, while leaving the 
concentration of the inhibitory IGFBP-4 constant (Giannini et al., 2001). 
- 18 -
1.4.2.5 EC receptors 
In the diabetic endothelium, the activity ofreceptors is central to the tissue's 
ability to regenerate following assault from the complications associated with poor 
glucose control. 
In human diabetic ischaemic cardiomyopathy, expression of the VEGF 
receptors, flt-1 and flk-1, were significantly lower compared to non-diabetic 
coronary heart disease patients, although VEGF expression was higher. This was 
accompanied by reduced signal transduction, which may account for the reduced 
neoangiogenesis in diabetic patients with ischaemic cardiomyopathy (Sasso et al., 
2005). 
Diabetic ulcers display distinct alterations in reparative angiogenesis. This is 
demonstrated in dermal endothelial cells through the down-regulation of tyrosine 
kinase receptor-A (Trk-A) in cutaneous wounds of type 1 diabetic mice, thus 
preventing endothelial cell proliferation (Graiani et al., 2004). 
Both macrovessel and microvessel ECs express the IGF-1 receptor (IGF-
1R) (Boes et al., 1991) to which IGF-1 binds to exert all of its known physiological 
effects (LeRoith et al., 1995). Although ECs express both IGF-1R and the insulin 
receptor (IR), the vasodilation induced by insulin might be mediated primarily via 
its stimulatory effect on the IGF-1R, which in certain micro and macrovascular EC 
lines is more abundant than IR (Chisalita et al., 2004). In STZ-diabetic rats, aortic 
IGF-1 mRNA has been seen to be unaffected, whereas IGF-1R mRNA was greatly 
increased, and aortic vasorelaxation was significantly greater in STZ- rats compared 
to age-matched control. Furthermore, insulin treatment not only reduced 
endothelial dysfunction in these rats, but also further increased IGF-lR expression 
(Kobayashi et al., 2002). 
In a spontaneous rat model of diabetes, vascular TGF-P receptor type 11 was 
expressed to a greater extent in pre and early stages of diabetes compared to age 
matched controls, which was associated with hyperinsulinaemia and vascular 
thickening (Hosomi et al., 2002). Recently, the TGF-P receptor type V signalling 
cascade, which eo-expresses with TGF-P receptors I, 11 and Ill, was found to cross-
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talk with other TGF-~ receptor, insulin receptor and IGF-1 receptor cascades, which 
may represent a new level of control over the responsiveness of the vascular tissue 
to diabetes-induced assault (Huang & Huang, 2005). 
1.4.2.6 Hypoxia 
In differentiated human umbilical vein endothelial cells (HUVEC) exposed 
to reduced oxygen, the initiating event of EC activation is a decrease in the activity 
of the mitochondrial respiratory chain activity (Janssens et al., 1995). The 
inhibition of mitochondrial oxidative phosphorylation alone, however, is not always 
sufficient to produce the effects of hypoxia. This is true in the case of gene 
expression in response to activation of the mediator ofhypoxia inducible 
transcription, hypoxia inducible factor-1 (HIF -1 ). 
HIF-1 is directly responsible for the induction of several hypoxia-inducible 
genes, many of which are potential contributors to the development of diabetic 
endothelial dysfunction, due to their central role in glucose transport and 
metabolism, angiogenesis, cell proliferation and survival. 
As already considered in this section, activation of ROS and subsequent 
~edox-sensitive expression ofVEGF, ET-1, inflammatory cytokines and adhesion 
molecules, combined with diminished NO bioavailability, leads to exaggerated 
endothelial cell damage and dysfunction. This process, at least in part, is thought to 
involve the participation of HIF-1 (Lavie, 2003). 
Therefore, expression of the factors implicated in the generation of 
endothelial cell dysfunction may be subject to HIF-1-mediated regulation, triggered 
by a state of pseudohypoxia generated in response to increased metabolic demand 
placed upon the cells subjected to pathologically high concentrations of glucose, 
such as would occur in poorly controlled diabetes. 
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1.5 Hypoxia Inducible Factor-1 (HIF-1) 
1.5.1 The HIF family 
HIF belongs to the basic helix-loop-helix (bHLH) /Per-ARNT-Sim (PAS) 
superfamily of eukaryotic transcription factors, which are made up of two proteins 
known as a, or the inducible sub-unit, and the aryl hydrocarbon receptor nuclear 
translocator (ARNT) or~ sub-unit. On activation, the two sub-units heterodimerise 
forming the functional HIF transcription factor. Under certain conditions, 
classically hypoxia, the functional transcription factor persists. Under normoxic 
conditions, it is targeted for degradation via the von Hippel-Lindau (pVHL) tumour 
suppressor protein (Maxwell et al., 1999). 
1.5.1.1 HIF-2 and HIF-3 
Although HIF-1 has been the most thoroughly researched, and will be the 
subject of the following investigation, there are two further members of the HIF 
family, termed HIF-2 and HIF-3. 
HIF-2a has a close sequence homology and similar properties to HIF-1a, 
and was initially described as endothelial and foetal specific (Wenger & Gassman, 
1997). Subsequently, along with HIF-la, HIF-2a was seen to be involved in the 
promotion of oncogene transformation, via induction ofVEGF in human breast 
cancer (Blancher et al., 2000), and human bladder cancer (Jones et al., 2001). 
Moreover, target gene expression and migration of renal carcinoma cells has been 
reported to be critically dependent upon HIF-2a (Sowter et al., 2003). Target genes 
dependent upon HIF-2a expression in renal carcinoma include VEGF, GLUT-I and 
plasminogen activator receptor (Carroll & Ashcroft, 2006). In non-cancerous cells, 
marked hypoxic induction of HIF-2a has also been identified in distinct cell 
populations of different organs in the rat, including brain, heart, lung, liver, 
pancreas and intestine (Wiesner et al., 2002). In the ischaemic brain, HIF-2a was 
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seen to mediate the transcriptional activation of EPO expression in astrocytes, 
thereby promoting neuronal survival during ischaemia (Chavez et al., 2006). 
The third a-class ofHIF subunit, HIF-3a, was first isolated in mouse in 
1998. The human homologue subsequently revealed high homology to HIF-la and 
HIF-2a (Hara et al., 2001), and was shown to have at least 6 alternatively splicing 
variants. Human HIF-3a is strongly expressed in heart, placenta and skeletal 
muscle, and weakly expressed in lung, liver and kidney. As is the case with HIF-la 
and -2a, the von Hippel-Lindau tumour suppressor (pVHL) is intricately involved 
in the regulation ofHIF-3a. It is not yet known whether the splice variants ofHIF-
3a are capable of transcriptional activation of genes not regulated by HIF-la or 
HIF-2a (Maynard et al., 2003). 
1.5.1.2 HIF-1 
HIP-la is the inducible subunit of the heterodimer, the regulation of which 
controls dimerisation and transactivation of HIF-1, as opposed to HIF-1 ~ which is 
constitutively expressed in the nucleus (Wang & Semenza, 1995). The N-tenninal 
half of HIF -1 a contains bHLH and PAS domains that are required for dimerisation 
and DNA binding. The C-terminal half contains domains required for degradation 
and transactivation; these are the oxygen dependent degradation domain (ODDD) 
which confers oxygen-dependent instability, two independent transactivation 
domains (TAD), N-TAD and C-TAD, separated by an inhibitory domain (ID) that 
negatively regulates the transactivation domains (Jiang et al., 1996). 
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Figure 1.4: Structure of HIF-1. Important functional domains of the HIF-1a and 
HIF-1 ~ subunits are indicated as follows: bHLH, basic-helix-loop-helix domain; 
ID, inhibitory domain; NLS-N and NLS-C, amino- and carboxyl- terminal nuclear 
localisation signal; PAS, Per-ARNT-Sim homology domain with internal A and B 
repeats; PSTD, proline-serine-threonine-rich protein stability domain which is 
targeted by the prolyl hydroxylases; ODDD, oxygen dependent degradation 
domain; C-TAD and N-TAD, amino- and carboxyl-terminal transactivation 
domain; REF-1 , redox factor 1; TRX, thioredoxin. The double headed arrow 
indicates that reduction of Cys800, which is mediated by REF-1 and TRX, is 
required for the interaction of the C-TAD with co-factor p300 or C terminal 
binding protein (CBP) (as adapted from Semenza, 2000b). 
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1.5.2 Role ofHIF-1 in the induction of hypoxia-responsive genes 
Hypoxia induces the expression of different genes whose products augment 
non-oxidative synthesis of ATP, increase the oxygen-carrying capacity of blood and 
multiply the number of capillaries irrigating the hypoxic tissue. All of these 
responses are considered to have physiological importance as they are adaptive, 
easily reversible and elicited with moderate levels of hypoxia. 
At the cellular level, adaption to hypoxia involves a shift from oxidative 
phosphorylation to anaerobic glycolysis, increased glucose metabolism and 
expression of hypoxic stress-related proteins. The most widespread molecular 
mechanism of hypoxia-dependent regulation is transcriptional induction of several 
groups of genes with well defmed roles in oxygen supply and/or metabolism via the 
binding of hypoxia-inducible factor-1 (HIF-1) (Wang et al., 1995b). Analysis of 
the 5' flanking region of many of these genes revealed a sequence consensus to 
HIF-1 (5'-RCGTG-3'), termed the hypoxia response element (HRE) situated 
upstream of the transcription initiation site. 
Over 70 HIF-1 regulated genes have been identified to date, the protein 
products of which play key roles in angiogenesis, vascular reactivity and 
remodelling, glucose and energy metabolism, along with cell proliferation and 
survival, shown in table 1.1 (Semenza, 2000c ). 
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Gene Product Function 
Adenylate kinase 3 Nucleotide metabolism 
a 18-adrenergic receptor Vascular tone 
Adrenomedullin Vascular tone, cell survival 
Aldolase A Glucose metabolism 
Aldolase C Glucose metabolism 
Carbonic anhydrase 9 pH regulation 
Ceruplasmin Irom metabolism 
Endothelin-1 (ET -1) Vascular tone and remodelling 
Enolase- I Glucose metabolism 
Erythropoietin Erythropoiesis, cell survival 
Glucose transporter 1 Glucose metabolism 
Glucose transporter 3 Glucose metabolism 
Glyceraldehyde-3-P-dehydrogenase (GAPDH) Glucose metabolism 
Haem oxygenase-! Vascular tone, cell survival 
Hexokinase 1 Glucose metabolism 
Hexokinase 2 Glucose metabolism 
Insulin-like growth factor (IGF) Cell proliferation and survival 
IGF-binding protein 1 Cell proliferation and survival 
IGF-binding protein 2 Cell proliferation and survival 
IGF-binding protein 3 Cell proliferation and survival 
Lactate dehydrogenase A Glucose metabolism 
Nitric oxide synthase 2 (NOS 2) Vascular tone, cell survival 
NIP3 Apoptosis 
p21 Cell proliferation 
p35srj Regulation ofHIF-1 activity 
Phosphofructokinase L Glucose metabolism 
Phosphoglycerate kinase I Glucose metabolism 
Plasminogen activator inhibitor 1 Angiogenesis 
Prolyl-4-hydroxylase a Collagen metabolism 
Pyruvate kinase M Glucose metabolism 
Transferrin Iron metabolism 
Transferrin receptor Iron metabolism 
Transforming growth factor ~3 (TGF- ~3) Angiogenesis, cell proliferation 
Triosephosphate isomerase Glucose metabolism 
Vascular endothelial growth factor (VEGF) Angiogenesis, cell survival 
VEGF receptor flt-1 Angiogenesis 
Table 1.1 Genes targeted for HIF-1-induced expression (as adapted from 
Semenza, 2000c) 
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1.5.2.1 Growth Factors and HIF-1 
The activity ofHIF-1 as the control centre for the hypoxic response was first 
observed through its ability to bind to the HRE of the primary regulator of 
mammalian erythropoiesis, erythropoietin (EPO) (Semenza & Wang 1992). 
Further to this, HIF-1 and its recognition sequence were found to be a common 
component of the mammalian cellular response to hypoxia, due to its activation in a 
variety of cell lines in which EPO is not expressed (Wang & Semenza 1993). 
The potent and specific endothelial cell mitogen, vascular endothelial 
growth factor (VEGF) is also activated by HIF-1 in hypoxic cells (Forsythe et al., 
1996). Hypoxia regulates expression of VEGF by increasing its transcription and 
by stabilizing its mRNA, through interaction with HIF-la. (Liu et al., 2002). As the 
primary angiogenic factor responsible for endothelial cell mitogenesis and capillary 
proliferation (Shweiki et al., 1992), inhibition ofVEGF may prove useful in the 
treatment of proliferative diabetic retinopathy, indicated by the ability ofVEGF to 
induce ICAM-1 and endothelial NOS which initiate early diabetic retinalleukocyte 
adhesion and consequent vascular damage in vivo (Joussen et al., 2002). 
1.5.2.2 Glucose Transporters and HIF-1 
A family of glucose transporters (GLUT) mediate the entry of glucose into 
cells; therefore an important factor in glucose delivery would involve the regulation 
of the expression and subcellular distribution of the glucose transporters. Two 
specific isoforms, GLUT-I (Mandarino et al., 1994) and GLUT-3, have both been 
detected in bovine retinal endothelial cells at the mRNA and protein levels (Knott et 
al., 1993). Later, both were detected at the level ofmRNA (Knott et al., 1996a) 
and protein (Knott et al., 1996b) in human retinal endothelial cells (HREC), 
although ,to date, only GLUT -1 has been detected in vivo. 
Upregulation of the insulin-independent GLUT -1 is stimulated during 
hypoxia in order to deliver more glucose for glycolysis. Through 
immunohistochemical staining, GLUT-I protein expression has been demonstrated 
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to be absent in the neovascular retina of people with PDR. As GLUT -1 expression 
is characteristic of tissues that posses a barrier function, the loss of selective 
permeability characteristic of PDR may be associated with an absence of facilitated 
glucose transport (Kumagai et al., 1994). 
In the endothelium of hypoxic brain tissue, expression of GLUT -1 and 
GLUT-3 has been seen to increase via HIF-1 induced transcription (Vannucci et al., 
1996). More recently, GLUT -1 has been found to be up-regulated under low 
oxygen in placental cell lines through HIF-1 interaction with a consensus HRE site 
of the GLUT-I promoter (Hayashi et al., 2004). 
1.5.2.3 Glycolytic enzymes and HIF-1 
As anaerobic glycolysis generates less ATP than oxidative phosphorylation, 
the enzymatic activity and gene expression of glycolytic enzymes is increased 
during hypoxia (Webster et al., 1987). This adaptive response to hypoxia involves 
the activation of genes that facilitate glucose transport and utilisation (Gleadle & 
Ratcliffe 1998). 
The rate-limiting enzyme in glucose metabolism, hexokinase 11 (HKII) is 
selectively regulated by HIF-1-dependent mechanisms in both normal and 
transformed cell lines (Riddle et al., 2000; Mathupala et al., 2001). In liver cancer, 
induction ofHIF-1a and HKII was not accompanied by an increase in VEGF, 
therefore indicating increased anaerobic glycolysis to be the primary target, as 
opposed to increased vascularisation (Y asuda et al., 2004). 
Anaerobic glycolysis is highly dependent upon the key regulator of carbon 
flux through glycolysis, fructose-2, 6 bisphosphate (F-2, 6-BP) (Kawaguchi et al., 
2001), which is a potent allosteric regulator of the key enzyme in glycolysis, 
phosphofructokinase (PFK-1). The activity ofF-2, 6-BP has been shown to be 
dependent upon HIF-1a expression, as both share many common induction 
pathways, including the hypoxia mimicking agents, cobalt and DFO. Induction was 
also replicated by inhibiting the prolyl hydoxylases responsible for the pVHL-
dependent destabilisation ofHIF-1a. The apparent dependence ofF-2,6-BP on 
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HIF-1a was further confirmed by its over-expression in pVHL-deficient cells, and 
lack of hypoxic induction in HIF-1a null mouse embryo fibroblasts (Minchenko et 
al., 2002). 
Cultured ECs exposed to hypoxia upregulate glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). GAPDH catalyses the sixth step in glycolysis: the 
conversion of glyceraldehydes-3-phosphate to 1, 3 bisphosphoglycerate, generating 
a high energy phosphate compound in an oxidation-reduction reaction. Although 
not a primary regulatory site for glycolysis, the activity of GAPDH is inhibited by 
several glycolytic metabolites, other small molecules and by association with cell 
membranes (Wang et al., 1980). GAPDH expression is regulated by hypoxia 
primarily at the level of transcription. The regulation of GAPDH by hypoxia 
appears to be cell-specific and involves HIF-1a (Graven et al., 2003). For 
glycolytic function, GAPDH is upregulated in the cytosolic fraction of hypoxic EC. 
However, increased levels of GAPDH has also been detected within the nuclear 
fraction, suggesting a non-glycolytic function, which may be related to the relative 
hypoxia tolerance of EC, which can survive for at least 96 hours in 0% oxygen 
(Graven & Farber, 1995). 
1.5.3 Mechanisms involved in the hypoxic regulation ofHIF-la expression 
1.5.3.1 Oxygen sensing 
Diverse oxygen sensing mechanisms have been proposed to mediate the 
hypoxic transcriptional response ofHIF-1a (Semenza, 1999). A number of these 
models implicate an iron-containing unit, in the form of either a haem group or an 
iron/sulphur cluster, which undergoes change on activation (Goldberg et al., 1998). 
The support for such a model is seen in the response to cobalt, which causes 
similar induction of hypoxia responsive genes through replacing iron in the 
synthesized porphyrines, but due to its poor ability to bind 0 2, it locks the haem 
protein into the deoxy form, thus mimicking hypoxia. Furthermore, the iron 
chelator desferrioxamine (DFO) is also able to stabilise HIF-a under non-hypoxic 
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conditions (Semenza, 1999) by replacing or removing the central iron of the 
putative haem oxygen sensor (Wenger, 2000). Carbon monoxide has a high 
binding affmity for the iron in haem molecules, also locking the haem protein in the 
deoxy conformation and substantially attenuating the hypoxic induction of EPO and 
VEGF mRNAs (Goldberg & Schneider, 1994). CO and NO are both haem binding 
ligands, both target the internal oxygen dependent degradation domain ofHIF-la 
and repress the C-terminal transactivation domain, therefore abrogating the hypoxic 
accumulation ofHIF-la protein (Huang et al., 1998). 
However, the lack of identification of specific proteins with this role in 
mammalian cells may discount this as a stand alone mechanism. It has been 
hypothesised that activation ofHIF-la associated with iron deficiency may be 
responsible for increased glucose tolerance in iron-deficient animals (McCarty, 
2003). This theory would rationalize previous studies in which glucose uptake was 
increased in iron-deficient animals and cells (Brooks et al., 1987). Increases in 
both haematocrit and body iron stores appear to be associated with 
hyperinsulinaemia and increased IGF-1, both characteristics of insulin resistance. 
Activation of HIF-1 a in this case may rationalise the finding that iron excess 
mediates some of the increased cancer risk associated with insulin resistance 
(Facchini et al., 1998). 
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Figure 1.5: Control of signalling through HIF-la in response to changing 0 2 
levels (as adapted from a review by Kewley et al., 2004). 
- 30-
ARNT 
1.5.3.2 Stabilisation ofHIF-la 
Despite early findings of increased expression of HIF-1 a and p mRNAs in 
the lungs of mice exposed to acute or chronic hypoxia (Wiener et al., 1996; Palmer 
& Johns, 1998), more recent evidence suggests that hypoxic regulation of HIF-1 a 
occurs not at the transcriptional level, but post-transcriptionally by protein 
stabilisation (Ratcliffe et al., 1998). This process is rapid, as exposure of human 
non-adherent HeLaS3 cells to hypoxia for less than 2 minutes revealed expression 
of nuclear HIF-1a protein induction and HIF-1 DNA binding (Jewell et al., 2001). 
Under normoxic conditions HIF-1 a protein is very unstable, with a half life 
of less than 5 minutes (Richard et al., 1999). Levels are kept low by means of a 
degradation system which is inactivated in response to hypoxia, therefore allowing 
accumulation ofHIF-1a protein. As shown in figure 1.5, direct hydroxylation of 
prolyl residues by prolyl hydroxylases (PHDs) triggers the degradation ofHIF-la 
under normoxic conditions. The PHDs are iron dependent enzymes that convert 
proline into hydroxyproline, a reaction which requires oxygen and 2-oxoglutarate 
(Epstein et al., 2001, Bruick & McKnight, 2001). 
Hydroxylation of the two conserved proline residues, Pro 402 and Pro 564 
within the ODDD, directs HIF-1a for degradation by the von Hippel-Lindau 
(pVHL) tumour suppressor protein under normoxic conditions (Maxwell et al., 
1999). The protein product of the von Hippel-Lindau gene serves as a recognition 
component for an E3-ubiquitin ligase complex that binds to and targets HIF-1a 
protein for proteolysis, thus preventing transcriptional activation of its target genes. 
Hydroxylation and subsequent interaction of p VHL with HIF-1 a, is inhibited under 
hypoxic conditions, resulting in stabilisation and accumulation of the HIF-1a 
protein (Yu et al., 1998; Jaakkola et al., 2001; lvan & Kaelin, 2001). 
In addition to inhibition of degradation, stabilisation of HIF -1 a protein 
depends upon the binding of transcriptional eo-activator proteins. Nuclear p300 
and CREB binding protein (CBP) are homologues of ubiquitously expressed 
proteins which possess histone acetyl-transferase activity (HAT) (Carrozza et al., 
2003). Transactivation ofHIF-1a requires the C-TAD ofHIF-1a to interact with 
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transcriptional eo-activator proteins, such as CBP and p300. This high affinity 
binding involves almost the entire C-TAD ofHIF-1a and extensive intermolecular 
hydrophobic interactions are formed between the C-TAD and CBP/p300, thus 
contributing to the stability of the complex (Dames et al., 2002). The binding of 
these proteins serves two functions, as a physical link between HIF-1a and the 
initiation complex of the target gene, and chromatin remodelling through their 
intrinsic acetyltransferase activity, which is required for gene transcription 
(reviewed by Semenza, 1998). Under normoxic conditions this interaction is 
blocked by hydroxylation of the asparagine residue Asn-803 within the C-T AD 
(Lando et al .. 2002). Other histone acetyltransferases, steroid-receptor coactivator-
1 (SRC-I) and transcription intermediary factor-2 (TIF-2) also interact with HIF-
la., enhancing activity in a synergistic manner with p300 (Carrero et al., 2000). 
1. 5.3 .3 Inhibition and competitive binding 
Originally considered to be a factor inhibiting HIF-1 (FIH-1) (Mahon et al., 
2001 }, FIH-1, which is an asparaginyl hydroxylase, has more recently been 
identified as an oxygen sensor involved in HIF-1a regulation (Lando et al., 2002). 
FIH-1 targets the asparagine 803 (Asn-803) residue for hydroxylation, thereby 
repressing transactivation ofHIF-1a. through preventing binding of the 
transcriptional co-factor p300/CBP to the HIF-la C-TAD (Lando et al., 2002). 
Like the PHDs, this hydroxylation enzyme is a member of the 2-oxoglutarate and 
iron-dependent dioxygenase family (Safran &Kaelin, 2003). 
Competition for binding to HIF -1 ~ also regulates the ability of HIF -1 a to 
activate target genes. Full length HIF-1a mRNA contains 15 exons, but a spliced 
varient ofHIF-la mRNA lacking exon 14 (sHIF-1a) has also been discovered 
(Gothie et al., 2000). The truncated HIF-1a. protein translated from the shorter 
mRNA is able to compete with normal HIF-1a protein for HIF-1~, and therefore 
decrease HIF-1 transcriptional activity. 
In renal carcinoma, a natural anti sense of the HIF -1 a. transcript ( aHIF) 
which is complementary to the 3' untranslated region (UTR) ofHIF-1a. has been 
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described (Thrash-Bingham & Tartof, 1999). This sequence does not encode a 
protein, yet it is widely expressed in normal and foetal tissues and has been found 
in breast cancer (Rossignol et al., 2002). The aHIF sequence contains several 
putative HREs so has the ability to create a negative loop of regulation of HIF-1 a 
expression through exposing the AU instability regions within the 3' UTR ofHIF-
la, thus increasing its degradation speed. Previous to these findings, only artificial 
antisense ofHIF-1a was known to inhibit mRNA translation in this manner 
(Caniggia et al., 2000). This potentially has implications for cell growth in a 
chronically hypoxic environment, where long term transcriptional regulation could 
be achieved through greater control via aHIF, rather than post-translational 
modifications of HIF-1 a, which are more suited to short term adaptions (Rossignol 
et al., 2002). 
-33-
Measurement bar (kb) 
100 400 600 800 1000 1100 1400 1600 1800 2000 2200 2400 1600 2800 31100 1100 3400 3600 3800 4000 4200 4400 4600 
AU 
rich 
S' region 3, ~1,12~~3~141~J~617~1J~91~,o~I~~~I-,2~1,J~,J-,s'-ln ______ _ 
3• I I 11 11 Ill 11 Ill 
HIF-lamRNA 
aHIF transcript 
Figure 1.6: Schematic representation ofHIF-la mRNA and its natural 
antisense, aHIF. The position of the 15 exons of the coding region ofHIF-la., the 
AU rich region ofHIF-la. (Genbank accession: U22431) is shown relative to aHIF, 
along with their respective lengths in kb. aHIF is complementary upon at least 
1027 bases of the HIP-la 3'UTR (as adapted from Rossignol et al., 2002). 
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1.5.3.4 Modification ofMAPK- and Pi3K-dependent pathways 
The relationship between MAPK signalling and HIF-1 protein expression 
was first observed by Wang and colleagues in 1995, through the use of the MAPK 
inhibitor Genistein, which resulted in decreased levels of the a and ~ subunits along 
with blocking of the DNA binding complex. MAPK is required for the 
transactivation activity ofHIF-1a, and inhibition ofMAPK disrupts the HIF-1a-
p300 interaction, suppressing the transactivation activity of p300. However, this 
regulation ofHIF-1 transactivation may have little effect on the hypoxic 
accumulation ofHIF-1a (Sang et al., 2003). This theory is supported by reports 
that p42/44 MAPK directly phosphorylate HIF-1a and regulate its transcriptional 
activity with no effect on HIF-1a protein levels induced by hypoxia (Richard et al, 
1999), thus demonstrating co-operation between hypoxia and growth factor signals, 
which ultimately lead to an increase in HIF-1- mediated gene expression (Salceda 
et al., 1997; Conrad et al., 1999; Richard et al., 1999). 
Recently, a functional relationship was found between induction of c-jun 
mRNA, c-jun N-terminal phosphorylation and the presence ofHIF-1a. 
Furthennore, JNK activity was seen to be dependent on enhanced glucose 
utilization mediated by HIF-1, therefore indicating that intracellular glucose levels 
link hypoxia-inducible JNK activity with oxygen sensing (Laderoute et al., 2004). 
Hypoxia-induced HIF-la expression can also be blocked in certain cell 
types, using Pi3K inhibitors such as LY294002 and wortmannin (Chandel et al., 
2000; Zhong et al., 2000). Further to this, several reports have demonstrated that 
the Pi3K/ Akt pathway modulates HIF-1 activation and activity in non-hypoxic cells 
(Zhong et al., 2000, Zundel et al., 2000; Mazure et al., 1997). Subsequently, it has 
been shown that insulin, epidennal growth factor (EGF), mutation in the tumour 
suppressor PTEN (Jiang et al., 2001), IGF-1 (Liu et al., 2001), 4-hydroxy estradiol 
(Gao et al., 2004), HER2/neu and other tyrosine kinases such as EGFR and V -SRC 
(Hudson et al., 2002) specifically increase the protein levels ofHIF-1a in human 
cancer cell lines via Pi3K-dependant pathways. Amplified signalling through Pi3K, 
and its downstream target mTOR, enhanced HIF-1a gene expression in PC-3 
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prostate cancer cell line, also indicting mTOR to be a potential upstream activator 
ofHIF-1 (Hudson et al., 2002). 
1.5.3.5 Redox signalling 
HIF-1 must remain in the reduced state in order to be able to bind to target 
DNA (Wang et al., 1995). Furthermore, redox sensitive stimulation of the HIF-1a 
subunit may be critical for the activation ofHIF-1 (Huang et al., 1996). The 
hypoxia inducible coactivators ofHIF-a are SRC-I and CREB-binding protein. 
These enhance the transactivation potential of HIF -1 a through binding to specific 
domains within the C terminus, the activity of which is strongly potentiated by the 
nuclear redox regulatory protein, redox factor-1 (Ref-1) ( Carrero et al., 2000). This 
finding proved logical, as it had already been established that Ref-1 is implicated in 
the up-regulation ofHIF-1a-dependent induction of gene expression (Huang et al., 
1996). 
However, non-hypoxic induction ofHIF-1-mediated gene expression may 
not follow this trend, as later studies showed VEGF mRNA and HIF-1a induction 
to be independent of ROS in arsenite-induced ovarian carcinoma (Duyndam et al., 
2001 ), or ROS production by nickel or cobalt (Salnikow et al., 2000). 
1.5.3.6 Time course ofHIF-la expression 
As previously described, stabilisation of HIF-1 a protein in response to 
hypoxia is a rapid process, with nuclear expression and target DNA binding evident 
after less than 2 minutes in HeLa cells (Jewell et al., 2001). The time course of 
expression of HIF-1 a may be a significant factor underlying hypoxic disease. An 
extended time course ofHIF-la expression is thought to be an important factor in 
pre-eclampsia (PE), whereby PE villous explants subjected to hypoxia showed 
significantly impaired HIF-la degradation compared to non-PE tissue after 90 
minutes re-oxygenation (Rajakumar et al., 2003). In a model of neonatal rat brain 
hypoxia-ischaemia, HIF-la protein expression peaked at 8h following 90 minute 
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occlusion of the middle cerebral artery, then declined subsequently at 24h in injured 
cortex (Mu et al., 2003). However, Li et al (2005) reported that 1h global 
ischaemia-hypotension in the rat produced a marked increase in HIF-1a 
protein expression in the hippocampus and cortex at 6h, which subsequently peaked 
at 48-96h. In a mouse dorsal skin flap model of segmental hypoxia, HIF-1 a mRNA 
expression was enhanced at 4h hypoxia, maximal at 6h and decreased back to 
normal levels at 8h (Vihanto et a., 2005). A previous study, however, reported that 
permanent focal ischaemia in rat brain induced a significant increase in HIF-la 
mRNA which increased up to 20h (Rosenberger et al., 1999). The Vihanto study 
also showed that after 24h, strong accumulation ofHIF-1a protein occurred in 
endothelial and adjacent cells. 
1.5.4 Non-hypoxic regulation of IDF-la expression 
1.5.4.1 Positive regulation 
HIF-1 activity in several cell types has been reported to be regulated by 
diverse non-hypoxic stimuli including, NO (Kimura et al., 2000), tumour necrosis 
factor-a (TNF-a) (Sandau et al., 2001), insulin, IGF-1 (Zelzer et al., 1998), and 
mechanical stress (Kim et al., 2002). 
Non-hypoxic agents have the capacity to induce HIF-1 activity to an equal 
or greater extent than hypoxia alone, and in contrast to the post-transcriptional 
control of hypoxia-induced HIF-1a stability, these non-hypoxic stimuli have been 
reported to regulate HIF -1 a through transcriptional and translational mechanisms, 
some involving PKC and/or Pi3K signalling (Kim et al., 2002; Kimura et al., 2000; 
Page et al., 2002; Sandau et al., 2001; Zelzer et al., 1998; Zhong et al., 2000). 
Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and 
tumour necrosis factor-a (TNF-a) have all been shown to increase HIF-1a 
expression (Agani & Semenza, 1998; Zelzer et al., 1998; Jeong et al., 2003) by 
pathways with are independent and parallel to that of hypoxia (Feldser et al., 1999). 
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Hypoxia-independent mechanisms by which HIF-la and HIF-1-dependent 
transcriptional activity are induced, could play a major role in vascular remodelling, 
as substantially elevated levels ofHIF-la in response to Angiotensin 11, thrombin 
and platelet-derived growth factor (PDGF) have been detected in vascular smooth 
muscle cells independent of the oxygen environment (Richard et al .. 2000). 
HIF-la is also potently induced by the dietary flavonoid, quercetin, under 
normoxic conditions, in a manner similar to that of hypoxia. This may be 
attributable to the subsequent fmding that HIF-la contains potential 
serine/threonine phosphorylation sites for a variety of kinases, including casein 
kinase 11, which is potently inhibited by quercetin, therefore stabilising HIF-la and 
allowing nuclear localisation of the protein in a transcriptionally active state 
(Wilson & Poellinger, 2002). 
Non-hypoxic activation ofHIF-la may involve the Warburg effect. By this 
mechanism, cancer cells produce lactate and pyruvate, the end products of 
anaerobic glycolysis, even in the presence of oxygen. Lu and colleagues observed 
that lactate and pyruvate were responsible for HIF-la expression in the absence of 
hypoxia, thereby demonstrating the potential implication for regulation ofHIF-la 
via the Warburg effect (Lu et al., 2002). 
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Figure 1.7. Signal transduction pathways leading to the expression ofHIF-1 
and the transactivation of downstream target genes (as adapted from Seme~~a, 
2002 and Zhong et al., 2000). Co-operative induction of signalling pathways in 
response to growth factors modulate the expression of HIF-1 a and subsequent 
transactivation or degradation. 
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Unlike hypoxia, insulin does not stimulate HIF-la accumulation through the 
inhibition of its degradation, but through a translation dependent mechanism 
resulting in increased HIF-la protein expression, augmented HIF-la DNA binding 
activity and HIF-1a stimulated reporter gene transcription. In addition, IGF-1 and 
IGF-2 have been reported to induce expression ofHIF-la. Subsequent expression 
of genes encoding !OF-binding protein-2 and 3 therefore indicate a role for HIF-1 a 
in an autocrine growth factor loop (Feldser et al., 1999). 
The finding that insulin regulates HIF-1a protein expression in a manner 
which is mainly Pi3K/mTOR-dependent (Treins et al., 2002) indicates the potential 
importance of non-hypoxic regulation ofHIF-1a in the pathogenesis of disease 
associated with diabetes. It was subsequently noted that hereguelin, which activates 
the tyrosine kinase receptor HER2located upstream of the Pi3K pathway, 
stimulates HIF-la synthesis in a similar manner to that of insulin (Laughner et a/, 
2001). 
Other receptors are also implicated in the activation and regulation of HIF-1 
expression (see figure 1.7), including epidermal growth factor receptor (EGFR) and 
insulin-like growth factor receptor (IGF-R), via the Pi3K/ Akt/FRAP pathway 
(Zhong et al., 2000; Laughner et al., 2001 ). Expression of the oncogenes m TOR 
and Ras, which are both implicated in Pi3K/MAPK signalling pathways also affect 
HIF-1 activity (Zhong et al., 2000: Treins et al., 2002). It has been noted that Ras 
upregulates the GLUT -1 promoter by increasing HIF-1 a protein levels and HIF-1 
binding (Chen et al., 2000). Furthermore, disruption of the gene encoding Cited2, a 
cAMP-responsive element-binding protein which competes with HIF-la to bind 
CBP/p300, was found to cause over expression ofHIF-la and its target genes, 
coinciding with abnormal neural and cardiac development in mice (Yin et al., 
2002). 
Many factors which contribu'e to the development of diabetic 
complications also affect HIF-la. The vasodilator, prostacyclin, stabilises HIF-la 
by downregulating ROS production in HUVEC (Chang et al., 2005) and the 
chemoattractant interleukin-1 P (IL-l p), is able to activate HIF-1 a mediated 
expression ofVEGF and its receptor VEGF-2 (Amano et al., 2004). In diabetes, 
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the plasminogen activator inhibitor- I (PAI-l) gene is expressed in the arterial wall 
during cell adhesion (Chang et al., 2003) decreasing fibrinolysis and increasing 
thrombogenicity. HIF-1 is a down-stream molecule ofPAI-1, and is also increased 
in the arterial wall in human diabetes (Pandolfi et al., 2001 ), therefore representing 
a potential mechanism contributing to accelerated atherosclerosis. 
1.5.4.2 Negative regulation 
Tumour suppressor gene products, including p VHL, PTEN and p53 are 
known to inhibit HIF-la protein expression (Semenza, 2002a). Interaction of the 
tumour suppressor protein p14ARF with HIF-1 can directly inhibit its transcriptional 
activity by sequestering the a-subunit into the nucleolus (Fatyol & Szalay, 2001 ). 
Progression of colorectal adenocarcinoma correlates with the loss of PTEN tumour 
suppressor activity, increase in HIF-la protein and mRNA and VEGF expression, 
which increased gradually as the pathological stage of cancer advanced (Jiang et al., 
2003). This action ofPTEN may be due to it encoding a specific phosphatase 
which negatively regulates Pi3K/ Akt, thus interfering with the activation of HIF-1 a 
(Zhou et al., 2002). 
1.5.5 Role of IDF-la in the development of physiological and 
pathophysiological processes associated with disease and cell damage. 
1.5.5.1 Carcinogenesis 
HIF-la has a complex role in carcinogenesis. In adult animals HIF-la is 
over-expressed in epithelial cancers and high grade pre-malignant lesions (Zhong et 
al., 1998). Involvement ofHIF-la in the vascularisation of tumours is clearly seen 
by means of its role in the activation of angiogenic mechanism(s). The increasing 
tissue mass results in areas of tumour that have reduced oxygen tension as a result 
of inadequate blood supply. 
-42-
The inevitable hypoxia activates HIF-1a, which then induces VEGF to drive the 
proliferation of endothelial cells. In Ha-ras transformed cells, analysis of the 5' 
flanking region of the VEGF promoter, indicates that a HIF-1-like sequence 
promotes a 15 fold increase in reporter gene activity (Mazure et al., 1996). 
In pancreatic cancer, HIF-la confers resistance to apoptosis and induction 
of metabolism-associated genes, GLUT-1 and aldolase A (Akakura et al., 2001). 
The tumour suppressor gene p53 promotes ubiquitination and proteosomal 
degradation of the HIF-la subunit (Ravi et al., 2000), therefore the loss ofp53 
during tumourigenesis results in a HIF-1a dependent switch to an angiogenic 
phenotype. 
A common trait of highly malignant tumours is the capacity to metabolise 
more glucose to lactate than their tissue of origin. It has been observed that the 
distal region of the hepatoma type 11 hexokinase (HKII) promoter displays 
consensus sequences for HIF-1, which overlap theE-box sequences known to be 
related to glucose response. Combined stimulation with glucose and hypoxia 
upregulate the expression ofHKII- 7-fold, compared to the 2-fold induction by 
glucose alone. This suggests responsiveness to hypoxia by a process that is 
modulated by glucose in rapidly proliferating hepatoma cells (Mathupala et al., 
2001). 
Both MAPK and the Pi3K/Akt pathways enhance HIF-1a levels in tumour 
cells or mitogen stimulated cells under nonnoxia (Zhong et al., 2000; Stiehl et al., 
2002) and such enhancement is deemed to involve control ofHIF-1a translation 
(Laughner et al., 2001 ). It has been suggested that Pi3K signalling is neither 
required nor sufficient for stabilisation ofHIF-1a (Arsham et al., 2002), however, it 
was later observed that Pi3K/Akt/FRAP signalling is required for HIF-1a and 
VEGF-A expression in 4-hydroxy estradiol (4-0HE2) induced carcinogenesis (Gao 
et al., 2004). Several mechanisms are known to be responsible for upregulation of 
the Pi3K pathway in human cancer, for example the gene coding for the catalytic 
subunit ofPi3K is amplified in cervical carcinoma (Ma et al., 2000) while the 
tumour suppressor PTEN is frequently lost in glioblastoma and endometrial cancer 
(Cantley et al., 1999; Besson et al., 1999). 
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1.5.5.2 Apoptosis 
Paradoxically, HIF-1a also participates in hypoxic cell death which may 
arise from activation ofproapoptotic mediators, the Bcl-2-binding proteins BNIP3 
and NIX which can inhibit the anti-apoptotic effect ofBcl-2 and stabilise wild type 
p53 (Bruick, 2000). Another cell-death molecule activated by HIF-1, simply 
known as HGTD-P, is situated downstream ofHIF-1a and triggers apoptosis via 
mitochondrial pathways. These cell death mediators may be activated by separate 
HIF-1-dependent pathways, as HGTD-P is stimulated in response to acute hypoxic 
insult, while BNIP3 responds to chronic hypoxia (Lee et al., 2004). 
1.5.5.3 Wound healing 
Wound healing proceeds through various stages of proliferation and tissue 
remodelling. In a mouse model of epidermal wounding, HIF-1 a, GLUT -1 and 
phosphoglycerate kinase-1 (PGK-1) mRNAs were detectable immediately after 
wounding (Elson et al., 2000). Coordinate gain ofHIF-1a expression and HIF-1 
function at specific stages of wound healing suggests that regulation ofHIF-la 
gene expression in this circumstance may occur at the level of mRNA and protein 
(Wang et al., 1995; Huang et al., 1996). The induction ofHIF-1a mRNA in the 
proliferative compartment of the epidermis in wound healing (Zhong et al., 1999) 
along with the close proximity of the underlying dermal capillaries to where 
expression is centred in the epidermal basal cells (Smith-McCune et al., 1997) 
suggests that the affected area is not necessarily hypoxic, therefore HIF-1a 
activation in this instance may be hypoxia independent. 
1.5.5.4 Diabetic complications 
Vascular expression ofHIF-la has been suggested to contribute to the 
manifestation of diabetic retinopathy (Ozaki et al., 1999; Lukiw et al., 2001 ). This 
in turn activates VEGF, which is a major factor in the development of uncontrolled 
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cell growth and vascular permeability of the retinal microvasculature characteristic 
of diabetic retinopathy (reviewed by Caldwell et al., 2003). On the other hand, 
diabetes coincides with a marked decrease in VEGF expression in ischaemic 
muscle (Rivard et al., 1999) and skin wounds (Frank et al., 1995) suggesting 
negative regulation of HIF-1 a. 
The exact cause of this regulation, however, is not clear. Reduction in 
VEGF receptor expression in response to hyperglycaemia, and subsequent 
abnormal VEGF signalling, has also been noted (Pinter et al., 2001). Therefore, 
gain ofHIF-la function may be advantageous in diabetic peripheral vascular 
disease, frequently complicated by chronic leg ulcers which can precipitate 
amputation. An undesirable hallmark of VEGF activity, however, is its ability to 
increase blood vessel permeability (Dvorak et al., 1999). In order to produce a 
healthy vasculature free from vascular leakage, oedema and inflammation, 
endothelial VEGF clearly needs to work in conjunction with other angiogenic 
factors (Bruick & McKnight, 2001). 
The co-ordinating role which HIF-la may have in such regulation is seen in 
transgenic mice which over-express epidermal HIF-1a. These mice develop a 
microvasculature which, in spite of induction of VEGF and an increase in 
microvascular density, is non-leaky at base line, and somewhat leakage resistant in 
response to acute inflammation (Elson et al., 2001), thereby implicating HIF-la as 
a global mediator of the angiogenic response. This action may be achieved through 
the ability ofHIF-la to regulate Angiopoietin-2 and Angiopoietin-4 (Ang-2 and 
Ang-4), which when expressed in conjunction with VEGF exhibit marked 
hypervascularity without excess vascular leakage, producing morphologically and 
functionally normal vessels (Yamakawa et al., 2003). 
Regulation ofVEGF in response to hyperglycaemia via HIF-la, however, 
remains controversial. It has been observed that insulin-induced HIF-1 a-dependent 
VEGF expression requires p38 MAPK and Pi3K, whereas hyperglycaemia-induced 
regulation ofVEGF expression is HIP-la-independent, requiring instead PKC and 
p42/p44 MAPK (Poulaki et a/, 2002). 
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1.5.6 Potential role of glucose in the regulation ofHIF-la 
The changes in oxygen tension and glucose concentration play an important 
role in metabolism, angiogenesis, tumourigenesis and embryonic development. 
However, little is known about the interaction of these two signals. Since HIF-1 
itself promotes glycolytic metabolism, enhancement ofHIF-1 by glucose 
metabolites may constitute a novel feed-forward signalling mechanism (Lu et al, 
2005). The effect of altered glucose and oxygen availability to tissues, and the 
subsequent effect this has on HIF-1 expression, is recognised in several disease 
states. However, the mechanisms underlying this association are largely unknown. 
In spontaneously diabetic rats, early induction of VEGF in liver and kidney 
at the onset of disease was shown to be associated with HIF -1 and CREB-1 both 
binding to the hypoxia response element (HRE) and/or the CREB response element 
(CRE) (Braun et al., 2001). In STZ-induced diabetic rats, high glucose was seen to 
blunt the HIF-HRE pathway and subsequent VEGF response to hypoxia (Katavetin 
et al., 2006). Diabetic kidney disease has shown excess glucose metabolism under 
normoglycaemic conditions to involve an increase in GLUT -1 levels coincident 
with increased nuclear HIF-la protein expression (Pfafflin et al., 2006). In human 
fibrosarcoma and pharyngeal carcinoma cell lines, absence of glucose and serum 
resulted in no hypoxic accumulation ofHIF-1a protein in the nuclear fraction of 
either cell line, with normal glucose concentrations proving more important than 
normal serum in restoring the full response to hypoxia (Vordermark et al., 2005). 
HIF-1-dependent increase in glucose metabolism and consumption has also been 
suggested as a mechanism by which cell death may occur in renal epithelial cells 
exposed to severe hypoxia (Biju et al., 2005). However, hypoxia induced changes 
in vascular cell growth have been seen to be altered by hyperglycaemia via 
inhibition ofHIF-la expression and activity (Gao et al., 2007). 
Cross-talk between oxygen and glucose is seen in the regulation of L-type 
pyruvate kinase (L-PK) gene expression in the liver, whereby reduction of glucose-
dependent induction ofL-PK under low oxygen tension appears to be mediated by 
interference between HIF-1a and an upstream stimulating factor at the glucose 
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response element (GlcRE). Furthermore, the GlcRE also functions as a hypoxia 
response element (HRE), as demonstrated through its ability to bind HIF -1 a 
(Krones et al., 2001; Kietzmann et al., 2002). 
Such evidence suggests co-operation between oxygen and glucose 
dependent control of metabolism at the level of transcription factors, therefore 
implicating HIF-la activation and consequent signalling to be the common feature 
linking the two. 
1.6 In vivo and in vitro models of experimental diabetes mellitus 
Diabetes is a multifactorial disease, the long-term consequences of which 
are the result of a multitude of metabolic and structural abnormalities occurring 
concomitantly. Therefore, it is very difficult to establish causal relationships 
between observed changes and the chronic complications associated with human 
diabetes (Bone et al., 1997). 
In vivo and in vitro models of experimental diabetes are powerful tools in 
the study of the pathophysiology of the disease, yet advantages and disadvantages 
are associated with both. The in vivo streptozotocin {STZ)-induced rat model of 
diabetes can never mimic the human disease exactly, especially in terms of 
longevity and development of chronic complications. However, it has proved to be 
very useful in the study of the initial metabolic and vascular insults which can 
trigger diabetic neuropathy (Cameron et al., 2001), retinopathy (Yu et al., 2001) 
and nephropathy (Sodhi et al., 2001), displaying many of the morphological and 
functional changes evident in human diabetic complications. 
To be able to fully investigate the pathways and mechanisms contributing 
to human diabetic complications, in vitro human cell culture models are perhaps 
preferable. However, vascular cells grown in culture form flat monolayers, not 
vessels as in nature, have no blood supply and no cooperation from other cell types. 
Therefore, such a simple system can never accurately represent that of a complex in 
vivo model. Nevertheless, by employing the cell culture model, the extracellular 
environment can easily be manipulated and monitored, which is not possible in 
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vivo, and specific cell lines which are relevant to pathogenesis of vascular 
complications are readily available for these studies. Furthermore, unlike the 
animal model, the human cell culture model is not hampered by the issue of species 
specificity, and therefore should yield findings which are more clinically relevant to 
human diabetes. 
1. 7 Aims of the study 
Although the mechanisms involved in the regulation and expression ofHIF-
la are becoming increasingly clear, the signalling pathways that determine HIF-la 
stabilisation, nuclear translocation and HIF-1 transactivational ability under 
hypoxic or normoxic conditions remain confusing and often contradictory. 
It is now widely accepted that non-hypoxic stimuli contribute to HIF-1 a 
expression. Furthermore, it is also becoming more apparent that several factors 
which are proposed to initiate and sustain the development of the chronic 
complications of diabetes are either upstream mediators or downstream effectors of 
HIF-1 a expression. 
Glucose has been inextricably linked to the development and progression of 
diabetic complications. Tissues subjected to poorly controlled blood glucose levels, 
such as those experienced in diabetes, develop a state of pseudohypoxia due to the 
increased demand for the expression of metabolic enzymes and pathways which are 
classically associated with reduced oxygen tension. 
By establishing whether glucose or a product of glucose metabolism has 
the ability to modulate HIF-la expression independently of or in conjunction with 
hypoxia, we would then be able to dissect some of the signalling pathways which 
may be contributing to this regulation, and perhaps represent a novel target to 
which logical strategies aimed at therapeutic intervention could be developed. 
Therefore, using an in vivo model of experimental diabetes (i) and an in 
vitro endothelial cell culture model thereafter (ii-vi), the aims of this study were the 
following; 
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(i) To determine the expression ofHIF-la in vivo, within the 
vasculature of a chemically-induced rat model of experimental 
diabetes. As the endothelium is the first line of defence to 
substances contained within the blood, this could highlight 
regulation of endothelial expression of HIF-1 a to be a significant 
vascular response to diabetic insult. 
(ii) To investigate the significance of endothelial HIF-1 a expression 
in response to elevated glucose in vitro using HUVEC. This 
would then allow the levels ofHIF-la protein and mRNA to be 
measured directly, in cells exposed to high glucose combined 
with normoxia or hypoxia. 
(iii) Use chemical inhibitors of transcription/translation pathways in 
cell culture to determine whether any change in expression of 
HIF-la mRNA in response to altered glucose concentration 
observed in (ii) 
is occurring at the level of transcription, mRNA stability or 
translation. Furthermore, assess whether the stability elements 
~ithin the 3'UTR ofHIF-la mRNA are being targeted and 
modulated by RN A-binding proteins. 
(iv) To assess the effect of any change in HIF-1 a expression on 
mRNA levels ofthe HIF-1-responsive genes GLUT-I and IGF-
lR and the natural antisense ofHIF-la, termed aHIF. 
(v) To investigate the potential influence ofPi3K and MAPK 
signalling cascades on glucose mediated regulation ofHIF-la, 
and also determine the effect of altered redox status through use 
of antioxidant compounds. 
(vi) Use ofnon-metabolizable analogues of glucose to determine 
whether any observable influence which elevated glucose 
concentration is having on HIF -1 a expression is attributable to 
glucose itself, or a product of its metabolism. 
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Chapter 2 
Materials and Methods 
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2.1 Streptozotocin-ioduced diabetic rat model 
Tissue samples taken from a rat model of chemically induced diabetes were 
kindly provided by Prof. M. A. Cotter and Prof. N. E. Cameron, of the Department 
of Biomedical Sciences, Aberdeen University. 
2.1.1 Streptozotocin treatment of rats 
The pancreatic beta-cell toxin strepozotocin (STZ) was administered to rats 
by single injection in order to produce a chemically-induced model of experimental 
type 1 diabetes. 
Adult Sprague Dawley stock rats were maintained by the Biological 
Services Unit at Aberdeen University, in accordance with the British Home Office 
Code of Practice for the housing and care of animals used in scientific procedures. 
Chemical induction of diabetes was carried out at Aberdeen University, using an 
established method involving the administration of STZ by intraperitoneal injection 
at a concentration of 45mglkg in sterile saline administered at 19 weeks. Regular 
blood sugar monitoring was used to detect the onset of diabetes, and animals were 
then sacrificed at 4 weeks (body weight (g): 362 ± 8; plasma glucose (nM): 49.9 ± 
5.5), 10 weeks (body weight (g): 328 ± 13; plasma glucose (nM): 54.2 ± 2.9) and 24 
weeks (body weight (g): 310 ± 10; plasma glucose (nM): 49.8 ± 4). Time matched 
controllitterrnates were treated with an injection of saline alone (body weight (g): 
443 ± 4; plasma glucose (nM): 7.6 ± 0.5). 
2.1.2 Preparation of-cryostat sections 
Tissue bundles were prepared from the treated and control animals. These 
consisted of aorta and sciatic nerve surrounded by skeletal muscle. For cryostat 
sectioning, the tissue bundles were frozen in isopentane pre-cooled in liquid 
nitrogen, and stored at -80°C. Prior to cutting, the temperature of the frozen tissue 
bundles was allowed to rise to -20°C. 
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2.2 Cell culture 
2.2.1 Cell culture materials 
Cell culture reagents were purchased from Invitrogen (Paisley, UK), all cell 
culture plastics and glassware from Fisher Scientific UK Ltd. (Loughborough, UK) 
and chemical agents from Sigma-Aldrich (Poole, UK), unless stated otherwise, and 
all were used as supplied. 
2.2.2 Human umbilical vein endothelial cells (HUVEC) 
All in vitro investigations were carried out using human umbilical vein 
endothelial cells (HUVEC), cultured from an immortalised cell line, purchased 
from The European Collection of Cell Cultures (ECACC). 
2.2.2.1 Cell growth conditions 
All procedures involving cells were earned out in a dedicated cell culture 
lab, under aseptic conditions in an Aura 2000 laminar flow air hood (Bioair 
Instruments). All solutions, plastics and glassware used in cell culture were sterile 
prior to use. Cells were routinely cultured in glucose-free Glasgow's Minimal 
Essential Medium (GMEM) containing 10% foetal calf serum (FCS), 1 unit/ml 
penicillin, lJ.lglml streptomycin, 2mM L-glutamine and 5mM glucose. Standard 
growth conditions were maintained at 37°C in a humidified atmosphere of 5% C02 
/95% room air in a Galaxy S incubator (Wolf Laboratories). 
Cell monolayers were propagated in 75cm2 culture flasks. Subculture was 
carried out using sub-confluent colonies of cells which displayed the characteristic 
cobblestone morphology when visualised with an inverted light microscope, and 
stained positive for von Willebrand factor (vWF) using immunocytochemistry 
(IHC). The media was replaced approximately twice weekly as indicated by a 
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colour change in the pH sensitive indicator. Used medium was poured away and 
the cell monolayer rinsed with Hank's balanced salt solution (HBSS), before adding 
15ml fresh growth medium to the flask. 
2.2.2.2 Routine sub-culture 
To harvest cells for subculture, growth medium was poured off and the 
monolayer rinsed three times with lOml calcium and magnesium free HBSS. The 
final wash was incubated for 1 0 minutes to remove all traces of medium. 
The cell monolayer was removed from the flask by adding 1 Oml 0.25% 
trypsin solution, and by gentle agitation the flask for no longer than 2 minutes. An 
equal volume of medium containing FCS was then added to the cell suspension to 
neutralize the enzymatic activity of the trypsin. The cell suspension was removed 
to a sterile universal tube, and the flask rinsed with 3ml medium which was also 
poured into the same tube. Cells in suspension were pelleted by centrifugation at 
8000-9000 x g for 8 minutes prior to removing the supematant and resuspending the 
cell pellet in 1 ml fresh medium. The cell suspension was then split at the desired 
ratio. For subculture, a split ratio of 1 to 4 was used, therefore 250J..ll cell 
suspension was added to sterile 75cm2 flasks, and supplemented with 15ml fresh 
medium. The flasks containing HUVEC were transferred to an incubator set to 
conditions as previously described and left undisturbed overnight to allow the cells 
to adhere and begin to grow. Growth was checked daily under the microscope and 
by observation of any change in the colour of medium, indicative of pH changes. 
2.2.2.3 Sub-culture for experimental procedures 
For all experimental procedures, cells were harvested from 75cm2 stock 
flasks as detailed in 2.2.2.2., under normal growth conditions, as laid out in 2.2.2.1. 
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2.2.2.3.1 Sub-culture ofHUVEC into 75cm2 flasks 
The cell suspension obtained from 1 x 75cm2 flask routinely contained 
sufficient cells to allow a 1 in 10 split into subsequent 75cm2 flasks, therefore 100!ll 
from lml cell suspension was added to the 75cm2 flask and supplemented with 
15ml growth medium. Flasks were then incubated under normal conditions and 
checked regularly under microscopy. On reaching 60% confluence, the cells were 
stepped down overnight in glucose-free/serum-free (GF/SF) GMEM, to facilitate 
synchronisation of cell growth at the start of the experimentation. 
2.2.2.3.2 Sub-culture of HUVEC into chamber slides 
Chamber slides containing two chambers of 2cm2 area were used for 
immunocytochemical analysis ofHUVEC. To seed the chambers, the cell count 
was obtained using the trypan blue dye exclusion method (2.2.3.1). Each well on 
the 2 well chamber slide was seeded with HUVEC at a density of 0.025 x 106 
cells/ml in a volume of 2ml. On reaching 60% confluence, the slides were stepped 
down over night in order to synchronise growth prior to treatment. 
2.2.2.3.3 Sub-culture of HUVEC into 96 well plates 
Cell number was counted as above, and each well in the 96-well culture 
plate was seeded with HUVEC at a density of 0.025 x 106 cells/ml, in a volume of 
200!ll. The cells were allowed to adhere and start to grow overnight, before being 
used in the alamar blue assay, as described in 2.2.3.2. 
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2.2.3 Cell viability and proliferation 
2.2.3.1 Trypan blue dye exclusion method 
On reaching a suitable stage of proliferation, the cells were harvested as laid 
out in 2.2.2.2., and the viable cell number determined by means of trypan blue dye 
exclusion, in order to seed growth chambers with the appropriate number of cells. 
An aliquot of cell suspension was mixed with trypan blue dye at a 1: 1 ratio, 
mixed gently and left to stand for 2 minutes to allow the dye to penetrate any non 
viable cells. During this time, the haemocytometer was assembled with a glass 
coverslip. Using a Pasteur pipette, a small volume of the cell suspension was 
applied to the edge of the coverslip and allowed to fill the area under the coverslip 
by means of capillary action. 
Using a microscope to see the two grids etched on either side of the 
haemocytometer, viable and non viable cells were counted in the 25 squares 
contained within the large square edged by double lines on both grids. The mean of 
the two sides of the slide was taken before calculating total viable cell number as 
follows; 
Number of cells/ml =cell count per large square x dilution factor x 10"4 cm3 
(volume of large square) 
2.2.3.2 Alamar blue cell growth assay 
Alamar blue is an indicator dye, formulated to quantitatively measure the 
proliferation of cells in culture. It consists of an oxidation-reduction (REDOX) 
indicator that yields a colorimetric change evident in the growth media (dark blue to 
pink) in response to metabolic activity. The assay plate is read using a colorimeter, 
to measure absorbance at 570nm (reduced) and 600nm (oxidised) wavelengths. 
For the assay, cells were harvested from 75cm2 flasks, as described in 
2.2.2.2, and the cell count was then obtained using trypan blue (section 2.2.3.1 ). 
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Cells were seeded in clear flat bottomed 96 well sterile cell culture plates, at a 
density of 0.025 x 106 cells/rnl. The plates were then incubated overnight under 
conditions as laid out in 2.2.2.1. The following morning, the plates were checked 
for cell adherence and initial growth by rnicroscopy. The old growth medium was 
carefully removed and replaced with fresh media combined with 10% (v/v) alamar 
blue (Serotec ). Plates were returned to the appropriate incubation conditions, and 
absorbance readings taken using an FL600 microplate reader (Bio-tec) after 0, 1, 6, 
24 and 29 hours. 
2.2.4 Artificial induction of Hypoxia 
A hypoxic environment was created artificially in vitro by subjecting the 
cells in culture to a chemical mimic of hypoxia, the iron-chelator desferrioxarnine 
(DFO) (Sigrna), or by incubation in a 5% 02/S% C02/ air environment created by a 
Galaxy S C02 incubator (Wolf Laboratories). 
2.2.4.1 Chemical induction ofhypoxia 
HUVEC were cultured in GMEM, containing 10% FCS and other cell 
growth supplements, at 37°C under 5% C02 /95% room air (norrnoxia) in 75cm2 
flasks (2.2.1.1). The cells were harvested and 2ml of cells at 1 x 106 cells/ml were 
seeded to each chamber of a 2 well chamber slides (2.2.2.3.2). 
On reaching approximately 60% cell confluence, the growth medium was 
removed and the cell monolayer rinsed twice with HBSS. Growth medium was then 
replaced with GF/SF GMEM in order to step-down the cells overnight. The 
following morning, the GF/SF GMEM was removed, and replaced with fresh 
growth medium containing 130~ DFO for 0-6 hours. After treatment, the test 
medium was removed, and slides rinsed three times in sterile phosphate buffered 
saline (PBS). The slides were then left to air dry before storing at -20°C until 
required. 
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2.2.4.2 Non-chemical induction of hypoxia 
Cells were cultured in the appropriate container depending on the procedure 
being undertaken, following methods described previously. The effect of hypoxia 
alone or in conjunction with other test agents was assessed through exposing the 
cells to lowered oxygen tension for the desired length of time, by means of an 
incubator that allowed for regulation of oxygen level, set to 5% 02/S% C02/ air, as 
opposed to 18% 0 2 normal air incubations. 
These conditions were created and maintained by purging 0 2 from the 
incubator with nitrogen. After exposure to hypoxia, the containers were rapidly 
removed and placed on ice, before washing three times with ice cold PBS to remove 
all traces of media. 
2.2.5 Alteration of glucose concentration and substitution with glucose 
analogues 
The response of the cells to altered glucose level was observed, along with 
the response to equivalent concentrations of selected glucose analogues. Incubation 
with D-glucose and analogues were also combined with non-chemical induction of 
hypoxia, as described in section 2.2.4.2., in order to investigate any synergism 
between the two stimuli. 
Routine subculture and maintenance of the cells was carried out in GMEM 
supplemented with 5mM glucose, thus simulating physiologically normal blood 
glucose level (euglycaemia). 
Glucose was made up at lM concentration in GF/SF GMEM. The solution 
was sterlised by filtration using a 0.2JJ.m filter (Nunc). The glucose in solution 
could then be stored at 4 °C before adding to GMEM to produce glucose 
concentrations of either 5mM or 20mM. 
Similarly, the glucose analogues 2-deoxyglucose (2-DG) and 3-orthomethylglucose 
(3-0MG) were used at equivalent concentrations. 2-DG can only be metabolised 
-57-
by the first step of glycolysis before becoming trapped within the cell, while 3-
0MG is not metabolised by the cell, and is free to enter and leave through active 
transport. 
2.2.6 Inhibition of signalling pathways in cell culture 
2.2.6.1 Transcription and translation 
Inhibition of mRNA transcription and protein translation were studied using 
the chemical inhibitors actinomycin D (Act D) and cyclohexamide (CHX), 
respectively. 
Act D was prepared under sterile conditions in dimethylsulphoxide (DMSO) 
and used in cell culture at a fmal concentration of 1 OJlg/ml. A commercially 
prepared solution of CHX dissolved in DMSO was used in cell culture at a final 
concentration of 1 Oflg/ml. 
Prior to use, either Act D or CHX was added to 1 OOml GMEM + 10% FCS 
+ supplements before applying the medium to the cells. The cells were then 
incubated with the separate inhibitors for 1, 6 and 24h with either 5mM or 20mM 
glucose, in nonnoxic and hypoxic conditions. The test agent solvent was controlled 
for by treating the cells as above with DMSO alone at an equivalent concentration 
in the media. 
2.2.6.2 Protein kinase activity 
PD98059 (Ca1biochem), a mitogen activated protein kinase (MAPK) 
inhibitor, and LY294002 (Promega) a phosphoinositol-3 kinase (Pi3K) inhibitor 
were purchased as commercially prepared solutions dissolved in DMSO. 
PD98059 was added to culture media to a final concentration of 2Jlg/ml, and 
L Y294002 to a fmal concentration of 1 OJlg/ml. Each inhibitor was incubated in cell 
culture and controlled for as described in section 2.2.6.1. 
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2.2.6.3 Redox signalling 
The antioxidant a-lipoic acid was dissolved in ethanol then added to GMEM 
+ 10% FCS + supplements to a final concentration of 250J.!g/ml. The media 
containing a-lipoic acid was then incubated with cells for 1, 6 and 24 h with either 
5mM or 20mM glucose in normoxia and hypoxia. The solvent was controlled for 
by incubating the cells as above with an equivalent concentration of ethanol. 
2.3 Immunochemical staining 
Immunohistochemistry (IHC) was employed to detect protein expression 
within cryostat sections of diabetic and control rat tissue. Immunocytochemistry 
(ICC) was used similarly for detection within cultured cell preparations. 
2.3.1 Avidin-biotin complex /alkaline phosphatase (ABC/AP) procedure for 
use with monoclonal mouse antibody 
2.3.1.1 Overview of ABC/AP 
The ABC/ AP procedure is an immunoenzymatic staining method for 
detection of an antigen by light microscopy. This method utilises the high affinity 
of avidin for a biotinylated secondary antibody linked to a primary antibody 
directed against the antigen. 
Alkaline phosphatase, which is used as the enzyme label for antigen 
detection, lyses a chromogenic substrate producing a red colour, thus indicating 
detection of the antigen. 
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Figure 2.1. Schematic diagram of preformed avidin-biotin-alkaline 
phosphatase complex reacting with biotinylated secondary antibody (as adapted 
from ' Immunochemical Staining Methods Handbook', Dako Corporation, 1989) 
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2.3 .1.2 IHC using ABC/ AP applied to cryostat sections of animal tissue 
Sections of rat tissue were prepared and stored as detailed in section 2.1. 
Previously prepared sections of rat tissue mounted on glass slides were removed 
from the -20°C freezer, and allowed 2-3 hours to come up to room temperature. 
Sections were fixed in ice cold acetone for 30 minutes in a fume cupboard, 
before air-drying on the bench for 10 minutes. Tissue sections were then delineated 
with a wax pen. Slides were equilibrated in tris-buffered saline (50mM tris, 40mM 
HCl, 0.9% NaCl, pH 7.5) (TBS) for 5 minutes, before tapping off excess liquid, 
taking care not to damage the tissue sections. 
Non-specific binding of the antibody was prevented by blocking the 
sections with 50J.Ll of 10% rabbit serum made up in TBS, for 30 minutes before 
tapping off the excess liquid. The primary antibody was applied to each section in 
50J.Ll aliquots. 
For the detection ofHIF-1a protein, anti-HIF-1a monoclonal mouse 
antibody (Affinity Bioreagents) was used at 1:200 dilution. Immunoglobulin (IgG 1 
isotype, Affinity Bioreagents) at 1:200 dilution was used as a negative control, with 
TBS alone as a background control. Incubation of the slides was optimised at 4°C 
overnight in a humidified chamber. After the incubation was complete, excess 
liquid was tapped off, and the slides were washed in TBS for 3 x 5 minutes at room 
temperature. 
The secondary antibody, biotinylated rabbit anti-mouse (Dako ), was made 
up in TBS with 5% rat serum to 1:300 dilution and applied in 50J.Ll aliquots to the 
sections, before incubati~g in a humidified chamber at room temperature for 20-30 
minutes. 
The avidin-biotin-alkaline phosphatase complex (ABC/ AP) solution was 
prepared following manufacturers instructions, and incubated at room temperature 
for 30 minutes. During this time, the slides were washed 3 x 10 minutes in TBS. 
The ABC/ AP solution was applied to each section, and incubated for 30 minutes in 
the humidified chamber at room temperature. 
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Slides were then washed for 3 x 10 minutes in TBS. During this time, the 
chromogenic Fast Red substrate solution was prepared according to manufacturers 
instructions, and haematoxylin solution (Fisons) filtered to be used for counter-
staining the slides. 
After washing was complete, the substrate was applied to the sections until a red 
colour was present, which was routinely 2-3 minutes. Counter-staining was carried 
out in filtered haematoxylin for 3 seconds, before rinsing the slides in distilled 
water and allowing to dry. 
Once dry, the slides were mounted by adding 3 drops of Ultra-mount (Dako) 
to cover the section before placing on coverslips. The slides were then viewed 
under light microscopy. 
2.3.1.3 ICC using HUVEC grown on chamber slides 
The ABC/ AP procedure using HUVEC grown on chamber slides was 
employed using the same protocol as for the cryostat sections of rat tissue, detailed 
in 2.3 .1.2. The only alteration involved substituting the 5% rat serum in the 
secondary antibody solution with 5% human serum. 
2.4 Polymerase chain reaction (PCR) 
The expression of specific genes was investigated in HUVEC by producing 
complementary DNA (cDNA) from cell samples and subjecting these to 
polymerase chain reaction (PCR) amplification. 
PCR produces multiple copies of the gene of interest, by targeting short 
complementary primer sequences to specific regions within the gene. By 
optimising the amplification process for any given DNA sequence, it is then 
possible to measure the level of mRNA expressed by the gene of interest as a 
function of PCR product concentration. 
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2.4.1 RNA extraction from whole cell preparations 
RNA extraction from whole cell preparations was carried out using 
commercially available kits from Qiagen. Buffers used in the procedure were 
provided with the kit, unless specified, full details of which are included in the 
manufacturer's handbook. 
2.4.1.1 Sample homogenisation using QIAshredder spin columns (Qiagen) 
Phosphate buffered saline (PBS) (Sigma) was treated with 0.01% 
diethylpyrocarbonate (DEPC) (Sigma) prior to autoclaving, in order to destroy any 
RNAase activity within the solution. Cell lysis buffer RL T was treated with 
1 OJ.1llml J3-mercaptoethanol (Sigma) prior to use, in order to disrupt cell walls and 
aid lysis. 
Cells were grown in 75cm2 flasks (2.2.1.3.1) and treated as previously 
specified. Flasks were rinsed twice with chilled DEPC treated PBS on ice, before 
disrupting cell walls by adding 600J.1l buffer RLT. Celllysates were then collected 
with a cell scraper. A maximum of700J.1l cell lysate was applied to a QIAshredder 
column sitting in a 2ml collection tube before centrifuging for 2 minutes at 12,000 x 
g to fully disrupt the cells. 
2.4.1.2 RNA extraction using RNeasy midi kit (Qiagen) 
One volume of 70% ethanol was added to the homogenised lysate, and 
mixed by pipetting. Up to 700J.1l homogenised sample, including any precipitate 
which formed on addition of ethanol, was applied to an RN easy spin column sitting 
in a 2ml collection tube. 
The tubes were centrifuged for 15 seconds at 8000 x g, and the RNA was 
bound to the membrane in the spin column. Where the sample volume exceeded 
700J.1l, subsequent aliquots were loaded into the same spin column, discarding the 
flow through after each centrifugation. Washing buffer RW1 was applied to the 
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RNeasy column, and centrifuged for 15 seconds at 8000 x g to wash. The RNeasy 
column was then transfered into a new 2ml collection tube, and 500fll of the second 
wash buffer RPE added before centrifuging for 15 seconds at 8000 x g to wash. 
The wash was repeated, and the tube centrifuged for 2 minutes at 12,000 x g to dry 
the RN easy membrane. To eliminate any chance of possible buffer RPE carryover, 
the column was placed in a new 2ml collection tube and centrifuged at 12,000 x g 
for 1 minute. 
To collect the RNA from the membrane, the column was placed into a new 
1.5ml collection tube, and 30-50fll ofRNAse free water was pipetted directly on to 
the RN easy membrane. The tubes were centrifuged for 1 minute at 8000 x g to elute 
the sample. The RNA was then ready for use, or stored at -20°C for 1 to 2 months, 
or at -80°C for more long term storage in ethanol. 
2.4.2 Assessment of concentration and purity of RNA 
Samples of extracted RNA were electrophoresed on agarose gel prepared at 
1.4%(w/v) in 50ml Tris borate EDTA buffer (TBE) (130mM Tris, 35mM boric 
acid, 2.5mM EDTA). The agarose powder in TBE was melted by heating in a 
boiling water bath. A horizontal mini gel electrophoresis tank (Biorad) was 
prepared, containing the gel mould set up with well forming comb. 
Prior to pouring, ethidiurn bromide was added to the molten agarose at a 
fmal concentration of 5ng/ml, to allow visualisation of the DNA under UV light. 
The well forming comb was removed along with the mould sealing gaskets when 
set, and electrophoresis buffer (TBE) was applied to just above the surface of the 
gel. 
To 8f.Ll of RNA, 2.5 f.Ll of loading buffer (7 parts water to 3 parts glycerol 
plus two tracking dyes, bromophenol blue and xylene cyanol, both at 0.25% (w/v)) 
was added, then applied to the gel. The gel was then run for 1 hour at 1 00 volts. 
Observation of 2 bands under UV light, representing the 28S and 18S 
ribosomes, indicated the presence of undegraded RNA. 
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The concentration of RNA in solution was measured spectrophotomically at 
260nm wavelength. The solution was diluted as follows in DEPC treated water. 
4)11 RNA + 996)11 DEPC dH20 (Dilution factor = 250) 
The concentration of RN A in solution was calculated taking into account 
that at 260nm, absorbance of 1 = 40 J.lg/ml RNA 
Abs 260 x dilution factor x 40 = X )lg/ml RNA concentration 
Absorbance was also measured at 280nm, in order to determine the purity of 
the RNA in solution, where a 260/280nm ratio of 2.00 indicated pure RNA. 
Samples were routinely found to have a ratio of 1.9 to 2.1, which was within an 
acceptable range. 
Where the RNA concentration in solution was too dilute (ie. less than 
455ng/J.ll which was the minimum required for reverse transcription, as described in 
section 2.4.3.1) samples were reprecipitated, before reconstituting in a smaller 
volume of sterile DEPC treated water. Two and a half times volume of ice-cold 
ethanol was added to the nucleic acid solution. The solution was then adjusted to 
0.3M sodium acetate (NaOAc) by adding 1110 volume 3M NaOAc, pH5.2 (Sigma). 
The solution was then mixed thoroughly and stored at -20°C for a minimum of one 
hour. The reprecipitated nucleic acid was centrifuged at 8000 x g for 5 minutes at 
4°C before decanting the supematant. 
The pellet was then washed twice with 70% ethanol and centrifuged at 8000 
x g at 4°C for 2 minutes. After removing the ethanol, the pellet was allowed to air 
dry, before reconstituting in an appropriate volume ofDEPC treated dH20. 
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2.4.3 Preparation of complementary DNA (cDNA) 
2.4.3.1 Reverse transcriptase polymerase chain reaction (RT-PCR) 
For RT-PCR, RNA was prepared at a concentration of5JJ.g in llJJ.l in a thin 
walled PCR tube, to which 1 JJ.l of a 0.5JJ.g/JJ.l 15-mer oligo-dT primer (Sigma-
Genosys) was added. Using a thermocycler (Techne Genius), the reaction was 
incubated at 70°C for 10 min, then 4°C for 2 minutes. Tubes were removed to ice 
for 1-2 minutes to cool, before pulse spinning. From a commercially available RT-
PCR kit (Sigma), the following components were then added to each tube, 
according to the manufacturer's instructions: 
4 JJ.l- 5x first strand buffer (250mM Tris-HCl pH 8.3, 375mM KCl, 15mM MgCh) 
1 JJ.l - 1 OmM deoxynucleotide triphosphate mix ( dNTP) (Roche) 
2 JJ.l - 0.1 M dithiothreitol (DTT) 
1 JJ.l- 200units/JJ.l murine Moloney leukaemia virus (M-MLV) reverse transcriptase 
The mixture was mixed gently, pulse spun and incubated for 10 minutes at 
room temperature. The tubes were then returned to the thermocycler set to the 
following program: 
Cycle 1; amplification - 50 minutes at 42°C 
Cycle 2; inactivation of reverse transcriptase - 5 minutes at 95°C 
The cDNA samples were made up to lOOJJ.l volume with sterile DEPC 
treated d.H20 prior to use or storage at -20°C. 
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2.4.3.2 cDNA priming 
The following table (2.1) contains details of the oligonucleotides used in 
priming amplification of specific sequences within the cDNA. Primer sequences 
were generated through use of Genbase primer design software available via the 
Human Genome Mapping Project (web site; www.hgmp.mrc.ac.uk). 
All primers were then synthesised by Sigma-Genosys, except for ~2-
microglobulin and insulin-like growth factor-1 receptor which were synthesized by 
Oswell DNA service, University of Southampton. 
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Table 2.1 Summary of cDNA primers used for PCR amplification of gene 
products. The amplification of each target gene sequence was achieved by binding 
of specific primers to their consensus sequences within the cDNA, allowing 
polymerase chain reaction (PCR) replication of the specific sequence. 
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Product Length Tm 0/o Ace. No Ref 
Name Primer size (bp) oc GC 
Hypoxia Inducible Factor 5'TCCATCTCCTACCCACATAC3' 365 20 54.8 50 U22431 Wanget 
type l Alpha (HIF-1a) 3' CTTTTGCTCCA TTCCA TTC 5' 19 55.7 42.1 al., 1995 
Antisense HIF-la (aHIF) 5' TGCTTCACTCATCCCATTCA 3' 390 20 64.3 45 U85044 Rossignol 
3' TTTTGCTCTTTGTGGTTGGA 5' 20 63.1 40 et al., 2002 
Glucose transporter type 1 5' TGAACCTGCTGGCCTTC 3' 398 17 62.7 58.8 K03195 Mueckler 
(GLUT-1) 3' GCAGCTTCTTTAGCACA 5' 17 54.9 47.1 et al., 1985 
Insulin like growth factor 1 5' GCCTCTCCGGGTTTGAAAATG 3' 381 21 54.2 52.4 M73724 Ulrich 
receptor (IGF-lR) 3' CCGGAGCCAGACTTCATTCCT 5' 21 56.2 57.1 1991 
J3rMicroglobulin (J3rM) 5'CCTTGAGGCTATCCAGCGTACTCC3' 321 24 60.7 58.3 M17987 Gussow et 
5'CCATGATGCTGCTTACATGTCTC3' 23 55.2 47.8 al., 1987 
- - --
-~ 
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2.4.3.3 In vitro amplification of cDNA by PCR 
2.4.3.3.1 Preparation of amplification reaction mix 
Specific sequences of interest within the cDNA were amplified using the 
primers listed in table 2.1. The reaction mix was prepared in a thin walled 
DNase free PCR tube from the following components supplied as a 
commercially available kit, as recommended by the manufacturer. 
5J.1l I Ox reaction buffer (50mM KCl, 1 OmM Tris-HCl, pH 8.3 and 1.5mM 
MgCh) 
lJ.Ll 1 OmM dNTP mix 
33.5J.Ll dH20 
0.5J.1l Taq DNA Polymerase (Thermus aquaticus) (Roche) 
The components were mixed and pulse spun. To the reaction mix, the 
specific primer and cDNA were then added and mixed gently. 
2.4.3.3.2 Amplification of DNA sequence 
The reaction tubes prepared in section 2.4.3.3.1 were transferred to the 
thermocycler (Techne Genius) and subjected to the following programs of 
sequential annealing, extension and denaturation. 
1. Primer annealing to target sequence for amplification -
2 min at 94°C, 1 min at 55C and 1 min 30 sec at 72°C 
2. Extension of primed sequence -
10 to 30 cycles of 1 min at 94°C, 1 min at 55°C and 1 min 30 sec at 72°C 
3. Denaturation of polymerase on completion-
50 sec at 94°C, 1 min at 55°C and 5 min at 72°C 
Samples were then cooled to 4°C before briefly centrifuging to collect contents. 
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2.4.4 Validation and analysis of double stranded DNA (dsDNA) 
2.4.4.1 Agarose gel electrophoresis 
Regions of interest within the cDNA were amplified by PCR, as detailed 
in section 2.4.3.3. Once samples were amplified, the PCR product was 
determined by means of analytical agarose gel electrophoresis. 
Agarose gel was prepared at 1.4% (w/v) as described insection 2.4.2. 
The following components were mixed then added to the wells. 
- 8 J.ll PCR sample 
- 3J.ll dH20 
- 2.5J.llloading buffer (7 parts water to 3 parts glycerol plus two tracking dyes, 
bromophenol blue and xylene cyanol, both at 0.25% (w/v)). 
In addition, two commonly used markers, PCR marker showing band 
sizes of 50- 1000 bp and Hindlll digested A.-DNA showing band sizes of 125 -
23,130 bp, were also loaded. The gel was run for 1 hour at 100 volts to separate 
fragments, then visualised under UV light using a gel documentation system 
(Uvi-pro). 
2.4.4.2 PicoGreen dsDNA quantitation kit 
PicoGreen quantitation reagent (Molecular Probes, Invitrogen) is an 
ultrasensitive fluorescent nucleic acid stain for quantifying dsDNA in solution. 
The stain will not measure single-stranded DNA, RNA or protein contaminants, 
therefore allowing highly accurate measurement of PCR product concentration 
as low as 25pg/ml. Therefore, combined with the presence of a single band on 
the agarose gel, we can be certain that only the DNA sequence of interest is 
measured. 
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PicoGreen reagent was diluted to 1 :200 from stock in Tris EDT A (TE) 
buffer (10mM Tris-HCl, 1mM EDTA, pH 7.5) supplied with the kit. The 
dsDNA standards were prepared in TE buffer according to the manufacturer's 
instructions, as detailed in table 2.3, and loaded into a black 96 well microtitre 
plate. 
2 J1g/mlDNA TE buffer (Jll) PicoGreen Final DNA cone 
stock (Jll) reagent in assay (nglml) 
250 0 250 1000 
25 225 250 100 
2.5 247.5 250 10 
0.25 249.75 250 1 
0 250 250 0 
Table 2.2 Summary of components required for PicoGreen quantification 
of dsDNA standards. 
The amplified PCR products of unknown concentration, as prepared in 
section 2.4.3.3, were diluted by adding a 1 OJ.il aliquot of PCR product to 90J.1l 
sterile dH20 and also applied to the microtitre plate. A 1 OOJ.il volume of 
PicoGreen reagent was then added to each well containing unknown sample to 
give a final volume of 200J.1l. 
The plate was read using a FL600 fluorescence microplate reader (Bio-
tek) and recordings were handled using KC4 software (Thistle Scientific). 
Fluorescence was measured at excitation and emission wavelengths of 485 and 
590, respectively. The concentration of dsDNA in the unknown samples was 
then measured by direct comparison to the known concentration in the 
standards. 
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2.4.4.3 Optimisation of amplification process 
In order for amplification of the sequence of interest to be within the 
linear phase, the volume of cDNA and number of cycles were varied. This was 
carried out by adding 1-5 ~1 cDNA plus 5 ~1 specific primer to the reaction 
buffer, before amplifying for 10, 15, 20, 25 or 30 cycles of the extension 
program (section 2.4.3.3.2). 
For each number of extension cycles carried out, a graph of resultant 
concentration ofPCR product, as measured by PicoGreen (section 2.4.4.2) was 
plotted against volume of cDNA used. The number of cycles for the optimum 
program was chosen by selecting the plot which produced a normal sigmoid 
curve, and from that plot the optimum volume of cDNA was considered to be 
that which fell within the most linear phase of the plot. 
2.5 Riboprobe preparation 
DNA fragments generated by PCR amplification of the HIF -1 a 
sequence, the primer for which is detailed in table 2.1, were obtained by the 
process described in section 2.4.3.3 then subjected to ligation mediated 
recombinant plasmid (LMRP) amplification by means of a bacterial cell host, in 
order to transcribe a single stranded RNA probe complimentary to the HIF-1a 
sequence. 
By the incorporation of a label into the RNA probe during transcription, 
detection of consensus HIF -1 a RNA expression within a cell preparation was 
then possible by means of enzymatic digestion of a substrate and formation of a 
colour precipitate. 
2.5.1 PCR product purification 
2.5.1.1 Preparative agarose gel electrophoresis 
The HIF-1a sequence was amplified from cDNA prepared from HUVEC 
RNA, following the protocol as laid out in section 2.4.3.3. Product size was 
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then validated using analytical agarose gel electrophoresis (section 2.4.1.1). 
Preparative agarose gel electrophoresis was used to extract the PCR product 
from the reaction mixture. 
Low melting point (LMP) agarose gel was prepared at 1.8% 
concentration (w/v) in 35ml Tris-acetate EDT A (T AE) buffer ( 40mM Tris-
acetate, lmM EDTA, pH 8.3). The gel was prepared as laid out in section 
2.4.4.1, using a preparative comb. The single central well was loaded with 250 
J.!l consisting of 200J,.ll sample and SOJ.!lloading dye, before carrying out the 
electrophoresis and visualising the gel, as described earlier. 
Following electrophoresis, a clean blade was used to excise the single 
band of DNA from the gel. Agarose containing the DNA was then aliquoted 
into 0.3g portions, and stored in 1.5ml tubes at 4°C for purification of the PCR 
product from the agarose. 
2.5.1.2 WIZARD PCR preps DNA purification system (Promega) 
The 1.5ml tubes containing 0.3 g agarose prepared in section 2.5 .1.1, 
were transferred to a water bath at 70°C, and incubated until the agarose was 
completely melted. Purification resin (Promega) was added to each melted 
agarose slice in a volume of 1ml. The solution was then mixed thoroughly for 
20 sec by pi petting and each sample was purified using a vaccum manifold. The 
minicolumnlsyringe barrel assembly supplied with the kit was inserted into the 
vacuum manifold, and the DNA /resin mix was applied to the syringe barrel. 
Briefly, a vacuum was applied to draw the mixture into the minicolumn, before 
immediately breaking the vacuum. 
To wash the mini column, 2ml of 80% isopropanol was added to the 
syringe barrel, followed by a replication of the vacuum to draw the isopropanol 
through the minicolumn. The resin was dried by continuing to draw a vacuum 
for 30 seconds after the solution was pulled through the minicolumn. The 
minicolumn was then removed from the barrel to a 1.5ml microcentrifuge tube 
and centrifuged for 2 minutes at 8000 x g to remove any residual isopropanol. 
The minicolumn was transfered to a new microcentrifuge tube, and 50J.!l dH20 
applied. 
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After incubation at room temperature for 1 minute, the minicolumn was 
centrifuged for 20 seconds at 8000 x g to elute the DNA fragment from the 
column. The purified DNA was then stored in the microcentrifuge tube at -20°C. 
2.5.1.3 Quantification of purified DNA 
Quantification of DNA was carried out as for RNA (section 2.4.2), but 
using the following equation; 
Abs 260 x dilution factor x 50 (Abs 260 of 1 = 50 pglml DNA) = X pglml DNA 
concentration 
2.5.2 Ligation mediated recombinant plasmid (LMRP) cloning 
Cloning of the PCR product was carried out using the pGEM-T Easy 
Vector System (Promega), which is a plasmid DNA vehicle into which the PCR 
product is ligated, enabling the replication of the PCR product upon 
transformation of a bacterial cell host. 
The site of ligation in the plasmid is within the lacZ gene coding for the 
enzyme ~-galactosidase, therefore successfulligation will interrupt this gene and 
prevent production of the enzyme. The plasmid also contains an uninterrupted 
gene conferring ampicillin resistance to the host cell on transfection. The 
cloning region of the vector also contains T7 and SP6 polymerase initiation sites 
allowing 5' or 3' transcription of the cloned insert, respectively, and multiple 
restriction sites, allowing digestion and release of the cloned insert. 
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Figure 2.2 pGEM-T Easy Vector circle map. The schematic diagram shows 
the location of the intact ampicillin resistance gene (Amp) and the lacZ 
sequence which codes for the enzyme P-lactamase. The lacZ gene contains the 
PCR product insertion site, and therefore is disrupted by ligation. Single 3' 
terminal thymidines added to both ends at the insertion site greatly improves the 
efficiency of ligation by providing a compatible overhang for PCR products. 
The cloning region of the vector contains recognition sites for multiple 
restriction enzymes, including Apa I near the T7 RNA polymerase transcription 
initiation site, and Sal I near the SP6 RNA polymerase transcription initiation 
site, allowing for release of the cloned insert by enymatic digestion (as adapted 
·from pGEM-T Easy Vector Technical Manual , Promega 1999). 
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2.5.2.1 PCR product ligation into pGEM-T Easy Vector (Promega) 
The sequence to be cloned was amplified by PCR as described in section 
2.4.3.3, followed by quantitation and purification (sections 2.4.4.1 and 2.5.2, 
respectively). 
Optimum concentration of PCR product to SOng plasmid vector was then 
established, by carrying out ligation reactions using 6, 19 and 32ng/J.tl PCR 
product. Optimal PCR product concentration was then determined to be 
32ng/J.tl. 
Allligation reactions were set up according to the manufacturer's 
recommendations, as outlined below in table 2.4. The components were mixed 
by pi petting and reactions were then incubated at 4°C overnight to obtain 
maximum number of transformed plasmids. 
Components Standard Positive Background 
reaction control control 
2X Rapid Ligation Buffer 5 J.tl 5J.tl 5J.tl 
pGEM-T Easy Vector (SOng) 1 J.tl 1 J.tl 1 J.tl 
PCR product (for 32ng/J.tl) XJ.tl 
- -
Control insert DNA - 2J.tl -
T4 DNA Ligase 1 J.tl 1 J.tl 1 J.tl 
Table 2.3. Components contained in the pGEM-T Easy Vector kit 
(Promega). Proportions required for the PCR product ligation reaction are as 
recommended by the manufacturer. 
2.5.2.2 Bacterial cell transformation 
Tubes containing the ligation reactions were briefly centrifuged to 
collect contents at the bottom. A 2J.tl volume of each ligation reaction was then 
added to separate l.Sml tubes on ice. Another tube was then set up on ice with 
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O.lng uncut plasmid for determination oftransformation efficiency ofthe 
competent cells. 
Vials containing the bacterial strain Escherichia coli (E-coli) JMl 09 
high efficiency competent cells (Promega) were removed from -70°C storage 
and placed on ice until thawed. The cells were then mixed by gentle agitation of 
the tubes. Aliquots of 50J,ll of cells were transferred to the tubes for standard, 
positive control and background ligation reactions, and 1 OOJ.!l was removed for 
determination of transformation efficiency. 
Tubes containing cells plus the ligation products (section 2.5.2.1) were 
gently agitated to mix, and placed on ice for 20 minutes. The tubes were then 
transferred to a water bath at exactly 42°C, in order to heat-shock the cells thus 
allowing the plasmid vectors to permeate the cell membrane. Tubes were then 
immediately returned to ice for 2 minutes. At room temperature, SOC growth 
medium (2% Bacto-tryptone, 0.5% Bacto-yeast extract, 10mM NaCl, 2.5mM 
KCl, 20mM Mg2+, 20mM glucose) was added in 950J.1l aliquots to the ligation 
reactions, and 900J.1l to the tube containing the cells transformed with uncut 
plasmid. All reactions were then incubated for 1.5 hours at 37°C with shaking at 
150 X g. 
2.5.2.3 IPTG/X-Gal screening of transformed bacteria 
Transformation efficiency was evaluated by the process of blue-white 
colony screening. Cells containing recombinant plasmid vector were unable to 
metabolise the synthetic substrate of P-galactosidase, X-Gal (Promega), which 
produces a blue colour on cleavage, due to the disruption of the lacZ gene. 
Therefore, cells containing an untransformed plasmid will appear blue and those 
containing transformed plasmid remain white. 
To ensure that only the cells containing the plasmid are able to grow, the 
antibiotic ampicillin is included in the growth medium, as the plasmid confers 
ampicillin resistance which is naturally absent from these cells. 
Two culture plates containing Luria-Bertani (LB) agar (1.5% agar, 1% 
Bacto-tryptone, 0.5% Bacto-yeast extract, 0.5% NaCl, pH 7.0)/ampicillin 
(100J.1g/ml)/ IPTG (0.5mM)/X-Gal (80J.1g/ml) were prepared for each reaction, 
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plus two plates for determining transformation efficiency. Aliquots of I OOJ.1l of 
each transformed culture was spread on duplicate plates. For the transformation 
control (transformed with 0.2J.1g/J.1l pAMP plasmid, which is also ampicillin 
resistant), a 1:10 dilution with sac medium was used for plating, owing to an 
expectation of high colony number. The plates were then incubated overnight at 
37°C. 
2.5.2.4 Plasmid Purification Midi Kit (Qiagen) 
A single white colony was picked from a freshly streaked selective plate 
and used to inoculate a starter culture of 2-5ml LB medium also containing 
ampicillin. The medium containing the colony was incubated for approximately 
8 hours at 37°C with vigorous shaking at 300 x g. The starter culture was then 
inoculated into 50ml fresh selective LB medium, and grown at 37°C for 12-16 
hours with vigorous shaking at 300 x g. 
Plasmid purification was carried out using a commercially available kit 
(Qiagen) in which all buffers and details of their composition were supplied. 
The bacterial cells were harvested by centrifugation at 6000 x g for 15 minutes 
at 4°C prior to addition of 4ml of resuspension buffer (50mM Tris-HCl, 1 OmM 
EDT A, 1 OOJ.1g/ml RNAse A, pH8.0). A 4ml volume of lysis buffer (200mM 
NaOH, 1% sodium dodecylsu1phate (SDS)) was then added and mixed gently 
but thoroughly by inverting 4-6 times before incubating at room temperature for 
5 minutes. Chilled neutralisation buffer P3 (3M potassium acetate, pH 5.5) was 
subsequently added in 4ml volume and mixed immediately by inverting 4-6 
times, and incubated on ice for 15 minutes. The solution was centrifuged at 
15,000 x g for 30 minutes at 4°C, before removing the supematant containing 
plasmid DNA. A QIA-tip (Qiagen) was equilibrated by applying 4ml 
equilibration buffer (750mM NaCl, 50mM MOPS, 15% isopropanol, 0.15% 
Triton-XlOO, pH 7.0), and allowing the column to empty by gravity flow. Next, 
the supematant was applied to the QIA-tip and allowed to enter the resin by 
gravity flow. The QIA-tip was subsequently washed with 2 x 10ml of wash 
buffer QC (lM NaCl, 50mM MOPS, 15% isopropanol, pH 7.0) before eluting 
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DNA with 5ml elution buffer QF (1.25mM NaCl, 50mM MOPS, 15% 
isopropanol, pH 7.0). 
The DNA was precipitated by adding 3.5ml (0.7 volumes) isopropanol at 
room temperature to the eluted DNA, mixing and centrifuging immediately at 
15,000 x g for 30 min at 4°C before carefully decanting the supernatant. 
The DNA pellet was washed with 2ml 70% ethanol at room 
temperature, and centrifuged at less than 15,000 x g for I 0 min. The pellet was 
allowed to air dry for 5-IO minutes, before reconstituting in IO~l TE buffer. 
DNA concentration in ng/J..LI was then quantified using a spectrophotometer at 
260nm wavelength, as detailed in section 2.5.1 
2.5.2.5 Restriction digest of plasmid DNA 
The plasmid vector DNA purified from the bacterial cell culture was 
then resticted at two sites using enzymes Apal and San (Promega), which cut 
cDNA near the SP6 and T7 restriction sites respectively, located at either side of 
the ligated PCR product. A double digest using both enzymes was performed in 
order to remove the insert DNA from the plasmid. The following components 
were contained within a commercially available kit (Promega) and mixed in a 
O.Sml sterile tube, in accordance with the manufacturers instructions; 
Sterile water 
10 x Restriction enzyme buffer (60mM Tris-HCl pH 9.7, 
l.SM NaCl, 60mM MgCh, I OmM DTT) 
Acetylated bovine serum albumin (BSA), IO~g/~1 
cDNA (plasmid DNA) 1 ~g/~1 
Apa1, IO~g/~1 
Sail, 1 OJ..Lg/~1 
16.3~1 
2.0~1 
0.2).!1 
1.0~1 
0.5).!1 
0.5~1 
The components were mixed gently by pi petting, then the tubes were 
placed in a thermocycler, and incubated for 1 hour at 37°C enhancing enzyme 
activation followed by 1 0 minutes at 70°C to promote enzyme denaturation. 
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The restricted samples were run on an analytical agarose gel, as detailed in 
section 2.4.4.1, along with a single digest ie; Apai or San alone and unrestricted 
plasmid DNA, for comparison. The plasmid contained only one site at which 
Apal or San could cut, as detailed below. These flanked the ligation site, 
therefore allowing the portion of the vector containing the insert to be removed. 
T7 (Apa 1) recognition sequence: 
S' ... G GGCC~C ... 3' 
3' ... C jCCGG 0 ... 5' 
Sp6 (Sa/1) recognition sequence: 
S' ... G~TCGA C .. .3' 
3' ... C AGCTjG .. S' 
A preparative agarose gel (section 2.5.1.1) was used to isolate and 
purify the plasmid after linearisation by single restriction enzyme digest as 
previously described, and cut out of the gel for further analysis. 
2.5.3 RNA labelling with digoxigenin-uridine-5'-triphosphate (DIG-UTP) 
by in vitro transcription with SP6 and T7 RNA polymerases (Roche) 
For the generation of RNA probes utilizing in vitro transcription, the 
sequence to be detected, in this case HIF-1a, was cloned into a vector containing 
phage transcription promoters that can initiate transcription in the presence of 
the corresponding RNA polymerase. 
When two different phage transcription promoters are placed on either 
side of the polylinker cloning sites of the vector in opposite orientations, it is 
possible to selectively transcribe sense and anti-sense RNA probes. Transcribing 
only one strand at a time prevents re-annealing of complimentary strands during 
hybridization. By inclusion of either labeled or unlabeled nucleotides, it is 
possible to make labeled or unlabeled probes for detection of specific RNA. 
A digoxigenin (DIG)-labelled riboprobe consensus to the ligated PCR 
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product was synthesised from an RNA polymerase reaction incorporating a DIG 
label directed by the T7 or SP6 initiation sites contained in the pGEM-T vector, 
producing sense or antisense riboprobes, respectively. This assay was 
conducted using a commercially available kit. Antisense probes were then be 
used to detect complementary sequences within tissue or cells, with the sense 
probe acting as a control. 
2.5.3.1 Standard transcription assay 
One micro gram of purified template DNA, from the single restriction 
digest outlined in section 2.5.3.2, or 4J..Ll control DNA (Promega) was added to a 
sterile, RNase free tube, before adding DEPC treated water to a final volume of 
13 J..Ll. 
The standard transcription assay was carried out using a commercially 
available T7 /SP6 RNA polymerase kit (Roche ), the exact content of which is 
included in the manufacturers instructions. The following components were 
then added on ice, as recommended by the manufacturer; 
10 X DIG-UTP labelling mixture 
10 X transcription buffer 
RNase inhibitor 
RNA polymerase SP6 or T7 
The contents of the tube were then mixed gently and centrifuge briefly, 
prior to incubating for 2 hours at 37°C. After this time the reaction was 
terminated by adding 2J..Ll of 0.2M EDT A (pH 8). The resulting DIG labelled 
RNA transcripts were then stored at -20°C. 
Based on the cDNA map information provided by the manufacturer of 
the pGEM-T vector (Promega), the anti-sense probe was that transcribed from 
the San linearised plasmid DNA with SP6 polymerase (Safl/SP6), and the 
Apai!T7 transcript was the sense control. 
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2.5.3.2 Dot blot determination oflabelling efficiency 
The samples ofT? or SP6 transcribed RNA were quantified by applying 
liJ.l aliquots directly on to a strip of positively charged nylon membrane 
(Hybond). To determine concentration of the sample, a series of dilutions of 
DIG-labelled control RNA (supplied with the kit) were also applied in 11-11 
aliquots, as indicated in table 2.5. Dilution and content of tubes 1-7 are as 
specified in the manufacturers instructions. 
RNA immobilised on the membrane was then fixed using a short 
wavelength (254nm) UV light crosslinker (Uvi-pro) at 12 Joules for 60 seconds, 
prior to enzyme immunoassay detection with anti-digoxigenin-alkaline 
phosphatase (DIG-AP) and the chemiluminescent substrate CSPD, detailed in 
2.5.3.3. 
RNA 
From tube 
Assay dilution Final 
RNA(J.d) supplied with Dilution 
Tube buffer Concentration 
kit 
(JJ.l) 
dilution of 
probe and 
10 ng/JJ.l 1 - - -
unlabeled 
control RNA 
2 2 1 18 1:10 I ng/JJ.1 
3 2 2 198 1:100 10 pg/JJ.1 
4 I5 3 35 1:3.3 3 pg/JJ.l 
5 5 3 45 1:10 I pg/JJ.l 
6 5 4 45 1:10 0.3 pg/JJ.l 
7 5 5 45 1:10 0.1 pg/JJ.l 
8 5 6 45 1:10 0.03 pg/J.tl 
9 5 7 45 1:10 0.01 pg/JJ.l 
10 0 - 50 - 0 
Table 2.4 Dilution of control RNA of known concentration. As specified in 
the manufacturer's guidelines. 
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2.5.3.3 DIG Luminescent Detection Kit (Roche) 
DIG-based chemiluminescence was used to detect RNA. All solutions 
are as specified in the manufacturers instructions (Roche). 
The hybridised probes were immunodetected with anti-DIG-AP, which 
are Fah fragments conjugated to alkaline phosphatase, and visualised with the 
chemiluminescence substrate CSPD. 
Nylon membrane containing the fixed RNA sample was briefly washed 
(1-5 min) in washing buffer (0.1 M maleic acid, 0.15M NaCl, pH 7.5, 0.3% 
Tween). The following incubations were then performed at 37°C with constant, 
gentle agitation; 
- 30 minutes in lOOml blocking solution (1% (w/v) blocking reagent (Roche), 
0.1M maleic acid, 0.15M NaCl, pH 7.5) 
- 30 minutes in 20ml DIG-AP antibody solution (75 mU/ml anti-DIG-AP, 1% 
(w/v) blocking reagent, 0.1M maleic acid, 0.15M NaCl, pH 7.5) 
- 2 x 15 minutes in 1 OOml washing buffer 
- Equilibrate 2-5 minutes in 20ml detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, 
pH 9.5) 
The membrane was then placed with the RNA side facing up on one 
sheet of a plastic film folder and 2ml diluted CSPD solution was applied. The 
membrane was immediately covered with the second sheet of the folder to 
spread the substrate ~venly and without air bubbles. The membrane was then 
incubated for 5 minutes at 15 - 25°C, before squeezing out the excess liquid and 
sealing the folder. The damp membrane was incubated for a further 5-15 
minutes at 3 7°C, to enhance the luminescent reaction. 
Enzymatic dephosphorylation of CSPD by alkaline phosphatase then led 
to light emission at a maximum wavelength of 4 77nm which was recorded on 
chemiluminescent detection film (Roche), as detailed in section 2.5.3.4 
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2.5.3.4 Exposure and development of chemiluminescent film 
All steps were carried out at room temperature in a designated dark 
room. The CSPD treated membrane was exposed to chemiluminescent detection 
film for 15 - 25 minutes at room temperature. Multiple exposures were taken to 
achieve the desired signal strength. After exposure of the film, it was developed 
and fixed according to the manufacturers' directions as follows; 
- 4 minutes in developer fluid (Kodak) 
- 4 minutes in dH20 
- 4 minutes in fixing fluid (Fisons) 
The developed films were then rinsed thoroughly under running water 
and allowed to dry before inspection. A light box was used to aid visualisation 
of the resulting image. 
2.5.4 RNA labelling with biotin by in vitro transcription with SP6 and T7 
RNA polymerases 
2.5.4.1 MAXIscript in vitro transcription kit (Ambion) 
LMRP preparation was carried out as before, in sections 2.5.1 to 2.5.3. 
In vitro transcription was employed in order to produce an anti-sense RNA 
probe, by using Sa/1 to linearise the recombinant plasmid and SP6 directed 
polymerisation. 
Using the MAXIscript protocol as detailed in the manufacturers 
instructions, components were mixed to produce sample, control and marker set 
transcripts, as detailed in table 2.6. 
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Component LMRP reaction Control reaction Marker 
Nuclease free water Up to 20).11 Up to 20).11 Up to 20).11 
Apa 1 .restricted LMRP DNA template 1).1g -
pTRI-Actin-mouse control DNA - 1).1g 
template - -
Century Marker Plus Template Set 2).11 2).11 
(Ambion) 1 ).11 1 ).11 
1 OX transcription buffer 1 ).11 1 J.Ll 
lOmMATP 1 J.Ll 1 ).11 
lOmMCTP 1 ).11 1 ).11 
lOmMGTP 2).11 2).11 
lOmMUTP 
SP6 RNA polymerase 
Table 2.5 SP6 directed in vitro transcription ofLMRP RNA. The anti-sense 
probe was compared with a 'no transcription' reaction control (pTRI-Actin-
mouse control DNA template contains no SP6 polymerase promoter site) and 
Century Marker Plus Template Set reaction (Ambion) producing 100-1000 
nucleotide RNA molecular weight markers. 
- 86-
-
-
0.5).1g 
2).11 
1 ).11 
1 J.Ll 
1 ).11 
1 ).11 
2).11 
2.5.4.2 BrightStar psoralen-biotin nonisotopic labelling kit (Ambion) 
The transcripts produced in section 2.5.4.1 were then labelled with a 5' 
terminal biotin, linked via a planar psoralen conjugate which has high affinity for 
nucleic acid, using the BrightStar psoralen-biotin nonisotopic labelling kit 
(Ambion) following the manufacturers instructions. 
Concentrations of0.5-50ng/J.1l RNA transcript were denatured by heating at 
1 00°C for 10 minutes then applied to a clean untreated 96 well plate on ice. In a 
dimly lit room, the vial containing psoralen-biotin dissolved in dimethylformamide 
was briefly centrifuged, and 1 J.1l added to each sample in 96 well plate and mixed. 
The samples were irradiated with 365nm UV light for 45 minutes to activate 
biotinylation by means of long wavelength UV light catalysed covalent binding of 
psoralen to nucleic acids. Samples were then transferred to sterile RNAse free 
microfuge tubes, and made up to 1 OOJ.1l volume with TE buffer. 
Dot blot analysis oflabeling effiency, as described in section 2.5.3.2, was 
performed using serial dilutions ofknown concentration labelled control DNA (lng 
- lOfg) along with the transcripts from section 2.5.5.1. The biotinylated nucleic 
acids were then stored at -20°C short term or -80°C long term. 
2.5.4.3 BrightStar BioDetect detection kit (Ambion) 
Detection ofbiotinylated nucleic acids immobilised on nylon membrane was 
then carried out. All steps were performed at room temperature with gentle 
agitation using commercially available buffers supplied with the kit. 
The membrane was washed 2 x 5 min in wash buffer before incubating for 
2 x 5 min in blocking buffer. An extended incubation was then carried for 30 min 
in blocking buffer. The biotin label was detected firstly by binding to strepavidin-
alkaline phosphatase (strep-AP), which will bind to the biotin, was diluted in 
blocking buffer ( 1 OJ.1ll1 Oml) and mixed gently before applying to the membrane and 
incubated for 30 min. The membrane was exposed to a further 10 min in blocking 
buffer prior to 2 x 2 min incubations in assay buffer to equilibrate the membrane. 
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Five millilitres of the chemiluminescent substrate COP-star solution was then 
applied and incubated for 5 min. Cleavage of COP-star by AP bound to biotin 
produced chemiluminescence which could be detected on film. The membrane was 
then quickly blotted and wrapped in a single layer of plastic. 
COP-star reached peak emission after 2-4 hours, and exposure times were 
varied in order to detect optimum signal. Development and fixation of the exposed 
film was then carried out, as detailed in section 2.5.3.4. 
2.6 In situ hybridisation (ISH) 
A DIG-labeled single stranded RNA probe, synthesised as described in 
section 2.5.3, complementary to HIF-la was used to probe whole cell HUVEC 
preparations for expression ofHIF-la RNA 
2.6.1 Fixation of cells grown on glass slides 
HUVEC were grown on glass slides as detailed in section 2.2.2.3.2. After 
treatment, the slides were removed from the incubator, and washed 3 x 5 min in 
OEPC treated PBS. Cells were then fixed with 4% parafonnaldehyde (PF A) for 10 
minutes in a fume cupboard, before further washing in PBS for 2 x 5 min. Cells 
were dehydrated in 70% ethanol at 4°C for 30 min then washed 2 x 5 min on ice 
before incubating with 4% PF A/0.2% Triton X for 10 min on ice. Another washing 
step was carried out, then incubation with 50% fonnamide/2 x standard saline 
citrate (SSC) buffer (0.9% NaCl, 0.4% sodium citrate) (50J.!Vwell) for 10 min at 
55°C. 
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2.6.2 Hybridisation of antisense RNA probe 
The in situ hybridisation (ISH) mix was prepared fresh in a 5ml volume 
prior to hybridisation, by mixing components as detailed below; 
Chemical Final concentration in mix 
2.5ml deionised formamide 50% 
0.09g NaCl 0.3M 
lOOJ!l Tris HCl (1M, pH 7.5) 20mM 
50J.Ll EDTA (0.5M,pH 8) 5mM 
50J.!1 NaH2P04 (1M) 10mM 
1 ml dextran sulphate 10% 
1ml5 x Dernhardt's reagent (1% w/v Ficoll, 1 X 
1% w/v polyvinylpyrolidone, 1% w/v BSA, 
800J.!l denatured salmon sperm, 400J.!l 10% 
SDS, 2.4ml 20XSSC) 
250J.1l tRNA (12.5mg/ml) 0.5mg/ml 
Table 2.6 Components of ISH mix buffer 
The slides were pre-hybridised in the ISH mix for 1h, before incubating the 
cells with DIG-labeled antisense probe, transcribed from LMRP cut with Sal I and 
polymerised by SP6 polymerase, the preparation of which is detailed in section 2.5, 
diluted 1 in 40 in ISH mix. The slides were then covered with parafilm cut to well 
sized coverslips and incubated overnight at 55°C. 
2.6.3 Washing and RNAse digestion of unbound probe 
After overnight incubation, slides were incubated in 5 x SSC for 30 min at 
55°C to allow the coverslips to come off. Fifty percent formamide/2 x SSC 
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(50J..1Vwell) was added for 30 min at 55°C. Slides were then washed twice in ISH 
wash buffer at 37°C. 
RNase digestion ofunbound single-stranded probe was achieved by adding 
2JJ.l RNase (20J..1g/J..1l) to 998J..1l wash buffer (0.4M NaCl, lOmM Tris-HCl, 5mM 
EDT A) and applying 1 OOJJ.Vwell. This was then allowed to incubate for 30 min at 
37°C, prior to washing 2 X 10 min in 2X sec at the same temperature. 
2.6.4 Immunological detection of bound probe 
Prior to immunological detection, the slides were equilibrated in wash buffer 
(0.1M Tris-HCl, 0.15 NaCl, pH 7.5), then incubated for 30 min in blocking buffer 
(5% bovine serum albumin (BSA), 0.1M Tris-HCl, 0.15 NaCl, pH 7.5) with 
agitation. The DIG-AP conjugate was prepared 1:500 in blocking buffer, and 
50J..1Vwell added before incubating in a humidified chamber at room temperature for 
30 minutes. Slides were then washed 2 x 15 min in wash buffer before 
equilibrating in substrate buffer (0.1M Tris HCl, 0.1M NaCl, 0.05M MgCh). 
The colorimetric AP-substrate NBT/BCIP (18.75 mg/ml nitro blue 
tetrazolium chloride, 9.4 mg/ml5-bromo-4-chloro-3-indolylphosphate) which was 
purchased as a ready made stock solution (Roche) was diluted by adding 200J.!l 
stock solution to lOml substrate buffer. The dilute NBT/BCIP solution was then 
applied 1 OOJJ.Vwell and the slides incubated in a humidifier box in the dark for up to 
1 hour, until a purple/blue coloured precipitate was detected. At this point, the 
reaction was halted by washing the slides in distilled water. The slides were then 
allowed to dry, before mounting with Aquamount (DAKO) and applying coverslips. 
Samples were then ready to be observed by light microscopy. 
-90-
2. 7 Ribonuclease protection assay (RP A) 
The ribonuclease protection assay (RP A) probed whole cell RNA extracted 
from treated cells using the procedure detailed in section 2.4.1. A biotin-labelled 
probe complementary to HIF-la RNA, synthesised as described in section 2.5.5, 
was mixed with the whole cell RNA in solution to allow binding of the probe to its 
consensus sequence. 
2.7.1 Hybridisation of probe and sample RNA 
An RP A III kit (Ambion) was used to hybridise biotin-labelled RNA probe 
to RNA from treated cells. For the hybridisation reaction, a probe concentration of 
150 -600pg perlOJ!g total RNA was used. For each reaction, sample and probe 
were mixed in sterile RN ase free microfuge tubes. Two control tubes were also 
included, containing the same concentration of probe plus lOJ!g yeast RNA. The 
probe and sample RNA were eo-precipitated, by adjusting conditions to 0.5M 
ammonium acetate, before adding 2.5 x volume of ethanol and mixing thoroughly. 
The tubes were then incubated at -20°C for 15 minutes before centrifuging at 
12,000 x gat 4°C and discarding the supernatant. The resulting pellet was then 
resuspended in lOJ!l hybridisation buffer (supplied with kit), vortexed, then 
centrifuged briefly. 
To allow the probe to hybridise to its complementary RNA sequences in the 
sample RNA, the tubes were incubated overnight at 42°C 
2.7.2 RNAse digestion of unhybridised probe and sample RNA 
To prevent unhybridised single-stranded probe from interfering with the 
detection of bound probe, it was removed by enzymatic digestion by RNAse. 
RNAse recognised and lysed unbound single stranded RNA but not hybridised 
double-stranded RNA. 
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The RNAse mixture was prepared using the following kit components, as 
instructed by the manufacturer; 
RNase digestion Ill buffer (supplied with kit) - 150Jll/tube 
RNaseA!fl mix (250 units/ml RNase A,IO,OOO units/ml RNAse Tl) - l.5J.tl/tube 
After briefly centrifuging the hybridisation tubes, 150J.tl of the RNase 
mixture was added to each of the sample RNA tubes and to one of the two yeast 
RNA tubes, to serve as a "no target" control. Tubes were briefly vortexed. 
Hybridisation buffer alone (minus RNase) was added to the second yeast RNA tube 
to provide a "no RNAse" control for confirmation of probe integrity. 
All tubes were incubated at 37°C for 30 minutes before terminating the 
reaction with 225J.tl RNase inactivation/precipitation Ill solution (supplied with kit). 
The samples were then incubated at -20°C for 15 minutes and microfuged at 10,000 
x g for 15 min at 4 °C before removing the supernatant. 
2.7.3 Separation and detection of protected fragments 
The pelleted protected fragments were resuspended in gel loading buffer 
(95% formamide, 0.025% xylene cyanol and bromophenol blue, 18mM EDT A, 
0.2% SOS) then incubated for 3 minutes at 90-95°C. Samples were loaded onto a 
5% TBE-urea ready gel (Bio-rad) in a Mini Protean (Bio-rad) vertical gel system. 
Samples were then electrophoresed for lh at 250 volts in TBE buffer. 
The nucleic acids within the gel were transferred to positively charged nylon 
membrane (Ambion) by electroblotting for lh at 250 volts in 0.5 x TBE buffer. The 
nucleic acids were then immobilised on the membrane by UV crosslinking, before 
being subjected to chemiluminescent detection following the protocol detailed in 
section 2.5.5.3. 
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Chapter 3 
HIF-la protein expression in a rat model of diabetes 
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3.1 Introduction 
Neuropathy is the most common complication associated with diabetes mellitus, 
affecting more than half of all patients (Tesfaye et al., 1996). 
Hyperglycaemia, which is a fundamental metabolic insult associated with 
diabetes, contributes greatly to incidence and severity of peripheral neuropathy. 
Complex interactions between metabolic and vascular factors associated with diabetes 
appear to affect nerve function through vascular effects (Cameron et al., 2001). Such 
abnormalities are more severe in endoneuria! capillaries than in the epineuriem, skin or 
muscle, indicating interaction between the endoneurium and the neurovasculature to be a 
strong regulatory factor in the manifestation of hyperglycaemia associated disease (Malik 
et al., 1993). 
A growing body of evidence indicates that the prevalence of tissue hypoxia is 
associated with the development of diabetic neuropathy (Cameron & Cotter, 1997). The 
effect of diabetes on endothelial cells may be particularly significant, as increased 
endothelial cell proliferation in response to hypoxia is in itself a trigger for maintenance 
of endothelial cell growth (Hudlicka et al., 2002). However, although there is greater 
impairment of diabetic nerve function with increased ischemia, reversal of hypoxia alone 
does not result in any significant improvement in nerve function measurements (V eves et 
al., 1996). Therefore, this may indicate a role for HIF-la in the co-operation between the 
signals of glucose and hypoxia in the diabetic vasculature. 
Vascular expression ofHIF-la has previously been suggested to contribute to the 
manifestation of diabetic retinopathy (Ozaki et al., 1999; Lukiw et al., 2001 ). However, 
despite the initiation of similar responses in the vasculature accompanying the diabetic 
nerve, expression of HIF -1 a has not been investigated in diabetic neurovasculature. 
Therefore, the aim of this study was to determine whether induction of HIF -1 a 
protein was occurring within the vasculature supplying the sciatic nerve of a 
streptozotocin (STZ) diabetic rat, and if so, whether the level of expression correlated 
with duration of disease. 
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3.2 Materials and methods 
Diabetes was induced in groups of rats by administering a 45mg/kg 
intraperitoneal injection of streptozotocin (STZ). STZ-induction of diabetes was 
controlled for by saline injection in a separate group of age-matched littermates. The STZ 
rats were then euthanized 4, 10 and 24 weeks after onset of diabetes, as detailed in 
section 2.1.1, along with the age-matched controls. 
Cryostat sections of sciatic nerve surrounded by skeletal muscle were prepared 
as in section 2.1.2, and mounted on glass slides. Sections of diabetic and non-diabetic 
age-matched control were subjected to immunohistochemical detection of HIF -1 a protein 
with HIF-la monoclonal mouse primary antibody, using the avidin-biotin 
complex/alkaline phosphatase procedure (section 2.3.1.2). 
lmmunodetected slides were subsequently counterstained and mounted before 
viewing under light microscopy. Specificity of the biotinylated secondary antibody was 
controlled for using IgG 1 as the primary antibody control and TBS alone as the buffer 
control. 
For each test group, n=3 was analysed, and in all cases images shown are 
representative of that group. 
3.3 Results 
3.3.1 IDF-la expression 4 weeks after STZ-induction of diabetes 
Only small localised areas of intense HIF-1a staining were evident within the 
vasculature surrounding the sciatic nerve in the diabetic sample after 4 weeks of disease 
(figure 3.1d). At this time point, very little difference in HIF-1 a protein expression was 
seen between STZ and control samples (figures 3.1 band d, respectively). No staining of 
vessels was observed within the nerve fibre of STZ or control samples at 4 weeks, and no 
non-specific binding was detected, as shown by the lack of staining in the IgG 1 control 
antibody samples (figures 3.1a and c). 
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Figure 3.1. Immunohistochemical detection of mF-la in the sciatic nerve 
vasculature of 4 week control and diabetic rats. For the diabetic and non-diabetic 
control, rats were given an intraperitoneal injection of 45mg/g streptozotocin or saline, 
respectively. Four weeks after onset of diabetes in the STZ rats, both the treated and age-
matched controls were euthanized. Sciatic nerve sections were subsequently mounted on 
slides for immunohistochemical detection ofHIF-la protein expression. The 
photomicrographs are; a) non-diabetic control treated with lgG 1 as antibody control. b) 
non-diabetic treated with HIF -1 a antibody. c) diabetic treated with IgG 1 as antibody 
control. d) diabetic treated with HIF-la antibody. Photomicrographs are representative 
of 3 separate experiments, and the micron bar in the top left hand corner of each 
photomicrograph represents 1 OOJ.Lm. 
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3.3.2 IDF-la expression 10 weeks after STZ-induction of diabetes 
A large accumulation ofHIF-la protein confined to the vasculature surrounding 
the sciatic nerve was detected in the 10 week diabetic sample. Staining was seen to be 
particularly intense in the capillaries providing blood to the sciatic nerve (figure 3.2t). 
This staining was considerably more intense than that seen in both the 4 week diabetic 
sample (figure 3.ld) and the 10 week diabetic control (figure 3.2c) which again displayed 
very little staining. No non-specific binding of the secondary antibody was evident, as 
seen by the lack of staining in the TBS and IgG 1 control samples (figures 3.2a, b, d and 
e). 
3.3.3 IDF-la expression 24 weeks after STZ-induction of diabetes 
Expression ofHIF-la protein was still abundant in the vasculature surrounding 
the sciatic nerve of the 24 week diabetic specimen (figure 3.3c) compared to the non-
diabetic age matched control (figure 3.3a). At the 24 week time point, expression in the 
vessels perfusing the nerve fibre was also evident for the first time (figure 3.3d). 
3.3.4 Effect of a-lipoic acid dietary supplementation on the level of HIFla protein 
in the sciatic nerve of the 24 week diabetic rat. 
Supplementation of the diet of the STZ-diabetic rat with the antioxidant a-lipoic 
acid caused a visable reduction in HIF-la protein expression at 24 weeks. Samples taken 
from 24 week a-lipoic acid supplemented STZ-diabetic rats revealed a decrease in the 
expression ofHIFla in the epineurium (figure 3.4c) compared to the unsupplemented 
STZ- diabetic animals (figure 3.4b). 
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Figure 3.2. Immunohistochemical detection ofiDF-la. in the sciatic nerve 
vasculature of 10 week control and diabetic rats. For the diabetic and non-diabetic 
control, rats were given an intraperitoneal injection of 45mg/g streptozotocin or saline, 
respectively. Ten weeks after onset of diabetes in the STZ rats, both the treated and age-
matched controls were euthanized. Sciatic nerve sections were subsequently mounted on 
slides for immunohistochemical detection of HIF-1a protein expression. The 
photomicrographs are; a) non-diabetic treated with TBS as buffer control. b) non-diabetic 
treated with IgG 1 as antibody control. c) non-diabetic treated with HIF-1a. d) diabetic 
treated with TBS as buffer control. e) diabetic treated with IgG 1 as antibody control f) 
diabetic treated with HIF -1 a. Photomicrographs are representative of 3 separate 
experiments, and the micron bar in the top left hand corner of each photomicrograph 
represents 1 OOJ..Lm. 
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Figure 3.3. Immunohistochemical detection ofiDF-la in the sciatic nerve 
vasculature of 24 week control and diabetic rats. For the diabetic and non-diabetic 
control, rats were given an intraperitoneal injection of 45mglg streptozotocin or saline, 
respectively. Twenty-four weeks after onset of diabetes in the STZ rats, both the treated 
and age-matched controls were euthanized. Sciatic nerve sections were subsequently 
mounted on slides for immunohistochemical detection ofHIF-la protein expression. The 
photomicrographs are; a) non-diabetic nerve and vasculature treated with HIF-la 
antibody. b) diabetic nerve and vasculature treated with negative antibody control lgGl. 
c & d) diabetic nerve and vasculature treated with HIF-1 a antibody, the latter showing 
intense staining within the nerve fibre. The micron bar in the top left hand corner of 
each micrograph represents 1 OOJ.Lm. 
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Figure 3.4. Effect of a-lipoic acid dietary supplementation on the level of HIFlu 
protein in the sciatic nerve of the 24 week diabetic rat. Immunohistochemical 
detection ofHIF-la protein revealed a significant decrease in the expression ofHIFla in 
the epineurium of the diabetic animals treated with a-lipoic acid (c) compared to the non-
treated diabetic animals (b). A negative control sample indicates the specificity of the 
HIFla staining (a). All photomicrographs are magnification of original X 420. 
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3.4 Discussion 
This phase of the investigation has demonstrated the chronic expression of HIF-
1a within the vasculature accompanying the sciatic nerve of a rat model of experimental 
diabetes. 
Cameron et al. (1991) reported that in STZ diabetic rats, sciatic nerve blood flow 
is reduced by 40 - 50% within a week or two of diabetes induction, leading to endoneural 
hypoxia due to hyperglycemia-induced blood flow reduction and subsequent decrease in 
the conduction velocity of the sciatic nerve (Cameron & Cotter, 1992). However, 
hypoxic stabilisation ofHIF-1a protein and subsequent DNA binding of target genes is a 
very rapid process (Jewell et al., 2001) therefore the delayed induction of HIF-1a which 
was observed at 10 and 24 weeks, may suggest that high glucose is somehow interfering 
with the upregulation ofHIF-1a under hypoxic conditions, pushing back the threshold at 
which hypoxia is able to induce HIF -1 a expression. 
Vascular complications in diabetes are almost certainly predated by endothelial 
dysfunction (Wautier et al., 1996). One mechanism that has been implicated, is reduced 
nitric oxide synthase (NOS) activity (Stevens et al., 1994) caused by increased oxidative 
stress (Baynes, 1991; Ceriello et al., 1993) resulting in impaired vasodilator response 
(Rodriguez-Manas et al., 1998). 
Endothelium-dependent vasodilation of arterioles that provide circulation to the 
sciatic nerve is impaired by diabetes (Terata et al., 1999). However, in contrast to larger 
vessels in the rat where acetylcholine-induced dilation is mediated solely by NO (Sobey 
& Faraci, 1997), dilation of arterioles adjacent to the sciatic nerve is not dependent solely 
on NO, but involves a combination of endothelial derived factors (Terata et al., 1999) 
which may potentially include endothelium-derived hyperpolarising factor (EDHF) and 
prostacyclin. 
The production of reactive oxygen species (ROS) is known to increase in people 
with poorly controlled diabetes, which is particularly significant for diabetic neuropathy, 
the etiology of which has a large vascular component (reviewed by Yorek, 2003). This is 
further enhanced by advanced glycation end product formation and polyol pathway 
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activation, along with PKC activation and omega-6 essential fatty acid dysmetabolism 
(reviewed by Cameron et al., 2001). 
Antioxidants have been shown to improve neuronal blood flow and motor nerve 
conduction velocity in diabetic rats (Cameron et al., 1993). Data obtained from STZ rats 
fed the antioxidant a-lipoic acid as a dietary supplement, revealed visibly reduced 
accumulation ofHIF-1a protein at 24 weeks diabetes (figure 3.4c). The role ofHIF-1a in 
the development of diabetes-induced vascular and neural dysfunction may therefore be 
linked to redox signalling cascades activated in response to hyperglycaemia, and 
therefore will affect the availability of NO in the endothelium. 
To summarise, this chapter showed regulation ofHIF-1a protein expression in 
the vasculature of a rat model of diabetes, which may demonstrate a level of interference 
by hyperglycaemia related metabolic events in the induction of HIF-1 a in the diabetic 
vasculature. Endothelium-dependent vasodilation of arterioles that provide circulation to 
the sciatic nerve is impaired by diabetes (Terata et al., 1999). Therefore, at this point, it 
is of interest to employ a vascular endothelial cell line model of diabetes, in order to 
further the understanding of pathways and mechanisms contributing to the regulation of 
HIF-1a within the diabetic vasculature. By having the ability to manipulate the 
extracellular environment, the potential mechanisms by which oxygen and glucose 
regulate expression HIF-1 a can then be investigated. 
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Evaluation of methods for the detection of HIF-la mRNA 
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4.1 Introduction 
Technical advances in the study of molecular genetics are making it 
possible to study the temporal, spatial, histological and cytological expression of 
many genes. For this study, evaluation of HIF-1 a mRNA expression in HUVEC 
exposed to altered glucose and oxygen concentration was undertaken, due to the 
potential transcriptional regulatory effect this may have on the expression of HIF-
1a protein. 
It is widely accepted that HIF-1a is not regulated at the level of 
transcription in response to hypoxia alone (Wenger et al., 1997; Ratcliffe et a!, 
1998). However, various other stimuli do have positive and negative effects on 
HIF-1a mRNA (Kim et al., 2002; Kimura et al., 2001; Page et al., 2002; Sandau et 
al., 2001; Zelzer et al., 1998; Zhong et al., 2000). Little is known about the effect 
ofthe combined stimuli of oxygen and glucose on I,-IIF-la mRNA expression, 
therefore determining a method by which this potential transcriptional regulation 
could be measured was central to the aim of this chapter. 
The most established method for detecting nucleic acid concentration is 
by UV absorbance spectroscopy, as pioneered by Heaven and colleageues in 1955. 
However, modem technologies are allowing more accuracy and less consumption 
of precious nucleic acid samples through the use of labelled probes and 
intercalating fluorochromes, which increase sensitivity and laboratory efficiency 
due to the high through-put nature of such formats (Ahn et al., 1996). 
The various methods have relative advantages and disadvantages. By 
assessing HIF -1 a mRNA by means of in situ hybridisation, ribonuclease protection 
assay (RPA) and reverse transcriptase polymerase chain reaction (RT-PCR), the 
suitability of each method will be addressed in terms of sensitivity, specificity and 
reproducibility. 
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4.2 Materials and methods 
4.2.1 In situ hybridisation (ISH) 
Detection ofHIF-1a mRNA by in situ hybridisation was carried out on 
HUVEC grown on chamber slides, as described in section 2.2.2.3.2. A DIG-
labelled riboprobe containing the HIF-1a anti-sense sequence was produced as 
described in 2.5.3. 
After stepping down overnight, HUVEC were treated with the chemical 
inducer of hypoxia, desferrioxamine (DFO) (130J.1M) for 0, 1, 2, 4 and 6 hours 
(section 2.2.4.1). Slides were then incubated with the anti-sense probe (positive 
control), sense strand (probe control) or ~-actin (internal control) before 
chromogenic detection of bound probe, as described in section 2.6. The slides were 
then viewed microscopically for intracellular location of probe binding, as indicated 
by a purple coloured precipitate. 
4.2.2 Ribonuclease protection assay (RP A) 
RP A utilised a biotin labelled RNA probe .Produced by in vitro 
transcription ofthe HIF-1a sequence labelled with biotin (section 2.5.4). HUVEC 
were grown in 75cm2 flasks (section 2.2.2.3.1) and stepped down overnight prior to 
incubating with 5mM or 20mM glucose or mannitol (osmotic control) in normoxia 
or hypoxia (ambient or 5% ~.respectively) for 1 and 6 hours. After treatment, the 
cells were harvested and the whole cell RNA extracted (section 2.4.1 ). The sample 
RNA and single stranded probe were eo-precipitated then separated by 
electrophoresis, as detailed in section 2.7. Protected HIF-la mRNA was then 
visualised by transferring the gel to nitrocellulose membrane for chemiluminescent 
detection (section 2.5.3.3). 
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4.2.3 Quantitative Picogreen analysis of RT -PCR 
PCR based quantitative analysis ofHIF-la mRNA was carried out by 
measuring fluorescence emitted by the binding of Picogreen nucleic acid stain to 
double stranded complimentary DNA (cDNA) reverse transcribed from HIF-la 
mRNA. 
As described in section 2.4.3, cDNAs containing the HIF-la sequence were 
produced from HUVEC treated with 5mM or 20mM glucose in hypoxia or 
normoxia for 1, 6 and 24 hours. This was also carried out for ~2-microglobulin 
(fuM), using the relative primers, which would serve as an internal control to 
normalise HIF-la expression. The PCR products were mixed with Picogreen 
reagent, and fluorescence measured against dsDNA standards on a microplate 
reader, as described in section 2.4.4.2. 
4.3 Results 
4.3.1 Riboprobe synthesis for detection of HIF-lu mRNA 
PCR amplification of HIF -1 a yielded a 365 bp product (figure 4.1) which 
was ligated into the pGEMT plasmid. After bacterial cloning of the ligated plasmid 
and double digest of the cloned fragment from the plasmid vector, a 467 bp product 
was visualised, consisting of the ligated HIF -1 a fragment plus 1 02 extra bases 
included in the cut from both ligation sites, as seen in lane 2 of figure 4.2. The full 
length plasmid DNA seen in lanes 3 and 4 resulted from a single restriction digest 
with Apa I and Sal I, respectively. 
The incorporation of DIG-labelling during in vitro transcription of the 
probe resulted in a concentration ofO.Olngl~llabelled probe for both SP6 and T7 
samples, as determined by dot blot analysis (figure 4.3). The biotin probe, which 
was labelled post-transcriptionally, produced a concentration of lngl~llabelled 
probe in both SP6 and T7 samples. 
- 110-
Chapter 4: Emlumion c?fmR;\',:1 dctc<:tion method,\ 
1000 
750 
500 
300 
150 
50 
+- 365 bp HIF-la 
Figure 4.1 Electrophoretically resolved HIF-la PCR product. Amplification 
ofHIF-la mRNA was achieved by PCR using primers specific for HIF-la. The 
PCR product was then resolved using a 1.4% agarose gel containing ethidium 
bromide visualised under UV light. The position of the 365 bp HIF-la fragment, 
which has 96% sequence identity shown by product sequencing (University of 
Aberdeen), is indicated and compared to the PCR marker (bp) positioned on the 
left. 
- 111 -
Chapter 4: Emluation ofmRNA detection methods 
Supercoiled plasmid DNA 
Relaxed plasmid DNA 
467 bp fragment containing HIF-la 
1 2 3 4 5 6 
Figure 4.2 Ligation mediated recombinant plasmid cloning. After PCR 
amplification, the HIF -1 a fragment was ligated into a plasmid vector which was 
then used to transfect bacterial cells for cloning. Plasmid DNA was recovered and 
purified before samples were run on 1.4% agarose containing ethidium bromide and 
visualised under UV light. The samples are; 1) intact plasmid DNA migrating in 
supercoiled (feint upper band) and relaxed form, 2) double digested plasmid DNA 
_ lower band 467 bp fragment containing the cloned HIF -1 a insert excised from 
plasmid DNA, 3) linearised 3015 bp plasmid DNA- single digest with Apa I, 4) 
linearised 3015 bp plasmid DNA- single digest with Sal I, 5) PCR marker and 6) 
Hin d III digested lambda DNA marker, both measured in base pairs. 
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Figure 4.3 Dot blot demonstrating the quantitation of DIG-labelled 
riboprobe. The transformed plasmid DNA containing the PCR product insert was 
linearised with a single restriction enzyme digest. Polymerisation directed by the 
T7 promoter generated a sense strand probe (negative control) and polymerization 
directed by the SP6 promoter generated an anti-sense strand probe (positive 
control). SP6 and T7 polymerisation was also carried out using control yeast DNA 
containing no insert. The blots from left to right represent; 1) control labelled DNA 
of known concentration (ng/J..d), 2) SP6 promoter anti-sense transcript, 3) T7 
promoter sense transcript, 4) SP6 promoter control transcript and 5) T7 promoter 
control transcript. By comparison to the DNA of known concentration, the 
transcripts were both 0.01 ng/J..Ll concentration. 
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4.3.2 In situ detection ofiDF-lu mRNA 
Expression of the internal control, P-actin (figure 4.4a) was abundant in 
HUVEC treated for 6 hours with DFO. Staining was particularly concentrated in the 
cytoplasm at the polar regions of many cells, indicating those which may be in the 
process of division. This indicated that the concentration of DFO and time period 
of incubation were not harming cell replication. In situ detection ofHIF-la. mRNA 
expression in DFO treated HUVEC did appear to show the presence of binding in 
the antisense treated sample (figure 4.4b) compared to the sense (figure 4.4c), and 
staining appeared mainly nuclear or perinuclear in the antisense treated sample. 
4.3.3 Ribonuclease protection ofHIF-lu mRNA 
Whole cell RNA was extracted from HUVEC treated with 5mM or 20mM 
glucose or mannitol (osmotic control) in normoxia or hypoxia (5% 02) for 1 and 6 
hours. Samples of RNA were then run on 1.8% agarose gel stained with ethidium 
bromide and visualised using UV light. Detection of 28S and 18S ribosomal RNA 
in an approximate ratio of 2: 1 demonstrating no degradation of the sample is 
evident in figure 4.5a. The RNA samples were then eo-precipitated with the biotin-
labelled probe at a concentration of lOJJ.g RNA to 240pg labelled probe. None of 
the treated RNA samples showed any sign of mRNA fragment protection when 
resolved on 5% acrylamide gel. The marker set and full length 467 bp non-
hybridised probe were both detected as shown in figure 4.5b. 
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Figure 4.4: In situ detection of mRNA expression in HUVEC. Cells were 
treated with growth medium supplemented with 130J!M desferrioxamine for 6 
hours, then incubated with the respective DIG-labelled riboprobe for detection of a) 
~-actin mRNA b) HIF-la mRNA antisense c) HIF-la mRNA sense. In all images 
the micron bar represents 50Jlm. 
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Figure 4.5 Ribonuclease protection of HIF-lu mRNA. a) RNA extracted from 
6h treated HUVEC was resolved on a 1.8% agarose gel stained with ethidium 
bromide and visualised under UV light, showing the presence of the 28S and 18S 
subunits. b) The transcribed biotin labelled riboprobe containing the anti-sense 
HIF-1a RNA sequence was run on a 5% denaturing polyacrylamide gel along with 
a marker set. Full length probe was seen to be 467 bases in length. 
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4.3.4 Optimum conditions for Picogreen detection ofHIF-la mRNA 
The optimum amplification conditions for HIF -1 a and the housekeeping 
gene ~2_microglobulin (~2M) were determined using cDNA from untreated HUVEC 
in order to obtain baseline expression. Single bands were detected for HIF -1 a 
(365bp) and ~2M (32lbp) when subjected to agarose gel electrophoresis. For both 
genes, optimum amplification was obtained with 15 cycles using 2fll cDNA, which 
was equivalent to O.Olf.!g cDNA, resulting in mRNA concentration values within 
the linear phase (figures 4.6b and 4. 7b, respectively). Despite a 15 cycle 
amplification ofHIF-1a producing a barely visable band when resolved on agarose 
gel (figure 4.6a) the sensitive nature ofpicogreen binding easily detected this 
sample. At 15 cycles, ~M mRNA bands were easily visible on agarose gel (figure 
4. 7a). Picogreen binding to P2M mRNA became saturated at higher amplification 
cycles than 15, therefore preventing measurement of change in expression between 
samples. 
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Figure 4.6 Determination of optimum cycle number for HIF-la amplification. 
a) PCR was carried out using primers specific for HIF-la and 2f.ll untreated 
HUVEC cDNA. The cycle number of the PCR program was altered and amplified 
HIF-la samples visualised on ethidium bromide stained agarose gel under UV light 
produced a single 365bp band. The resolved samples represent; 1) PCR marker, 2) 
30 cycles, 3) 25 cycl.es, 4) 20 cycles and 5) 15 cycles. b) The optimum volume 
of cDNA required for 15 cycle amplification was quantified by Picogreen analysis 
of DNA concentration. This was determined to be 2f.ll, equivalent to 0.01f.Lg cDNA, 
due to its position within the linear phase of amplification. 
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Figure 4.7 Optimum expression of fhM as an internal control for IDF-la 
a) A single 321 bp band of l3zM detected after 15 amplification cycles of an 
untreated cDNA. b) The optimum volume of cDNA required for 15 cycle 
amplification of JhM was quantified by Picogreen analysis of DNA concentration. 
This was determined to be 2J.Ll cDNA, equivalent to 0.01J.Lg, due to its position 
within the linear phase of amplification. 
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4.4 Discussion 
Methods for the detection of mRNA are important for investigation of the 
role of transcriptional pathways in HIF-1a gene expression. In situ hybridisation 
(ISH) has proved a powerful tool, as seen in a mouse model of cerebral ischemia 
where changes in sub-cellular location ofHIF-la mRNA expression were observed, 
even though the total level of expression as detected by RT -PCR remained 
unchanged (Marti et al., 2000). ISH has also been used to detect an increase in 
HIF-1 a mRNA in a mouse model of epidermal wound healing and carcinogenesis 
(Elson et al., 2000). 
In this study, in situ detection of P-actin mRNA using a commercially 
prepared riboprobe (figure 4.4a) showed ISH to be a suitable method for detecting 
the presence ofmRNA in HUVEC. HUVEC probed with the synthesised HIF-1a 
antisense showed evidence of binding (figure 4.4b) compared to that of the HUVEC 
probed with the HIF-1a mRNA sense sequence (figure 4.4c). However, the 
location of the binding in this case was not cytoplasmic, as was the case for P-actin, 
but nuclear. On closer inspection of the apparent HIF-1a mRNA antisense binding 
(figure 4.4b), the strand-like appearance and alignment in dividing cells was more 
characteristic of DNA than RNA. 
Using RP A, it is possible to detect as few as 105 copies of a particular 
mRNA sequence in a complex total RNA sample, and because probe hybridisation 
to the target mRNA occurs in a liquid matrix, this allows optimal three-dimensional 
interaction between the two molecules (Rottman, 2002). However, no protected 
HIF-la mRNA fragments were detected in any of the treatments, despite the 
detection the full length native probe (figure 4.5b). Lack of detection may be due to 
the non-isotopic labelling of the probe, indeed, available literature detailing HIF-1 a 
detection by RPA cites radioactive labelling (Ameri et al., 2004), which is more 
sensitive for the detection of low abundance mRNAs. 
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Even more sensitive than RP A, is RT -PCR, which can detect 50-100 copies 
of m.RNA. This method has proved favourable for the detection of HIF -1 a mRNA, 
being frequently cited in the literature for detection in a variety of tissues and cell 
lines including human placental tissue (Caniggia et al., 2000) human ovarian 
carcinoma (Nakayama et al., 2002), glioblastoma (Sondergaard et al., 2002) and 
mouse wound cells (Albina et al., 2001). Measurement ofRT-PCR by optical 
density (OD) has shown HIF-1a mRNA expression levels to be significantly higher 
in colorectal adenocarcinoma SW 480 cells in hypoxic compared to normoxic 
conditions. The OD method, however has been found to have the highest variance 
contributable to laboratory sample handling, compared to the fluorogenic Picogreen 
method which has the least (Haque et al., 2003). 
Picogreen measurement ofRT-PCR was determined to be the most suitable 
for measurement ofHIF-la mRNA in this study. This was based upon the ease 
with which the experimental conditions could be optimised and the speed at which 
multiple samples could be read using a plate reader, resulting in a quantifiable 
measurement ofmRNA expression with low standard error between replicates. RT-
PCR also allowed the measurement of a control to which HIF -1 a expression could 
be normalised. Studies examining gene expression with RT-PCR typically 
normalise their mRNA data to a constitutively expressed housekeeping gene. A 
gene frequently chosen to normalise expression is P-actin, which is often found to 
be the most stable gene in diabetic glomeruli and in primary mesangial cells 
exposed to 20mM glucose (Biederman et al., 2004). However, P-actin, GAPDH 
and cyclophilin vary widely in hypoxia, with GAPDH considered particularly 
unsuitable as its transcription in hypoxia has been correlated in cancer cell lines 
with upregulation ofHIF-1a protein levels (Zhong et al., 1999). 
The choice of P2 microglobulin CP2M) as a control compared favourably with 
reports of it as a control for mRNA expression in hypoxic placental endothelium 
(Orange et al., 2003) and more specifically for HIF-la mRNA measurement in 
breast cancer biopsy (Cayre et al., 2003). Expression of P2M also remains 
unchanged following endurance or resistance exercise in skeletal muscle (Mahoney 
et al., 2004) negating the possible effect of lactic acid on control gene expression, 
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which was important to this study due to the potential for increased anaerobic 
glycolysis under hypoxic conditions. 
A notable limitation ofRT-PCR, however, exists in the fact that it is the 
cDNA which is measured and not the mRNA directly, as is the case for the other 
methods investigated. It was for this reason that it was important that we determine 
the optimum profile for amplification of the target sequence prior to taking 
experimental measurements. Furthermore, any changes in the level ofHIF-la 
mRNA cannot be attributed to any difference in sub-cellular location. This would 
require the complementary experimental conditions using ISH. 
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Chapter 5 
Effect of glucose and hypoxia on HIF -1 a expression in 
HUVEC 
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5.1 Introduction 
Induction of HIP-la in response to diabetes, such as that observed in this 
study within the neurovasculature of the STZ rat, and by others in the manifestation 
of diabetic retinopathy ( Ozaki et al., 1999; Lukiw et al., 2001 ), may be occurring in 
response to a variety of non-hypoxic stimuli implicated in the manifestation of 
diabetic complications. Such stimuli may include growth factors, cytokines, NO, 
thrombin and angiotensin (Agani et al., 2002; Amaral et al., 2001; Kim et al., 2002; 
Kimura et al., 2000; Sandau et al., 2001; Zelzer et al., 1998; Zhong et al., 2000). 
Despite the many metabolic and haemodynamic changes elicited by 
diabetes, sustained exposure of vascular tissues to hyperglycaemia is the main 
contributor to the pathogenesis of diabetic angiopathy. The role of HIF -1 a in the 
induction of vascular angiogenic factors and expression of genes involved in 
glucose transport and metabolism is clear, however, little is known of the ability of 
glucose to regulate expression of HIP-la. Although most reports cite HIF-la 
regulation to be post-translational, transcriptional regulation has been indicated as a 
potential mechanism by which HIF-la is regulated, such as in the induction ofHIF-
la mRNA in wound healing detected in a transgenic mouse model of neoplasia 
(Elson et al., 2000). Wound healing is an example of a physiological process 
impaired by hyperglycaemic disease, thus indicating that transcriptional events may 
be central to glucose-regulated expression ofHIF-la. 
Due to their location within the intimal layer of the vessel wall and their 
predisposition to glucose induced injury, as demonstrated by previous groups 
(Knott et al., 1996; Hammes, 2003, Creager et al., 2003), vascular endothelial cells 
are a prominent target for high ambient glucose induced injury which may be 
responsible for triggering the induction of structural and functional alterations 
associated with diabetes. 
Human umbilical vein endothelial cells (HUVEC) which are known to 
express HIF-1 (Gaddipati et al., 1999) would provide a suitable model in which to 
study the effect of hypoxia and high glucose on HIF-la mRNA and protein 
expression in vitro. By employing an established vascular cell line, such as 
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HUVEC, we are ensuring a reproducible and robust system as required for the 
identification of molecular markers of gene expression. This is preferable to the 
technically difficult and time consuming isolation of endothelium from the in vivo 
rat model, which would probably yield an insufficient cell number for the varied 
and complex experimental requirements proposed. However, the caveats to using a 
cell line are fully recognised. 
5.2 Materials and Methods 
5.2.1 Determination of cell growth and viability 
Human umbilical vein endothelial cells (HUVEC) maintained in 75cm2 
flasks (section 2.2.2.3.1) were harvested as detailed in section 2.2.2.2, before 
reseeding in 96 well plates, as described in section 2.2.2.3.3. Alamar blue indicator 
was added to growth medium containing either 5mM or 20mM glucose, and cells 
incubated under normoxia or hypoxia, as described in section 2.2.4.2. Cell growth 
was then measured at 0, 1, 6, 24 and 29 hours by determination of absorbance at 
570nm using an automated plate reader (section 2.2.3.2). 
5.2.2 Incubation of HUVEC with altered glucose and oxygen concentration 
HUVEC were grown in 75cm2 flasks (section 2.2.2.3.1) then incubated in 
growth media as prepared in section 2.2.5, containing 5mM glucose or 20mM 
glucose in normoxia or hypoxia for 1, 6 and 24 hours, as described in section 
2.2.4.2. Total RNA was then extracted from the HUVEC (section 2.4.1) and 
cDNAs produced by reverse transcription (section 2.4.3 .1 ). 
5.2.3 Determination of gene expression by Picogreen quantification of PCR 
products 
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The cDNAs transcribed from treated HUVEC were subsequently primed for 
specific target gene amplification by PCR, as detailed in section 2.4.3.3. 
Expression ofHIF-1a, HIF-1a antisense (aHIF), glucose transporter type 1 (GLUT-
1) and insulin-like growth factor-1 receptor (IGF-1R) mRNAs were determined by 
PCR directed by short nucleotide primer pairs specific for the amplification of the 
target gene, as laid out in table 2 .1. Amplification of the target gene was then 
measured quantitatively on a plate reader using Picogreen fluorogenic substrate and 
read using a microplate reader (section 2.4.4.2). Data shown in figures 5.2, 5.3, 5.4 
and 5.6 represent the mean of 3 separate PCR reactions for each time point and 
condition. Each of the 3 separate PCR reactions for each time point and condition 
were carried out using cDNA produced from a different cell population. The PCR 
product resulting from each of the 3 reactions was subsequently read in triplicate on 
the multi-well plate reader, in order to account for intra-experimental error. 
5.2.4 Inhibition of RNA transcription and protein translation 
HUVEC grown in 75cm2 flasks (section 2.2.2.3.1), were then exposed to 
concentrations of glucose and oxygen as described previously in the presence of 
either an inhibitor of RNA transcription, actinomycin D (Act D) or an inhibitor of 
protein translation, cyclohexamide ( CHX) for 1, 6 and 24 hours, as described in 
section 2.2.6.1. cDNAs were then produced from the treated cells as described in 
section 2.4.3.1, subjected to PCR amplification ofHIF-la mRNA (section 2.4.3.3) 
and measured using Picogreen fluorogenic reagent (section 2.4.4.2). 
5.2.5 Immunocytochemical detection ofHIF-la protein expression in HUVEC 
HUVEC maintained in 75cm2 flasks (section 2.2.2.3.1) were harvested as 
previously described and seeded on 2 well chamher slides (2.2.2.3.2). The HUVEC 
grown on chamber slides were then incubated for 24 hours in concentrations of 
glucose and oxygen as described previously (2.2.4.2). 
The slides were then subjected to immunocytochemical detection ofHIF-1a 
protein with HIF-la monoclonal mouse primary antibody, using the avidin-biotin 
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complex/alkaline phosphatase procedure (sections 2.3.1.2 and 2.3.1.3). 
Immunodetected slides were subsequently mounted before viewing by light 
microscopy. 
5.2.6 Data Analysis 
Statistical analysis of data was carried out using one-way analysis of 
variance (ANOV A) followed by post-hoc tests. Level of significance was then 
conveyed using the following notation; * (p<0.05), **(p<O.Ol), ***(p<0.001). 
5.3 Results 
5.3.1 Effect of altered glucose and oxygen concentration on HUVEC growth 
Prior to experimentation, it was important to ascertain what effect the test 
conditions which were to be employed would have on HUVEC proliferation and 
viability. Growth curves obtained from measurement of oxidation of Alamar blue 
substrate in culture, as demonstrated in figure 5.1, showed that in all treatments, 
proliferation of HUVEC continued beyond 24 hours, which was ~o be the maximum 
incubation period used in this study. 
Up to 6 hours, no significant difference in proliferation was detected 
between growth conditions. Throughout the entire growth period monitored, 
HUVEC incubated in media containing a high concentration of glucose and those 
incubated in hypoxic conditions produced very similar growth curves, both of 
which demonstrated a higher rate of proliferation than cells subjected to standard 
growth conditions (5mM glucose, normoxia). The combination of high glucose and 
hypoxia had an additive effect on the proliferation rate after 6h incubation, which 
by 24h was significantly greater than that of all other conditions, most notably the 
normal growth conditions (p<0.001). 
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Figure 5.1. HUVEC growth curves in response to altered glucose and oxygen 
concentration. HUVEC were seeded at a density of 0.025 x 106 cells/m! on a 
microtitre plate and allowed to grow overnight under standard conditions. Cells 
were then incubated with fresh growth media supplemented with either 5mM or 
20mM glucose and 10% (w/v) Alamar blue substrate. The plates were subsequently 
incubated under normoxic or hypoxic conditions (ambient or 5% 0 2, respectively), 
and cell proliferation measured at 0, 1, 6, 24 and 29 hour intervals on a colorimetric 
microplate reader as absorbance at 570nm. Results shown are the mean of n=3. 
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5.3.2 Effect of altered glucose and oxygen concentration on HIF-la mRNA 
expression. 
HUVEC incubated in 5mM glucose under normoxia showed steady state 
levels ofHIF-la mRNA expression throughout the time period examined. Also, no 
significant change was observed when oxygen tension was decreased to 5%, 
whether combined with 5mM or 20mM glucose. However, after 24h incubation in 
20mM glucose under normoxia, HIF -1 a mRNA expression was detected to be 
significantly higher (p<O.OOI) than all other samples, as shown in figure 5.2 
5.3.3 Contribution of transcription and translation pathways to regulation of 
IDF-lamRNA. 
In order to determine whether the increase in HIF -1 a mRN A detected in 
response to 20mM glucose at 24 hours was mediated by transcriptional or 
translational responses, the media was supplemented with the respective inhibitors, 
Act D and CHX. 
As demonstrated in figure 5.3, the increase in the level ofHIF-la mRNA 
detected in response to 20mM glucose is unaffected by blocking transcription. 
However, the mRNA level in the correlating hypoxic sample, which was not seen to 
change in the absence of Act D, now appears to decrease indicating that 
transcription ofHIF-la mRNA does occur in these conditions. 
In figure 5.4, it can be seen that the elevated expression ofHIF-la mRNA in 
response to 20mM glucose is blocked by the inhibitor of protein translation, CHX. 
Unlike Act D, CHX was not observed to have a significant effect on any of the 
hypoxic responses at 24 hours. 
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Figure 5.2: Effect of time, glucose and oxygen concentration on HIF-la mRNA 
expression. HUVEC were exposed to 5mM or 20mM glucose under 5% or 
ambient 0 2 for 1, 6 and 24 hours. Total RNA was then extracted and used for 
reverse transcription. The resultant cDNAs were subsequently primed for HIF-l a 
and B2 microglobulin (BzM) amplification by PCR, which was measured 
quantitatively on a plate reader using Picogreen. At 24 hours, expression in the 
nonnoxic 20mM sample is significantly higher than all other samples. Results 
shown are expressed as the ratio of HIF-1 a PCR product measured (ng) to that of 
B2M (ng). Data shown are representative of n=3. 
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Figure 5.3: Effect of Act Don HIF-la expression at 24h in 20mM glucose. 
HUVEC were incubated for 24h in media containing 20mM glucose with or 
without Act D under normoxic conditions. Total RNA was then extracted and used 
for reverse transcription. The resultant cDNAs were subsequently primed for HIF-
la. and B2M amplification by PCR, which was measured quantitatively on a plate 
reader using Picogreen. Act D did not affect the stability of HIF -1 a. expression 
detected with 20mM glucose under normoxia. Results shown are expressed as the 
ratio ofHIF-la. PCR product measured (ng) to that ofB2M (ng). Data shown are 
representative ofn=3. 
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Figure 5.4: Effect of CHX on HIF-la expression at 24h in 20mM glucose. 
HUVEC were incubated for 24h in media containing 20mM glucose with or 
without CHX under normoxic conditions. Total RNA was then extracted and used 
for reverse transcription. The resultant cDNAs were subsequently primed for HIP-
la and B2M amplification by PCR, which was measured quantitatively on a plate 
reader using Picogreen. CHX significantly decreased the stability of HIF-1 a 
expression detected with 20mM glucose under normoxia. Results shown are 
expressed as the ratio ofHIF-la PCR product measured (ng) to that ofB2M (ng). 
Data shown are representative ofn=3. 
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5.3.4 Effect of altered glucose and oxygen concentration on expression of 
genes induced by IDF-la, and its natural antisense, aHIF. 
GLUT-I and IGF-lR are involved in glucose transport and metabolism, 
respectively, and both are know to be involved in HIF-la signalling. Relative 
levels ofGLUT-1 and IGF-lR mRNA expression, as measured by detection of their 
PCR products, was found to be unaffected by high glucose concentration 
throughout the incubation period (0-24h), as shown in figure 5.6. The level of 
aHIF, also demonstrated in figure 5.6, was seen to increase slightly at 6h (p<O.OS), 
however this had returned to basal levels by 24h. 
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Figure 5.6: Expression of GLUT-1, IGF-lR and aHIF mRNA compared to 
that ofHIF-la in response to 20mM glucose. HUVEC were incubated in media 
containing 20mM glucose under normoxia for 0, 1, 6 and 24 hours . Total RNA was 
then extracted and used for reverse transcription. The resultant cDNAs were 
subsequently primed for HIF-1a, GLUT-I , IGF-lR, aHIF and B2 microglobulin 
amplification by PCR, which was measured quantitatively on a plate reader using 
Picogreen. Unlike HIF-1a, GLUT-1 and IGF-1R mRNA levels remained 
unchanged throughout the experiment. The level of aHIF increased slightly 
(p<0.05) at 6h compared to Oh, then dropped at 24h. Results shown are in relation 
to the value obtained at t=O expressed as arbitrary units, and are representative of 
n=3. 
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5.3.5 Effect of altered glucose and oxygen concentration on mF-la protein 
expression 
HIF-la protein expression was then investigated, in order to ascertain the 
effect of altered glucose and oxygen concentration on protein at 24h. 
Under conditions of 5mM glucose, normoxia, HIF -1 a protein expression 
was observed in HUVEC after 24h. Protein expression in these cells was seen to be 
peri-nuclear, and in many cells concentrated at the poles, as seen in figure 5.7c. 
Incubation of HUVEC for 24h under normoxic conditions in media 
supplemented with 20mM glucose again showed peri-nuclear staining, however 
staining intensity was visibly reduced compared to the correlating 5mM glucose 
sample (figure 5.7d). 
Under hypoxic conditions with 5mM glucose, HIF-la. protein is strongly 
expressed in the whole nucleus of most cells, as would be expected (figure 5.7e). 
However, hypoxia combined with 20mM glucose not only shifted expression to the 
peri-nuclear region of the cells (figure 5.7f), but also caused a visible reduction 
compared its 5mM glucose equivalent (figure 5.7e). Despite this, expression did 
appear greater than in the equivalent normoxic sample (figure 5.7d). 
- 140-
Figure 5.7: Immunocytochemical detection of HIF-la protein expression in 
HUVEC. HUVEC were seeded on chamber slides at 0.025 x 106 cells/ml. After an 
initial growth period, cells were then exposed to 5mM or 20mM glucose under 
normoxic (ambient Oz) or hypoxic (5% Oz) conditions for 24h before 
immunodetection ofHIF-la protein expression. The following photomicrographs 
show; a) HUVEC probed with control antibody (lgG 1) in order to determine 
antibody specificity, b) HUVEC incubated with TBS alone as buffer control, c) 
HIF -1 a protein detected in HUVEC treated with 5mM glucose under normoxia, d) 
20mM glucose under normoxia, e) 5mM glucose under hypoxia and 0 20mM 
glucose under hypoxia. The micron bar in top left hand corner of each micrograph 
represents 50J.Un. Images shown are representative of n=3. 
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5.3 Discussion 
Endothelial cells are known to be largely hypoxia-tolerant, as their ability to 
proliferate in low oxygen tension is essential for the maintainence of vascular 
endothelial integrity (Graven et al., 1993, Tucci et al., 1996). The combination of 
hypoxia and hyperglycaemia also occurs frequently in diabetic disease, whereby 
rapidly proliferating tissues associated with secondary complications become 
ischemic due to inadequate vascular supply. 
In this study, it was demonstrated that when applied individually, hypoxia or 
glucose levels occurring in hyperglycaemia, stimulate cell growth to a greater 
extent than that seen under standard growth conditions over the 29h period 
monitored. Furthermore, when combined the two stimuli have an additive effect 
upon cell proliferation. Hypoxia has previously been identified as a trigger for a 
positive feedback mechanism whereby changes in endothelial cells maintain 
proliferation (Hudlicka et al., 2002). Therefore, these observations suggest that 
cross-talk between the two signals may enhance this mechanism. 
No change in HIF-la mRNA level was observed in response to hypoxia at all 
time points, compared to that of standard growth conditions. This is in agreement 
with several studies that have shown that under these conditions, HIF-la is 
regulated at the level of the protein, with mRNA remaining stable (Huang et al., 
1996., Gradin et al., 1996., Hara et al., 1999). 
However, 20mM glucose under normoxic conditions significantly increased 
the level ofHIF-la mRNA detected at 24 hours. This response may therefore 
indicate that regulation of mRNA expression by elevated glucose represents a 
mechanism by which HIF-la is regulated in endothelial cells. As such, regulation 
ofHIF-la at the level of transcription may represent a coordinative adaptive 
responses to hyperglycaemia in the diabetic milieu. 
To further understand the observation of increased HIF-1a mRNA expression 
in cells exposed to high glucose in normoxia at 24 h, assessment of transcriptional 
and translational regulation ofHIF-1a mRNA was necessary. It was found that 
inhibition of transcription using Act D had no significant effect on the increase in 
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HIF-1a mRNA expression detected, suggesting that increased levels are due to 
enhanced mRNA stability, as opposed to increased transcription. Interestingly, 
although high glucose combined with hypoxia had no effect on HIF-la mRNA 
level, treatment with Act D did cause a small yet significant reduction in the level 
ofHIF-la mRNA detected in this sample. 
Inhibition of protein translation using CHX did prevent increased detection in 
20mM glucose with nonnoxia. This indicates the requirement for de novo protein 
synthesis for the hypoxia-independent stimulation ofHIF-la mRNA by high 
glucose, which has also been implicated in the action of other non-hypoxic stimuli 
on HIF-1 a expression (Shi et al., 2005; Frede et al., 2005). 
The natural antisense of the HIF-1a transcript (aHIF), which is complementary 
to the 3' untranslated region of HIF -1 a, does not encode a protein, but is implicated 
in the degradation ofHIF-la mRNA (Thrash-Bingham & Tartof, 1999). At 6h, 
exposure of HUVEC to high glucose under nonnoxia caused a small but significant 
increase in the level of aHIF detected. This did not coincide with any change in 
HIF-1a mRNA at the same time point; however, it may have contributed to the 
maintenance of baseline level HIF-1a mRNA. Therefore, increased aHIF may keep 
the HIF -1 a mRNA levels in check in response to increasing levels of stimulation. 
The return of aHIF levels to baseline at 24h exposure to high glucose may indicate 
that such a level of exposure to glucose is out with the control of aHIF, thus 
offering an explanation for the increase in HIF-la mRNA level detected at this 
time. 
In order to determine whether observed changes in the level ofHIF-la mRNA 
were specific for HIF-la or due to a generalised change in mRNA level, the 
expression of GLUT -1 and IGF-1 R mRNA was measured in equivalent samples. 
As an inherent effect of increased extracellular glucose concentration is altered 
uptake, it was therefore important to investigate the effect ofhigh·glucose on 
GLUT-I mRNA in relation to that ofHIF-1a. It was subsequently shown that 
exposure ofHUVEC to high glucose had no significant effect on GLUT-I mRNA 
levels, although high extracellular glucose has been shown to decrease GLUT-1 
mRNA levels in fibroblasts and pericytes (Whitesell et al., 1990, Mandarino et al., 
1994). Previous groups have'observed no reduction in expression ofGLUT-1 
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protein in response to elevated glucose in human retinal endothelial cells (Knott et 
al., 1996), bovine retinal endothelial cells (Mandarino et al., 1994) or bovine aortic 
endothelial cells (BAEC) (Kaiser et al., 1993). Although in this study protein 
levels were not measured, the mRNA data obtained does elude to a general 
endothelial cell response to high glucose, such as that described by previous 
groups. 
The critical balance between the positive metabolic and negative angiogenic 
properties of IGF-1 in the prevention and treatment of diabetic complications has 
been highlighted (Knott, 1998). HIF-la may participate in the responsiveness of 
the tissue to IGF-1, as previous studies have indicated functional IGF-1 receptor 
(IGF-IR) to be essential for chemically induced non-hypoxic induction ofHIF-la 
(Agani et al., 1998). This study found that 20mM glucose in the presence of 
normoxia had no effect on the level ofiGF-lR mRNA detected. Although this 
does not tell us anything about IGF-1, it may indicate that elevated glucose is not 
affecting the sensitivity ofthe tissue to IGF-1. 
The lack of change in GLUT-I or IGF-IR mRNA levels coincident with 
elevated HIF-la mRNA demonstrates that increase in mRNA level detected in 
response to high glucose is specific to HIF -1 a. Therefore, this poses the question as 
to what is happening to HIF-la protein expression at 24h in elevated glucose. 
In this study, abundant detection ofHIF-la protein in the nucleus of 
endothelial cells exposed to hypoxia agrees with expression found in endothelial 
cells derived from heart tissue in response to myocardial hypoxia (Lee et al., 2000). 
It was also shown that HUVEC are very sensitive to hypoxia, due to the large 
increase in HIF-la protein expression in response to 5% oxygen with 5mM glucose, 
compared to ambient oxygen levels, a response which is not evident under the same 
conditions in human lung epithelial cells (Uchida et al., 2004). When SmM glucose 
was replaced with 20mM, HIF-la protein expression detected in HUVEC was not 
only visibly reduced, but also appeared primarily in the peri-nuclear region rather 
than within the nucleus. 
Elevated HIF-la mRNA level detected at 24h in 20mM glucose under 
normoxia actually coincided with visibly reduced protein expression at this time, 
compared to standard growth conditions. The observation of reduced expression of 
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HIP-la protein in HUVEC treated with 20mM glucose combined with hypoxia, 
may represent a negative feedback mechanism by which HIF -1 a protein is down 
regulated under conditions of high glucose. However, in normoxia, increased HIF-
1a mRNA level as a result of increased stability in 20mM glucose suggested a 
block on translation ofmRNA to protein, resulting in absolute levels ofmRNA 
building up within the cell, and protein decreasing. Therefore, reduced HIF -1 a 
protein in response to 20mM glucose may be elicited via different mechanisms 
under hypoxic and normoxic conditions. 
The effect of elevated glucose on HIF -1 a expression are in partial agreement 
with those ofCatrina and colleagues (2004), who reported hyperglycaemia to 
reduce hypoxia induced protein stability in human dermal microvascular endothelial 
cells (HDMEC). Catrina's observation of no change in mRNA expression or 
protein expression in response to high glucose alone is not contradictory to our 
findings, but may highlight the different responses to glucose which are elicited in a 
microvascular EC line (HDMEC) compared to a macrovascular EC line (HUVEC). 
This information therefore requires the consideration of mechanisms 
responsible for the induction ofHIF-la mRNA in the presence of high glucose. As 
the significance of mRNA stability has already been highlighted in the course of 
this study, the next stage will address the question of which signalling pathways are 
initiating this stability, what is the contribution of glucose metabolism and, as 
protein translation is implicated in the response, are RNA binding proteins being 
expressed which will interact with the instability element ofHIF-1a mRNA. 
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Chapter 6 
Mechanism of regulation of HIF -la mRNA level in 
HUVEC 
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6.1 Introduction 
In this study, it has been seen that incubation of HUVEC with high glucose 
stabilised HIF-la mRNA levels at 24 hours under normoxic conditions. As this 
was not seen in the equivalent hypoxic sample, it was therefore important to 
determine the mechanism/s by which glucose may be regulating HIF-la mRNA 
independently of hypoxia. 
Signalling by reactive oxygen species (ROS) is a potential mechanism by 
which high glucose may be regulating the stability ofHIF-1a mRNA, as 
hyperglycaemia is known to increase oxidative stress beyond the protective 
capabilities of the cell. ROS are also able to feed into and enhance other signalling 
pathways, such as p42/44 MAPK (Chess et al., 2005). In clinical trials, the potent 
antioxidant a-lipoic acid has been reported to improved glucose metabolism in 
human diabetes (Jacob et al., 1995) and be beneficial in the treatment of diabetic 
neuropathy (Ziegler et al., 1999). Indeed, this study has shown that supplementing 
the feed of STZ rats with a-lipoic acid diminishes HIF-1 a protein expression in the 
vasculature supplying the sciatic nerve, as shown in chapter 3. 
Pi3K and MAPK signalling pathways are implicated in the action of non-
hypoxic mediators of HIF-1 a protein stabilisation, including that of AGEs (Treins 
et al., 2001) and cytokines (Hellwig-Burgel et al., 2005). In order to understand 
the implication of high glucose in the stabilisation ofHIF-la mRNA via these 
signalling pathways, the effects of specific inhibitors of p42/44 MAPK (PD98059) 
and the pllO subunit ofPi3K (LY294002) on HIF-la mRNA level detected in 
HUVEC exposed to high glucose under normoxia were studied. 
Finally, in order to elucidate the contribution of hexose metabolism to the 
regulation ofHIF-la mRNA stability, the influence of replacing D-glucose with the 
glucose analogues, 2-deoxyglucose (2-DG) and 3-orthomethylglucose (3-0MG) 
was also studies. These analogues can be transported into the cell but not fully 
metabolised, therefore allowing the ability to distinguish whether hexose transport 
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or metabolism is mediating the permissive effect of high glucose on the stability of 
HIF-1a mRNA. 
6.2 Materials and Methods 
6.2.1 Effect of the antioxidant a-lipoic acid on level ofHIF-la mRNA 
detected. 
HUVEC were grown in 75cm2 flasks (section 2.2.2.3.1) then incubated in 
growth media containing 20mM glucose supplemented with 250)J.g/ml a-lipoic acid 
(2.2.6.3) under normoxic conditions for 1, 6 and 24 hours. HIF-la mRNA level 
was then measured by Picogreen detection ofPCR product (2.4.3.3 and 2.4.4.2). 
6.2.2 Effect of inhibition of protein kinase activity on level ofHIF-la mRNA 
detected. 
HUVEC were cultured in 75cm2 flasks as before, and exposed to either 5 or 
20mM glucose in conjunction with normoxia were supplemented with either PI3K 
inhibitor, L Y294002 or p42/44 MAPK inhibitor, PD98059, at 1 O).lg/ml and 2Jlg/ml 
respectively, as detailed in section 2.2.6.2. The effect of inhibition of each kinase 
on HIF-la mRNA expression in HUVEC after 1, 6 or 24h was then assessed by 
PCR and Picogreen detection, as detailed earlier in this chapter. 
6.2.3 Effect of glucose analogues, 2-deoxyglucose and 3-orthomethylglucose, 
on HUVEC growth and IDF-la mRNA level detected. 
6.2.3.1 Determination of cell growth and viability 
HUVEC growth was measured using alamar blue (section 2.2.3.2), when 
incubated in either 5mM or 20mM of 2-deoxyglucose (2DG) or 3-
orthomethylglucose (30MG) (2.2.5) in place of glucose, combined with normoxia 
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or hypoxia. Measurements were was then taken at 0, 1, 6, 24 and 29 hours using a 
plate reader (section 2.2.3.2). 
6.2.3.2 Determination ofHIF-la mRNA level 
HUVEC were grown in 75cm2 flasks (section 2.2.2.3.1), then incubated in 
20mM 2DG or 30MG in place ofD-glucose (2.2.5) under normoxic conditions for 
24h. cDNAs were then produced from the treated cells as described in section 
2.4.3.1, which were then subjected to PCR amplification ofHIF-1a mRNA (section 
2.4.3.3) and measured using Picogreen detection (section 2.4.4.2). 
6.2.4 Data Analysis. 
Statistical analysis of data was carried out using one-way analysis of 
variance (ANOV A) followed by post-hoc tests. Level of significance was then 
conveyed using the following notation; * (p<0.05), **(p<O.Ol), ***(p<O.OOl). 
6.3 Results 
6.3.1 Effect ofthe antioxidant a-lipoic acid on level ofHIF-la mRNA level 
detected 
Incubation of HUVEC in media containing 20mM glucose supplemented 
with a-lipoic acid resulted in reduced detection ofHIF-la mRNA compared to that 
detected in the a-lipoic acid-free media, as shown in fig 6.1. This reduction was 
most significant at 24h (p<O.OOl), with resultant detection level similar to that seen 
in samples where HIF-la mRNA was not subject to stabilisation by high glucose. 
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Figure 6.1: Effect of a-lipoic acid on HIF-la mRNA level detected. HUVEC 
were incubated in media containing 20mM glucose with or without a-lipoic acid, 
under normoxic conditions for 1, 6 and 24 hours. Total RNA was then extracted 
and used for reverse transcription. The resultant cDNAs were subsequently primed 
for HIF-la and B2M (internal control) amplification by PCR, which was measured 
quantitatively on a plate reader using Picogreen detection. Treatment with a-lipoic 
acid resulted in reduced HIF-la mRNA detected at 24h (p<O.OOl). Results shown 
are expressed as the ratio ofHIF-la PCR product measured (ng) to that ofB2M 
(ng), and is representative of 3 separate experiments. 
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6.3.2 Effect of protein kinase inhibition on level of HIF-la mRNA detected 
Incubation of HUVEC in media containing 20mM glucose supplemented 
with either the Pi3K inhibitor L Y294002 or p42/44 MAPK inhibitor PD98059, 
resulted in reduced level ofHIF-la mRNA detected at all time points compared to 
the equivalent inhibitor-free samples, as shown in figure 6.2. At lh, both inhibitors 
reduced detection to a similar extent (p< 0.01). At 6h, the level ofHIF-1a mRNA 
detected is further reduced in response to treatment with p42/44 MAPKi, although 
level of detection in the Pi3Ki treated sample is unchanged from lh. At 24h, 
however, detection level ofHIF-la mRNA with p42/44 MAPKi was raised 
compared to that seen at 6h, yet this level was still significantly lower than that 
detected in the equivalent inhibitor-free sample (p< 0.01). Inhibition ofp42/44 
MAPK at 24h allowed partial stabilisation ofHIF-la mRNA in response to 20mM 
glucose, however inhibition of Pi3K at 24h substantially reduced the ability of 
20mM glucose to stabilise HIF-1a mRNA (p<O.OOl) or inhibited the signals the 
facilitate stabilisation. 
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Figure 6.2: Effect of Pi3Ki and p42/44 MAPKi on HIF-la mRNA level 
detected. HUVEC were exposed media containing 20mM glucose with or without 
Pi3K inhibitor (Pi3Ki) or p42/44 MAPK inhibitor (MAPKi) under normoxic 
conditions for 0, 1, 6 and 24 hours. Total RNA was then extracted and used for 
reverse transcription. The resultant cDNAs were subsequently primed for HIF-la. 
and B2M amplification by PCR, which was measured quantitatively on a plate 
reader using Picogreen detection. At 24h, HIF-la. mRNA detected in both Pi3Ki 
(p<O.OOl) and p42/44 MAPKi (p<O.Ol) treated samples was significantly lower 
than in the inhibitor free sample. Results shown are expressed as the ratio ofHIF-
1 a. PCR product measured (ng) to that of B2M (ng), and are representative of 3 
separate experiments. 
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6.3.3 Effect of the glucose analogues, 2-deoxyglucose and 3-
orthomethylglucose, on growth of HUVEC 
Under normoxic conditions, increasing D-glucose concentration from 5mM 
to 20mM resulted in a significant increase in proliferation (p<O.OOl), as shown in 
figure 6.4. This was also the case under hypoxic conditions (p<O.Ol), with both 
measurements appearing higher than the equivalent normoxic samples, although 
this was not significant. 
The analogue 2DG had no significant effect on cell growth at 24h at either 
concentration, whether under normoxic or hypoxic conditions. Furthermore, 
proliferation was maintained at a similar level to that seen under standard growth 
conditions (5mM glucose, normoxia). 
Incubation of HUVEC with 5mM 30MG did result in increased 
proliferation under hypoxic conditions compared to the equivalent D-glucose and 
2DG treated samples. At 20mM, however, 30MG had no significant effect on 
proliferation in normoxia or hypoxia compared to equivalent samples with the other 
two analogues. This was also significantly lower than that seen under hypoxic 
conditions with 5mM 30MG (p<O.Ol). 
6.3.4 Effect of the glucose analogues on HIF-la mRNA expression at 24 hours 
As demonstrated in figure 6.4, HUVEC incubated for 24h with media 
containing 20mM of either 2-DG or 3-0MG in place of D-glucose under normoxic 
conditions, did not display stabilisation ofHIF-la mRNA, as was observed in 
response to the equivalent sample incubated with D-glucose. Furthermore, no 
difference was observed in the level of detection in either of the 20mM analogue 
treated samples under hypoxic conditions compared to the D-glucose equivalent. 
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Figure 6.3. HUVEC growth in response to glucose analogues at 24h. HUVEC 
were seeded at a density of 0.025 x 106 cells/m! on a microtitre plate and allowed to 
grow overnight under standard conditions. Cells were then incubated with fresh 
growth media supplemented with D-glucose, 2DG or 30 MG and 10% (w/v) 
Alamar blue substrate. Plates were subsequently incubated under normoxic 
conditions, and cell proliferation measured at 24h on a colorimetric microplate 
reader as absorbance. Results shown are representative of n=3. 
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Figure 6.4: Effect of glucose analogues 2DG and 30MG on HIF-la mRNA 
detection HUVEC were exposed to 5mM or 20mM of the glucose analogues 2-
deoxyglucose (2DG) and 3-orthomethylglucose (30MG), under normoxia for 24 
hours. Total RNA was then extracted and used for reverse transcription. The 
resultant cDNAs were subsequently primed for HIF-la and B2M (internal control) 
amplification by PCR, which was measured quantitatively on a plate reader using 
Picogreen detection. Neither analogue was capable of recreating the increase in 
HIF-la mRNA level detected in response to D-glucose (p>O.OOI). Results shown 
are expressed as the ratio ofHIF-la PCR product measured (ng) to that ofB2M 
(ng), and representative ofn=3. 
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6.3 Discussion 
Endothelial cells could conceivably generate ROS from an NAD(P)H oxidase 
system, xanthine oxidase, or the mitochondrial electron transport (ET) chain. A 
growing body of evidence suggests that mitochondria respond to cellular hypoxia 
by paradoxically increasing their generation of ROS (Chandel et al., 2000a). ROS 
appear to initiate intracellular redox signaling and to contribute to a broad range of 
adaptive responses in hypoxic cells, including HIF-1 activation (Chandel et al., 
2000b; Chandel et al., 1998). 
Alpha-lipoic acid (LA) has been shown to lower glucose levels in animal 
models of diabetes and human type 2 diabetes (Packer et al., 2001). LA is capable 
of crossing biological membranes and altering the redox status of cells (Tirosh et 
al., 2003) and is an essential co-factor in oxidative metabolism via the pyruvate 
dehydrogenase (PDH) complex. This results in the reduction of serum lactate and 
pyruvate concentrations by direct stimulation ofPDH activity, as observed in 
diabetic rats (Large & Beylot, 1999). 
Lu and colleagues reported that pyruvate inhibits the activity ofprolyl 
hydroxylases which degrade HIF-la protein under normoxic conditions, therefore 
maintaining the stability ofHIF-la protein (Lu et al., 2005). Therefore, our 
fmdings of reduced HIF-1a mRNA stability in HUVEC incubated in 20mM glucose 
in the presence of LA may demonstrate that pyruvate is also capable of controlling 
HIF-la stability at the level ofmRNA. However, this does not explain why the 
same effect is not seen in response to hypoxia, as anaerobic respiration due to 
lowered oxygen will also result in production of pyruvate. 
LA is known to activate several components of the insulin signalling pathway 
including Pi3K and MAPK (Konrad et al., 2001). Both Pi3K and MAPK pathways 
are implicated in enhancing HIF-1 protein expression and activity in tumour cells or 
cells stimulated by mitogenic signalling under normoxic conditions (Stiehl et al., 
2002; Zhong et al., 2000). Of the few reports which detail the effect of such 
signalling on HIF-1a mRNA, Pi3K is highlighted as an essential pathway in various 
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cell lines, while MAPK signalling appears to be of less significance (Tacchini et al., 
2001; Moeller et al., 2005). In this study, Pi3K signalling was also seen to have a 
significant effect on the level ofHIF-la mRNA in 20mM glucose with normoxia, 
as mRNA level detected at all time points was lower than in the equivalent inhibitor 
free sample. Increased HIF-la mRNA level was observed in response to high 
glucose at 24h with inhibition ofp42/44 MAPK. In this case, absolute level of 
mRNA detected was not as high as that in the equivalent inhibitor free sample; 
however, the increase noted in the MAPKi sample was preceded by a marked 
reduction at 1 and 6h, therefore the magnitude of the increase was similar to that 
detected without inhibitor. This suggests that Pi3K signalling is necessary for the 
response to high glucose at 24h, and although p42/44 MAPK would appear to also 
be involved, inhibition of the p42/44 MAPK pathway does not actually prevent the 
increase in HIF-1 a mRNA. 
At 24h, cell proliferation in the presence of 20mM D-glucose was increased 
compared to 5mM, in both normoxic and hypoxic samples, with hypoxia generally 
increasing cell growth compared to normoxia. In normoxia or hypoxia, increasing 
the concentration of 2DG from 5mM to 20mM had no significant effect on cell 
growth, which is not surprising, as the cell can't fully metabolise this analogue. 
Interestingly, all 2DG treatments at 24h resulted in proliferation rates which were 
not significantly different to that observed under standard growth conditions (5mM 
D-glucose, normoxia). It would seem, therefore, that 2DG despite only being 
recognised by hexokinase and trapped in the cell at that point, is not having a 
detrimental effect on cell growth. 30MG, due to the methylation at position 3 is 
not recognised by hexokinase, not metabolised and free to leave the cell (Bessel et 
al., 1972). Under normoxic conditions, SmM 30MG increased cell proliferation 
compared to its D-glucose equivalent. At 20mM, proliferation was equal to its D-
glucose equivalent. This was also the case under hypoxic conditions. 
Neither 2DG or 30MG could recreate the increase in HIF-1a mRNA stability 
seen at 24h in 20mM D-glucose with normoxia. As it has already been determined 
that cells are actively proliferating under conditions where D-glucose is replaced by 
a non-metabolizable analogue, the inability of either analogue to stabilise HIF -1 a 
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mRNA is not likely caused by any adverse effect on cell growth, but rather a 
product of hexose metabolism mediating the permissive effect of high glucose. 
Specifically, it appears that metabolism of glucose beyond glucose-6 phosphate is a 
necessary step. Therefore, it could be postulated that a metabolite of glucose 
beyond the first step, or perhaps energy or ROS generated as a result of glucose 
metabolism, is responsible for its effects on the stability of HIF-la mRNA. 
HIF-1 itself promotes glycolytic metabolism through the.ind~ction of target 
genes such as GLUT-I, PFKF and MCT4. In HUVEC, this study has found that 
enhancement of the stability ofHIF-la mRNA by glucose metabolites, or indeed 
the mediators of glycolysis, is coincident with reduced HIF -1 a protein expression. 
Therefore, metabolism of large amounts of glucose, along with the by products 
and/or enzymes involved in that process, may reduce the cells' ability to cope with 
an emerging state of pseudohypoxia. 
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Chapter 7 
General Discussion 
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7.1 Summary of findings 
This study has shown HIF-1 a protein to be expressed in the vasculature 
accompanying the sciatic nerve of a streptozotocin (STZ) rat model of diabetes. 
The increased HIF-la protein expression represented a chronic response to the 
disease, with elevated expression detected at 10 weeks disease duration. Expression 
was confmed to the vasculature, and at 24 weeks, in addition to expression in 
vasculature surrounding the nerve, HIF-la was also detected within the intraneural 
vasculature ofthe sciatic nerve. Furthermore, supplementation of the STZ rat with 
a-lipoic acid visibly reduced the expression oftiiF-la protein in the vasculature 
surrounding the sciatic nerve at 24 weeks. 
Due to the location of the endothelium within the vessel as primary intimal 
contact for substances contained within the blood, an in vitro cell culture model of 
diabetes using HUVEC was employed in order to investigate the role of glucose in 
the induction ofHIF-1a expression in the diabetic vasculature. At 24h, the level of 
HIF-la mRNA detected increased significantly in response to incubation with 
20mM glucose under normoxic conditions. This response appeared to arise from 
enhanced stability of the mRNA which was dependent upon de novo protein 
synthesis, as opposed to increased transcription. 
Despite the enhanced stability ofHIF-la mRNA in response to high glucose 
at 24h in HVVEC, HIF-la protein expression appeared to be reduced at this time 
point compared to that detected under normal growth conditions (5mM glucose, 
nonnoxia). Furthennore, expression ofHIF-la protein also appeared to be reduced 
in the 20mM hypoxia sample compared to its 5mM equivalent, although no 
difference in mRNA levels were detected. 
No change in mRNA level was detected in the HIF-la regulated genes 
GLUT-1 or IGF-1R at 24h in response to 20mM glucose in nonnoxia. At 6h 
incubation in 20mM glucose combined with nonnoxia, a small but significant 
increase in the level of the natural antisense ofHIF-1a mRNA (aHIF) was detected; 
however, this increase was not seen at 24h. 
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The mechanism by which high glucose concentration elicited increased 
stability of HIF -1 a mRN A expression appeared to be dependent upon signalling 
through Pi3K-dependent pathway/sand the presence ofROS, as indicated by the 
application a-lipoic acid preventing the increase in HIF-la mRNA level observed in 
response to high glucose alone. 
The effect ofD-glucose on HIF-la mRNA, as detailed above, was also 
observed to be directly attributable to the metabolizable nature of the hexose, as 
partial or non metabolizable analogues of D-glucose were incapable of conferring 
enhanced stability upon HIF-la mRNA at 24h under the same conditions. 
7.2 Discussion 
Hypoxic regulation ofHIF-la expression has been well documented since 
the discovery of the transcription factor by Semenza and W ang in 1992. It is also 
appreciated that HIF-1 is subject to complex modulation in normoxia, and in 
contrast to the post-transcriptional control of hypoxia-induced HIF-1a stability, 
non-hypoxic stimuli have been reported to regulate HIF-1 a through transcriptional 
and translational mechanisms involving ROS, PKC and Pi3K signalling (BelAiba et 
al., 2004; Page et al., 2002; Sandau et al., 2001; Zelzer et al., 1998). 
Chronic expression of HIF -1 a protein may indicate a crucial role for HIF -1 a 
in mediating endothelial cell damage elicited by high circulatory concentrations of 
glucose, such as that experienced in poorly controlled diabetes. In this study, HIP-
la protein expression was not found to be increased before 10 weeks disease 
duration in the rat model, therefore, we can postulate that hypoxia resulting from 
ischemia is not the sole cause, as hyperglycaemia-induced sciatic nerve blood flow 
reductions (Cameron et al., 1991) result in tissue hypoxia at a much earlier stage of 
disease (Young et al., 1992). Therefore, it would seem likely that upregulation is 
caused by hyperglycaemia in conjunction with hypoxia, which would suggest a 
level of cross-talk or interference between oxygen and glucose signalling, such as 
that demonstrated in the regulation of the glycolytic enzyme L-type pyruvate kinase 
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(L-PK) gene expression in the liver (Krones et al., 2001), in which HIP-la may 
have a central role. 
Although poor perfusion can't be ruled out as an explanation for the 
upregulation of HIP -1 a protein expression detected in the intraneural vasculature at 
24 weeks, the persistence of hyperglycaemia-induced metabolic disruption may also 
contribute to this observation. Intraneural vascular expression of HIP-la may also 
serve as a marker of poor prognosis, indicating thickening of the intraneural vessel 
wall associated with progression of diabetic peripheral neuropathy. 
While preparing this thesis, a study was published suggesting that HIP -1 a 
protein detected by Western blotting is transiently expressed within diabetic nerves, 
peaking at between 4 and 6 weeks and declining at 8 weeks after induction of 
diabetes (Chavez et al., 2005). This group conclude that expression ofHIP-1a and 
its target genes do not represent a sustained response to chronic injury. However, 
the duration of the Chavez study was only 10 weeks, and did not take into account 
the influence of the vasculature supplying the nerves. Using IHC, we saw no non-
vascular HIP-1 a protein expression within the nerve at any time point, but rather 
confined to the vessels surrounding the nerve at 10 weeks, which then progressed to 
vessels within the nerve at 24 weeks. 
Despite reports of oxygen sensing and HIP-1 stabilization not involving the 
mitochondria (Srinivas et al., 2001; Vaux et al., 2001) it has been indicated that a 
functional electron transport chain (ETC) is required for the hypoxic stabilization of 
HIP-la protein via increased ROS (Chandel et al., 2000). Increased levels ofROS 
reduce nitric oxide (NO) and compromise the perfusion of the peripheral nerve 
(Cameron et al., 1991; Cameron and Cotter, 1997). Paradoxically, HIP-la has also 
been found to be essential for the hypoxic regulation of inducible NO synthase 
(iN OS) gene transcription in endothelial cells (Palmer & Johns, 1998). 
Under hypoxic conditions, HIP-la and ROS may be involved in reciprocal 
regulation, whereby induction of HIP-la by ROS decreases mitochondrial oxygen 
consumption, ultimately leading to reduction ofROS (Papandreou et al., 2006). 
This may be as a result ofthe ability ofHIP-1 to trans-activate pyruvate 
dehydrogenase kinase l (PDKl), thereby reducing production ofROS by 
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preventing pyruvate from being metabolised by pyruvate dehydrogenase during the 
tricarboxylic acid cylce (TCA) (Kim et al., 2006), while maintaining ATP 
production via glycolysis. Therefore, hypoxic activation ofHIF-1a acts as a 
metabolic switch which shunts glucose metabolites from the mitochondria to 
glycolysis (Guzy et al., 2005). 
The action ofROS scavengers such as a-lipoic acid, are markedly attenuated 
by NOS inhibitor eo-treatment, therefore antioxidant repair ofROS mediated 
damage may potentially be dependent upon the induction of NOS by HIF-1a. 
Thomsen et al. (2002) saw a transient increase in NOS within streptozotocin-
induced diabetic rat sciatic nerve at 8-10 weeks, which coincides with the time 
point at which upregulation ofHIF-1a protein was first noted in this study. 
It would also seem that when NO is present in increased concentrations, it then has 
a negative feed-back effect on HIF-1a. This may be accounted for by the fact that 
NO is also able to inhibit mitochondrial respiration, thus increasing the availability 
of free oxygen (Mateo et al., 2003) which can then be redistributed throughout the 
cell, and utilised by PHDs to degrade HIF-la in hypoxia (Hagen et al., 2003). 
The antioxidant a-lipoic acid has been shown to lower glucose levels in 
animal models of diabetes and human type 2 diabetes (Packer et al., 2001 ). One 
hypothesis involves the stimulation of glucose transport by a-lipoic acid (Greene et 
al., 2001) yet the mechanism of action and fate of glucose in the presence of a-
lipoic acid remains to be elucidated. The effect of a-lipoic acid on blood glucose 
level at 24 weeks for the animals used in this study is not known, however at 8 
weeks there was no significant reduction in blood glucose level in a-lipoic acid 
treated animals compared to diabetic control (Gibson et al., 2003). 
Results generated for this thesis have demonstrated inhibition ofHIF-la 
protein accumulation in the 24 week diabetic rat in response to supplementation 
with a-lipoic acid, suggesting that expression of HIF -1 a in the diabetic rat 
vasculature may also be associated with induction of ROS by high glucose. As 
such, it is perhaps the ability of a-lipoic acid to correct redox imbalance, rather than 
reduce elevated glucose level per se, which is abrogating HIF-la protein expression 
in the vasculature. Furthermore, this regulation may be occurring prior to the 
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translation ofHIF-1a protein, as a-lipoic acid is also known to act as an effective 
iron chelator (Coleman & Walker, 2000; Packer et al., 2001). As previously 
discussed, iron chelators are potent inducers ofHIF-1a protein stability; therefore 
reduction ofHIF-1a protein expression in the vasculature suggests that a-lipoic acid 
may actually be affecting HIF-1a at a pre-translationallevel. Results obtained from 
the HUVEC model did indeed show a-lipoic acid to prevent increased HIF-1a 
mRNA level in response to high glucose, although it is as yet unknown what effect 
this had on the expression ofHIF-1a protein. 
A potential cause of peripheral neuropathy is endothelial cell hyperplasia 
(Britland et al., 1990). Endothelial cells are highly predisposed to glucose induced 
injury, as demonstrated by previous groups (Knott et al., 1996; Hammes, 2003; 
Creager et al., 2003). However, just what effect such injury has on cell 
proliferation is subject to debate, and likely affected by the micro or macrovascular 
origin of the endothelial cell line. It has been reported that high glucose is toxic to 
micro and macrovascular endothelial cells in vitro, resulting in retarded cell 
proliferation (Ceriello et al., 1996), disturbed cell cycle and increased DNA damage 
(Lorenzi et al., 1986; Lorenzi et al., 1987). In BREC, high glucose has been seen to 
result in decreased DNA synthesis, yet this was not accompanied by any change in 
proliferation (Knott et al., 1998). This study demonstrated proliferation of 
HUVEC to increase in response to high glucose to a similar extent as in response to 
hypoxia, both of which were significantly higher than under normal growth 
conditions. Zanetti et al. (2001) and Wu et al. (1999) both detected increased 
HUVEC cell death on incubation with 28mM and 30mM glucose, respectively, 
following an incubation period of 48h. These observations, however, may be due to 
the build up of toxic by-products resulting from the metabolism of very high 
concentrations of glucose. Furthermore, cell death may also arise from over-
crowding after such an extended growth period, as our investigation showed cell 
proliferation in 20mM glucose approaching a plateau at 29h. The concentration of 
glucose used in the afore-mentioned study is also very high, while we feel justified 
in the use of 20mM, as a physiological blood glucose level of just 8.3mM is 
considered high enough to put the person with diabetes at risk of serious 
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complications (Service & O'Brien, 2001). Increased cell growth may even be 
attributable to HIF-1a expression in certain cases, as Yu and colleagues (2004) 
reported that HIF-1a does actually exert an anti-apoptotic effect in HUVEC stressed 
by severe hypoxia. 
Under normoxic conditions, ROS formation has been shown to destabilize 
HIF-1a protein (Kietzmann et al., 2000; Yang et al., 2003) which may account for 
the reduced HIF-1a protein expression observed in this study in HUVEC exposed to 
high glucose. Callapina and colleagues (2005) reported that induction of ROS in 
fact had a differential effect upon HIF-la stability in normoxic conditions, where 
high concentrations of superoxide blocked prolyl hydroxylase (PHD) activity and 
induced HIF -1 a accumulation under normoxic conditions, while low concentrations 
had the opposite effect. If this is the case in HUVEC, the observation of no 
increase in protein expression in the 24h normoxic and hypoxic samples treated 
with high glucose may indicate a lesser accumulation of ROS than that found in a 
10 or 24 week diabetic animal, where protein was seen to increase. This would 
seem logical, and therefore account for the opposing effect of high glucose 
combined with hypoxia on HIF-1a protein expression in the rat and HUVEC 
models of diabetes. 
Several studies have indicated that chemically diverse nitric oxide (NO) 
donors also induce HIF-1a stabilization, HIF-1 DNA binding and HIF-1 
transactivation under normoxic conditions (Brune & Zhou. 2003). Similar to ROS, 
they achieve this effect by targeting the PHDs (Metzen et al .. 2003). In bovine 
aortic endothelial cells, high glucose has been shown to decrease the expression of 
constitutive NOS (cNOS) and iNOS, thus decreasing NO (Guo et al., 2000). 
Although NO and peroxynitrite (ONOO) (formed on reaction of NO with 
superoxide) can cause endothelial and neuronal cell death in vitro, in animal models 
of diabetes, reductions in endothelial NO production can inhibit vasodilatation and 
cause nerve ischemia. Therefore, ideal therapeutic approaches should limit the 
formation of superoxides and ONOO while preventing reductions in vascular NO. 
Although pre-translational regulation ofHIF-la has been demonstrated in 
carcinogenesis (Jiang et al., 2003) and wound healing (Zhong et al .. 1999), a novel 
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observation to arise from this study was the increase ofHIF-la mRNA stability at 
24h in HUVEC exposed to high glucose in normoxia. The increase in mRNA 
detected was not due to increased transcription, shown through the transcription 
inhibitor actinomycin D (Act D) having no effect on the level detected under high 
glucose conditions. However, the protein synthesis inhibitor cyclohexamide (CHX) 
was seen to prevent increase ofHIF-1a mRNA levels in response to high glucose. 
This indicated the necessity for de novo synthesis of a protein, which may be an 
RN A-binding protein, a protein kinase or phosphatase involved in signalling, or the 
HIF -1 a protein itself. This is in agreement with previous findings in retinal 
pigment epithelial cell lines (Treins et al., 2002) whereby protein translation was 
considered to be a key factor in stabilisation ofHIF-la mRNA. 
In cortical neurones, such a response represents a protective mechanism in 
response to oxidative stress, leading to enhanced DNA binding ofHIF-1a and 
increased expression of glycolytic enzymes (Zaman et al., 1999). In this case, 
regulation of HIF -1 a mRNA stability at 24h in high glucose is also likely to be 
dependent upon oxidative stress, shown by the ability of a-lipoic acid to prevent 
this stability. 
The observations made were likely occurring via regulation of certain protein 
kinase signalling pathways activated by high glucose concentrations (Srivastava et 
al., 2002). Campbell & Trimble (2005) have shown phosphorylation of Akt 
(downstream ofPi3K) and p42/44 MAPK to increase after 24h in VSMC exposed 
to high glucose. Potential signalling pathways regulating the expression of HIF -1 a 
under hypoxic and normoxic conditions at the level of transcription and translation 
are still subject to debate, however, p42/p44 MAPK has been implicated in HIF-la 
phosphorylation and promotion of transcriptional activation by HIF-1 (Conrad et 
al., 1999, Richard et al., 1999). MAPK also seems to regulate the basal activity of 
HIF-1 expression under normoxic conditions (Sang et a/, 2003). On the other hand, 
induction ofHIF-1a mRNA has been observed to be dependent upon the Akt-Pi3K 
pathway, but not p42/44 MAPK in human skin fibroblasts (Moeller et al., 2005) 
and HepG2 cells (Tacchini et al., 2001). 
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At 24h exposure of HUVEC to high glucose, this study found that inhibition 
ofp42/44 MAPK reduced but did not abolish the stability ofHIF-1a mRNA in 
response to high glucose, while inhibition of Pi3K not only abolished increased 
stability, but also lowered basal levels. Under high glucose conditions, Akt 
activates the MAPK pathway (Campbell et al., 2004). Therefore, by inhibiting Akt, 
this will also reduce the activity of MAPK and its downstream targets, which may 
explain why we found inhibition ofPi3K to have the greater effect. It is therefore 
possible to correlate our finding to those of Moeller and colleagues (2005) who 
determined induction ofHIF-1 and subsequent activation of transporters and 
enzymes involved in glucose metabolism to be completely abrogated by inhibition 
of the Pi3K pathway, yet preserved under inhibition of the MAPK pathway. 
McBain et al., (2003) reported that BREC exposed to high glucose 
concentrations are not sensitive to the HIF-1 regulated gene IGF-1 when compared 
to 5mM controls, and that this was in part due to a reduced activation of the p42/44 
MAPK pathway. In this study, mRNA levels of other HIF-1 target genes, the IGF-1 
receptor (IGF-1R) and glucose transporter GLUT-1, were found to be unaffected by 
high glucose after 24h incubation. This is not surprising, as the observation concurs 
with reduced HIF -1 a protein expression and aberrant sub-cellular location at this 
time, which would therefore result in disruption of the expression of glucose 
sensitive genes targeted by HIF-1. 
Enhanced stability ofHIF-1a mRNA in response to high glucose in HUVEC 
may also have been attributable to altered expression of the natural anti sense of 
HIF-1a mRNA (aHIF), which binds to the instability element within the 3'UTR, 
targeting the mRNA for degradation (Thrash-Bingham et al., 2002) and is 
expressed widely in normal and tumour tissue (Rossignol et al., 2002). 
Observation of an increase in the level of aHIF preceding the increase in HIF -1 a 
mRNA at 24h, may indicate that at 6h the level ofunbound aHIF is seen to increase 
due to it competing with something else which targets the 3'UTR ofHIF-1a 
mRNA, such as an RNA binding protein. Such a protein would require conditions 
of high glucose for production, and have the ability to bind the 3 'UTR therefore 
modulating the ability of the mRNA to fold in stable secondary structures (Dreyfuss 
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et al., 1993). Any such disruption to the 3'UTR could prevent the binding of aHIF, 
and therefore prevent the mRNA being targeted for degradation. 
The mRNA-stabilizing protein HuR, when expressed in the cytoplasm, is 
often accompanied by an increased association with the nucleocytoplasmic shuttling 
protein, pp32 (Cherradi et al., 2006). IfHuR were binding in this case, it may also 
rationalise the perinuclear location of HIF -1 a protein expression in addition to 
increased stability of the mRNA. The glycolytic enzyme, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is also known to be an RN A-binding protein 
(Nagy et al., 1995). HIF-1 binding is necessary for the upregulation ofGAPDH in 
EC under hypoxic conditions (Graven et al., 1999) but nothing is known of 
GAPDHs effect on HIF-1a. IfGAPDH were found to be binding and having such 
an effect on HIF-1a, this would enhance the theory that abundant GAPDH may also 
be involved in the regulation of a variety of cellular processes independently of its 
characteristic metabolic activity (Nagy et al., 2000). Another glycolytic enzyme, 
lactate dehydrogenase (LDH) may also serve multiple roles in RNA metabolism 
beyond its role in glycolysis (Pioli et al., 2002). Like GAPDH, LDH is known to 
be regulated by HIF-1 under hypoxic conditions (Firth et al., 1995); however, we 
have no knowledge of how it may affect HIF -1 a in normoxia under conditions of 
high glucose, making these glycolytic enzymes ideal candidates for follow-up 
studies. 
Expression ofHIF-la protein in response to hypoxia was clearly evident at 
24h in the nucleus ofHUVEC. At the outset, this demonstrated HIF-1a to be 
responsive to chronic hypoxia in endothelial cells, a trait which is not shared by all 
cell types, as lung epithelial cells are subject to acute regulation, shown by HIF-1 a 
protein peaking at 4h hypoxia, thereafter declining up to 12h (Uchida et al., 2004). 
In cells treated with high glucose for 24h, HIF-la protein expression was 
visibly decreased in both normoxic and hypoxic HUVEC compared to those treated 
with 5mM glucose, thus indicating glucose interfering not only with HIF-1a mRNA 
expression, but extending to the level of protein expression. Furthermore, 
conditions of high glucose also resulted in the little expression which was evident 
being perinuclear. This is significant, because for HIF-1 to function as a 
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transcription factor, HIF-la requires to enter the nucleus in order to dimerize with 
HIF -1 ~. thus forming the functional unit. 
Reduced protein expression along with change in sub-cellular location at 24h 
in high glucose, may both result from the effect of regulatory protein binding to 
HIF-1 a mRNA, as described previously. Therefore, this suggests that the majority 
ofHIF-1a mRNA detected at 24h in high glucose may have accumulated as a result 
of its inability to be translated to protein. Furthermore, binding of RN A-regulatory 
proteinls, in addition to regulating stability, may also have a role in the trafficking 
of mRNA to the cytoplasm for packaging into protein (Tretyakova et al., 2005). If 
this process is hampered in any way by elevated glucose, this could explain the 
reduced protein expression and aberrant sub-cellular location, all of which ties in 
with the earlier discussion of results relating to inhibition of translation, RNA 
binding proteins and induction ofHIF-1 targeted genes. 
Findings of reduced HIF-la protein expression are partially in accordance 
with those ofCatrina and colleagues (2004), who reported hyperglycaemia to 
reduce hypoxia induced protein stability in human dermal microvascular endothelial 
cells (HDMEC). This study, however, reported that no effect on HIF-1a protein 
expression was observed in HDMEC exposed to high glucose in the presence of 
normoxia. Observations made in the present study may therefore be organ specific 
rather than endothelium specific, as the kinetics ofHIF-1a expression are known to 
vary between organs (Stroka et al., 2001). However, we can not directly compare 
the results from this study with that of Catrina, as we utilised a macrovascular cell 
line as opposed to microvascular. The actual stage of growth and conditions in 
which the cells were maintained in the Catrina study also differed quite 
considerably from this study. They exposed confluent cultures to media containing 
high glucose concentrations for 24 h preceding the experiment, whereas this study 
used 80% confluent cultures which had been incubated overnight in glucose free 
media in order to synchronize cell growth prior to applying the test conditions. 
These factors, therefore, may also account for the differences observed. 
Considering the ability of HIF -1 to transactivate a variety of enzymes 
involved in the metabolism of glucose, it was prudent to question whether high 
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glucose per se or a product of its metabolism was responsible for the observations 
of increased HIF -1 a stability in response to high glucose concentration. 
Replacement of D-glucose with partially/non-metabolisable analogues did not 
mimic the effect of high D-glucose on mRNA stability at 24h under normoxic 
conditions. It has previously been reported that the end products of anaerobic 
glycolysis, lactate and pyruvate, are responsible for stabilization of HIF-la protein 
independently of hypoxia, whereas the citric acid cycle intermediates 2-
oxoglutarate and succinate did not have this effect (Lu et al., 2005). The 
observations of Lu et al. were made in a cancer cell line and were not in response to 
elevated glucose concentration, but neither were they in response to hypoxia, 
thereby providing evidence of the ability of the Warburg effect to regulate HIF-la. 
Therefore, in relation to this study, it presents the possibility of increased levels of 
pyruvate, resulting from increased metabolism of glucose, feeding into 
mitochondrial respiration with subsequent elevated production of ROS, as oxygen 
availability is not a limiting factor therefore the TCA cycle is not inhibited. 
Previous investigation into the significance of HIF -1 expression in the diabetic 
microvasculature has highlighted the negative effect of its pro-angiogenic 
capabilities, such as is seen in diabetic retinopathy (Lukiw et al., 2001) and tumour 
progression (Zhong et al., 1998). However, induction of HIF-1 may also function 
as a metabolic switch which shunts glucose metabolites from the mitochondria to 
anaerobic glycolysis (Guzy et al., 2005) thus reducing the production ofROS. 
Therefore, reducing the level ofHIF-la protein within the nucleus may negate its 
protective effect in preventing induction of ROS via inhibition of mitochondrial 
respiration. 
In the rat model, HIF -1 a protein expression was seen to increase in the 
vasculature after 10 weeks of diabetes. However, HUVEC treated with high 
glucose in the presence or absence of hypoxia did not show any upregulation of 
HIF-1a protein expression, but rather increased the level ofmRNA, but only in 
normoxic conditions. As discussed at the outset (section 1.6), these two models 
can not be directly compared. The complexity of the animal model does not allow 
- 171 -
us to state whether glucose or hypoxia alone are the cause of changes observed, as 
the physiological system has many other factors impacting upon it. 
Observations made in the rat model did, however, provide rational for further 
investigation in the endothelial cell model of diabetes, due to the endothelium being 
in direct contact with the blood, although the results obtained appear conflicting. If 
conclusions can be drawn from the results obtained from these two models relating 
to the expression ofHIF-1a protein, it may be that vascular smooth muscle cells 
(VSMC) are in fact the primary source of elevated HIF-1 a protein expression in the 
rat model, as opposed to endothelial cells. A recent report has found that exposure 
of human VSMC to moderate hypoxia is sufficient to elicit increased cellular levels 
of HIF -1 a protein which then promote proliferative responses (Schultz et al., 2006). 
Excessive proliferation ofVSMC in response to elevated HIF-1 arising from 
high glucose could therefore contribute to thickening of the vascular media, which 
would narrow the vessel lumen thus aggravating tissue ischaemia It is possible, 
therefore, that the effects of pseudo hypoxia arising from increased glucose levels 
and/or hypoxia experienced by the endothelium are magnified in VSMC. It is well 
known that EC and VSMC interactions play a critical role in the ability of the vessel 
to respond to vascular injury. Indeed, it was noted by Hodges and colleagues 
(2005} that chemical induction ofHIF-1a indirectly stimulated EC growth by 
directly stimulating VEGF production in VSMC, although there was no VEGF 
production detected in EC. This obviously highlights the caveats of working with 
isolated cell culture models, but also shows the individual responses of different 
vascular cells types to be working toward a common goal, in this case cell 
proliferation. 
Antioxidant treatment reduced the appearance ofHIF-la protein in the 24 
week rat model of diabetes. Paradoxically, this may suggest that HIF-1a has a 
protective role in the vasculature exposed to high glucose. The reasoning for this 
may lie in the ability of HIF-1 to act as a metabolic switch, which is capable of 
channelling glucose away from the mitochondria and into anaerobic respiration in a 
high ROS environment (Guzy et al., 2005); therefore, reduction ofROS in response 
to antioxidant treatment would also result in reduction ofHIF-1a. In HUVEC, a-
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lipoic acid may play a role in maintaining baseline level ofHIF-la mRNA under 
conditions of high glucose, such as that seen in cardiomyocytes where reduction of 
oxidative stress inhibited the mitochondrial apoptotic pathway via maintenance of 
baseline HIF-la mRNA levels, as observed in cardiomyocytes exposed to hypoxia 
(Vassilopoulos & Papazafrri, 2005). Despite its reproducibility and relative ease of 
use, RT-PCR as a method ofmRNA quantification is not without its limitations. As 
highlighted in chapter 4, RT-PCR does not directly measure mRNA expression, but 
rather amplification of the gene of interest reverse transcribed from cDNA. 
Therefore, this must be recognised when interpreting mRNA data based solely on 
RT-PCR. Ideally, RT-PCR data should be verified using RPA, which is a method 
by which mRNA may be measured directly. In this study, attempts to detect 
mRNA by RP A were not successful. One reason for the lack of detection may have 
been the non-isotopic labelling of the probe. Indeed, available literature detailing 
HIF-la detection by RPA cites radioactive labelling (Ameri et al .. 2004), which is 
more sensitive for the detection of low abundance mRNAs. 
By stabilizing HIF-la mRNA and allowing its accumulation in EC, high 
glucose may chronically reduce the expression ofHIF-la protein below basal level 
in a normoxic environment to such an extent that the tissue becomes susceptible to 
oxidative damage. In a physiological system, this may be impacted upon by the 
responses of other vascular cell types, such as VSMC, which may potentially over-
express HIF-la protein and its target genes in response to elevated glucose, the 
confirmation of which would be a primary aim of any future work. 
Therefore, a scenario where EC already damaged by ROS are subject to 
excessive proliferation resulting from the production of factors such as VEGF by 
VSMC, would surely culminate in an endothelium which is seriously depleted of its 
ability to cope with unregulated blood glucose, thus perpetuating the chronic 
vascular complications associated with diabetes 
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7.3 Future work 
Firstly, as discussed in the latter section of 7 .2, the response of VSMC to 
elevated glucose must be considered in order to relate the events occurring in 
isolated EC to a realistic physiological situation, where these two vascular cell types 
are in permanent contact and able to communicate with one another. 
In terms of extending existing data, it would be useful to validate the 
fmdings which relate to mRNA expression with in situ hybridisation (ISH). As 
discussed in chapter 4, the benefit of using ISH is that mRNA can be measured 
directly, which is not the case in Picogreen detection which measures mRNA 
indirectly as PCR product. Optimising the ISH protocol would in addition allow for 
the identification of exactly where in the cell the mRNA is being expressed, which 
could also have implications for binding of regulatory proteins 
The majority of the published work within this field indicates that HIF-1 a 
mRNA levels do not change, despite the fact that the 3'UTR of the mRNA contains 
sequences known to be associated with mRNA stability. As we determined 
increased levels ofHIF-1a mRNA in response to high glucose to depend upon 
enhanced stability, it is necessary to establish what is the exact involvement of the 
3 'UTR. The significance of mRNA stability in terms of protein translation was also 
not fully addressed within this study, as the reduced expression of protein which is 
referred to in this report is not based upon quantitative measurements, but rather 
visual appreciation by IHC detection in HUVEC, therefore Western blotting would 
need to be employed to validate this. What was perhaps of greater significance to 
the interpretation of the results, was the subcellular location of the protein 
expression, as opposed to actual protein level, therefore it is also important to 
investigate the dual role of the 3 'UTR in directing stability and subcellular 
localisation of the mRNA, and the consequence of protein binding on these 
processes. 
The involvement of signalling pathways, including Pi3K and MAPK should 
also be verified at the level ofHIF-la protein expression. We hypothesised that 
Pi3K may feed into p42/44 MAPK signalling; which could also be verified by dual 
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inhibition ofboth pathways. Furthermore, stabilization ofmRNA often depends on 
activation of p38 mitogen-activated protein kinase (p38 MAPK) (Fechir et al., 
2005). Therefore it would be of interest to see what effect inhibition of p38 MAPK 
would have upon RNA-protein binding and subsequent expression ofHIF-la 
mRNA and protein. 
The contribution of mitochondrial generation ofROS to HIF-la expression 
should also be considered, as initial experimentation in both the rat and HUVEC 
model of diabetes implicated antioxidant treatment in the reduction of HIF -1 a 
protein and mRNA detection, respectively. At this point, it is essential to 
investigate HIF-la protein status in the HUVEC model of diabetes treated with 
antioxidant, and it would also be very interesting to look at the levels of expression 
in the 4 and 10 week rat model supplemented with a-lipoic acid. Further 
investigation into the role of the mitochondria would be possible by detecting the 
effect ofthe mitochondria-targeted antioxidant, mitoubiquinone (MitoQ) on HIF-la 
mRNA and protein under conditions of high glucose. An inhibitor of the TCA 
cycle, monofluoroacetate, could also be used to verify whether or not ROS of 
mitochondrial origin is central to any observation. 
Our fmding of the inability of the non-metabolizable analogues of glucose to 
induce stability ofHIF-la mRNA must also be further investigated at the level of 
protein expression. By using inhibitors of the glycolytic enzymes, such as GAPDH 
or phosphoglycerate kinase, the critical point the metabolism of glucose which may 
dictate the observed effects on HIF-la expression could be predicted, or with the 
use of pyruvate dehydrogenase, whether these results are indeed dependent on the 
end product of anaerobic glycolysis. 
In conclusion, regulation ofHIF-la at the level of protein and mRNA has 
demonstrated a novel mechanism by which oxidative demand placed upon the cell 
through the need to metabolise high concentrations of glucose may be contributing 
to the progression of vascular complications. As such, this research requires to be 
validated and further extended, in order to explore whether targeting this 
mechanism could represent a therapeutic strategy for the reduction and prevention 
of chronic vascular disease associated with diabetes. 
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Buffers and solutions 
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Buffers and solutions 
All reagents were purchased from Sigma, unless stated otherwise. 
ABC/ AP substrate buffer 
1.7ml Naphtol AS-MX Phosphate sodium salt 
lrnM Levamisol 
3.5mM Fast red TR salt 
in Veronal acetate buffer 
Bacterial cell lysis buffer 
200mMNaOH 
1%SDS 
Blocking solution 
1% (w/v) blocking reagent (Roche) 
O.lM maleic acid 
0.15M NaCl, pH 7.5 
Chemiluminescent detection washing buffer 
O.lM maleic acid 
0.15M NaCl, pH 7.5 
0.3% Tween 
50x Dernhardt's reagent 
1% w/v Ficoll 
1% w/v PVP 
1% w/v BSA 
800J..Ll denatured salmon sperm 
10% SDS 
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Detection buffer 
O.IM Tris-HCl 
O.IM NaCl, pH 9.5 
DIG-AP antibody solution 
75 mU/ml anti-DIG.,AP (Roche) 
1% (w/v) blocking reagent (Roche) 
O.IM maleic acid 
0.15M NaCI, pH 7.5 
DIG detection blocking buffer 
5%BSA 
O.IM Tris-HCl 
0.15 NaCI, pH 7.5 
DIG detection substrate buffer 
0.1M Tris-HCl 
0.1MNaCl 
0.05MMgCh 
DIG detection wash buffer 
0.1M Tris-HCl 
0.15M NaCl, pH 7.5 
DNA loading dye 
50% Glycerol 
1 OOmM Na EDT A 2H20 
1%SDS 
0.1% Bromophenol blue 
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Equilibration buffer 
750mMNaCl 
50mMMOPS 
15% isopropanol 
0.15% Triton-XIOO, pH 7.0 
GMEM 
3mM Glutamine (Gibco BRL) 
10% Tryptose phosphate broth (Gibco BRL) 
1 OOU/ml Penicillin (Gibco BRL) 
100J.1g/ml Streptomycin (Gibco BRL) 
1mM Hepes (Gibco BRL) 
1.8% NaOHC03 (Gibco BRL) 
HUVEC lysis buffer 
1%w/v SDS 
lmM sodium orthovanadate 
0.01M Tris-HCl, pH 7.4 
ISH wash buffer 
0.4MNaCl 
10mM Tris-HCl 
5mMEDTA 
LB-1.5% agarose/ampicillin/IPTG/X-gal 
1.5% agar (Oxoid) 
1% Bacto-tryptone (Oxoid) 
0.5% Bacto-yeast extract (Oxoid) 
0.5% NaCl, pH 7.0 
1 OOJ.1g/ml ampicillin 
0.5mM IPTG 
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80~g/ml X-gal 
lOx PCR reaction buffer 
50mMKCl 
lOmM Tris-HCl, pH 8.3 
1.5mMMgCb 
Plasmid elution buffer 
1.25mMNaCI 
50mMMOPS 
15% isopropanol, pH 7.0 
Plasmid purification neutralisation buffer 
3M potassium acetate, pH 5.5 
Plasmid purification resuspension buffer 
50mM Tris-HCl 
10mMEDTA 
100~g/ml RNAse, pH8.0 (Ambion) 
Plasmid purification wash buffer 
1MNaCI 
50mMMOPS 
15% isopropanol, pH 7.0 
10 x Restriction enzyme buffer 
60mM Tris-HCI pH 9.7, 
1.5MNaCl 
60mMMgCh 
1 OmM DTT (Promega) 
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RNA loading dye 
50% Glycerol 
lmMEDTA 
0.4% Bromophenol blue 
0.4% Xylene cyanol 
SOC growth medium 
2% Bacto-tryptone (Oxoid) 
0.5% Bacto-yeast extract (Oxoid) 
lOmMNaCI 
2.5mMKCI 
20mMMg2+ 
20mM glucose 
20X SSC buffer 
3MNaCl 
0.4M Citric acid 
pH to 7.0 
TAE buffer 
40mM Tris-acetate 
lmM EDTA, pH 8.3 
TBE buffer 
130mM Tris 
35mM boric acid 
2.5mMEDTA 
TE buffer 
l.OmM Tris-HCl, pH 7.4 
lmMEDTA 
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TBS buffer 
O.OSM Tris-HCl, pH 7.6 
0.15MNaCl 
Veronal acetate buffer 
0.028M Sodium acetate (trihydrate) 
0.28M Sodium diethyl barbiturate 
pH 9.2, store at 4°C 
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